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Abstract
CXC-motif chemokine Receptor 4 (CXCR4) and Atypical ChemoKine Receptor 3 (ACKR3)
are two 7-transmembrane domain receptors often studied together due to their common
ligand CXC-motif chemokine Ligand 12 (CXCL12) and the implication of said ligand
in several pathophysiological processes, cancer growth and metastasis formation among
them.
This thesis project started with the aim of clarifying the interaction between these re-
ceptors and their second messengers, namely the different G proteins and arrestins, upon
stimulation with different ligands, establishing a relationship between them in order to
adjust the model of biased agonism to this system. Chapter 3 indeed gathers the efforts
made to design and test molecular sensors that might have helped to understand whether
the two receptors, alone or combined, give different types of signal in relation to differ-
ences in their expression or to different ligands. Even though several approaches were
followed, this goal was not reached in full. The products generated from this first big
molecular part had been propedeutical to the characterization of a new class of nanobod-
ies against CXCR4 and ACKR3 synthesized by a project partner company.
Further, the focus narrowed on ACKR3, whose role on CXCR4-dependent cell migration
was investigated in vitro through CRISPR. Indeed the first part of Chapter 4 describes
that the lack of human ACKR3 in Jurkat cells showed a significant reduction in the
amount of cells migrated towards CXCL12, indicating that ACKR3 has an indirect role
in CXCR4-dependent cell migration. In the second part tumor growth dependent of
ACKR3 alone was investigated: the knock-out of murine ACKR3 in LLC cells demon-
strated that ACKR3 has a positive role in tumor growth regardless the expression of
CXCR4.
Finally, the project headed towards the characterization of a very discussed interaction,
namely that between human ACKR3 and human Adrenomedullin. Chapter 5 was ded-
icated to this topic, and several approaches led to the conclusions that this interaction
exists, is slightly less potent than that with canonical chemokine ligands, but has a ther-
apeutic potential still undiscovered. The results and the models build a strong body
of evidencethat converge on the aforementioned conclusions, and constitute a cue to
consider this interaction worthy of further consideration.
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Chapter 1
Introduction
1.1 G protein-coupled receptors (GPCRs)
GPCR is a fundamental acronym in pharmacology. G protein-coupled receptors con-
stitute the most frequently targeted superfamily of cell-membrane receptor proteins as
they play a significant role in human pathophysiology: even though they constitute 12%
of human druggable targets, 33% of all the small-molecule drugs on the market target
them (Santos et al., 2016).
The core structure of a GPCR is that of a protein which spans the plasma membrane
with 7 α-helical domains, linked one to another by alternating intra- or extracellular loop
domains, an extracellular N-terminal, and an intracellular C-terminal. Because of this
simplified structure, GPCRs are often referred to as 7-transmembrane domain receptors
(7-TMD), serpentine receptors, or heptahelical receptors.
A wide plethora of cellular and physiological processes involve the action of GPCRs, as
they can mediate responses to hormones, neurotransmitters, metabolites and pathogens,
and are involved in vision, olfaction and taste (Rosenbaum et al., 2009).
1.1.1 Structure of a GPCR
Studying the structure of GPCRs allows us to better understand the mechanisms in-
volved in signal transduction and helps in the design of smarter drugs. Since the first
structure reported, bovine rhodopsin (Palczewski et al., 2000), great steps have been
made in terms the technology of crystallography, generating more stable crystals and
14
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higher resolution structures: all of these improvements have resulted in the availability
today of over 100 GPCR structures (Rosenbaum et al., 2007), (Tate and Schertler, 2009).
Together with the core structure of a GPCR, we are now able to describe with great pre-
cision, for some of the receptors, the exact topological site where ligands bind, what kind
of conformational change the receptor undergoes, which cytosolic domains interact with
various intracellular proteins and predict the ability of a molecule to target a receptor
(Zhang et al., 2015).
GPCRs have evolutionarily conserved features that are common to many of them. A
recurrent feature is the length of ECL2 (ExtraCellular Loop 2), which is the longest
extracellular loop in almost all GPCRs (Kmiecik et al., 2014). Furthermore, ECL2 is
involved in disulphide bridges with residues in TM3 (TransMembrane domain 3), whose
function is to contribute to receptor stability (Venkatakrishnan et al., 2013). The trans-
membrane region represents the core of a receptor, and functions as a “communication
wire”between the ligand-binding pocket and the intracellular proteins downstream of
the receptor itself (Katritch et al., 2013). The occurrence of an eighth helix (H8) par-
allel to the plasma membrane and separated from TM7 by a short linker is reported in
most GPCRs: this together with the ICLs (IntraCellular Loops) is involved in receptor
activation and interaction with signalling effectors (Wess et al., 2008).
1.1.2 Classification of the GPCR superfamily
GPCRs differ from each other in several ways, such as the structure of their non-
transmembrane domains, the nature of ligands with which they can interact, their expres-
sion pattern, the signalling pathway(s) activated upon receptor stimulation, and their
pathophysiological role. Several attempts have been made to understand in depth which
common traits could be the fil rouge that can be used to roughly group the members of
this superfamily, and so far there are two commonly used systems of classification: the
ABCDEF system (Attwood and Findlay, 1994) and the GRAFS system. The ABCDEF
system has the advantage of being comprehensive, in that it includes all the GPCRs
present in vertebrates and invertebrates, however some families do not have representa-
tives in humans, such as the family of fungal pheromone receptors (family D) and the
cAMP receptors (family E). The GRAFS classification (Figure 1.1) was instead devel-
oped as the result of a comprehensive bioinformatic approach applied to human data, and
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this allowed all the human receptors to be sorted into 5 families: Glutamate, Rhodopsin,
Adhesion, Frizzled/Tas2 and Secretin receptors, the first letter of which family names
form the acronym GRAFS itself (Fredriksson et al., 2003).
metabotropic-Glutamate-like receptors
This family of receptors includes all the 8 metabotropic glutamate receptors, the GABA-
B1/2 receptors, the extracellular calcium-sensing receptor CaSR, the four taste receptors
(TAS1) (Fredriksson et al., 2003), and corresponds to Class C of the ABCDEF classifi-
cation. Those receptors are functional only when they form dimers: one monomer binds
the ligand, and the conformational change makes the other monomer trigger signalling
(Brauner-Osborne et al., 2007). The family is characterised by a large amino-terminal
domain, typically made of 280-580 amino acids, which forms two lobes and it is usually
referred to as Venus Flytrap Domain (VFD): when the orthosteric ligand binds between
the two lobes, they move towards one another (Cao et al., 2009).
Rhodopsin-like receptors
This family corresponds to the Class A GPCRs family of the ABCDEF classification and
includes the majority of human GPCRs (Fredriksson et al., 2003). The shared features
of the members belonging to this family lies in the primary structure of the receptors:
almost all of them have a DRY motif (or D(E)-R-Y(F)) at the junction between TM3
and IL2, whilst TM7 is characterised by a NSxxNPxxY motif. A few receptors do not
have these features, but they are classified within this family because of their phylogeny
(Fredriksson et al., 2003).
Adhesion receptors
Adhesion GPCRs (aGPCRs) are 7 transmembrane domain proteins with a very large N
terminal region (NTF, or N-Terminal Fragment), which is cleavable from the membrane
spanning domain (called also CTF or C-Terminal Fragment) by proteolysis (Monk et al.,
2015). The name Adhesion derives from the fact that their NTF is rich of domains
that are involved in cell-to-cell or cell-to-matrix interaction (Langenhan et al., 2013). A
hallmark of aGPCRs is the presence of the GPCR proteolysis site (GPS) immediately
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upstream of TM1, which in almost all aGPCRs is embedded in a GPCR autoproteolysis-
inducing (GAIN) domain (Liebscher et al., 2013). Adhesion GPCRs are now subject to
a new nomenclature, which starts with ADGR (Adhesion GPCR) followed by a letter
that indicates the subfamily, and a number (Hamann et al., 2015).
Frizzled/Tas2 receptors
This family includes ten frizzled receptors (FZD1-10), smoothened receptors (SMO) and
twenty-five T2R receptors. Frizzled and Tas2 receptors have no obvious similarities, but
bioinformatic analysis has identified common consensus sequences that cluster these 2
apparently diverse groups, such as motifs IFL in TM2, SFLL in TM5 and SxKTL in
TM7, that are unique to this family (Lagerstro¨m and Schio¨th, 2008). The nature and
functions of the ligands in the two groups are different: indeed Wnt ligands are involved
in embryo development (Zhang et al., 2018), while T2Rs ligands are molecules related
to taste sensing (Haraguchi et al., 2018).
Secretin-like receptors
The name of this family derives from the first of these receptors discovered, the rat
SCTR (Secretin Receptor) (Ishihara et al., 1991). Common features within this family
are the presence of conserved cysteine residues in the first and second extracellular loops,
which stabilise the structure of the receptor by bridging between them or together with
less conserved cysteines in the N terminal domain (Lagerstro¨m and Schio¨th, 2008), and
the fact that their endogenous ligands are peptides which share high aminoacid identity
(Fredriksson et al., 2003).
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Glutamate-like receptors Frizzled/Tas2 receptors
Rhodopsin-like receptors
Adhesion receptors Secretin-like receptors
Figure 1.1: GPCR classification. Top left: Glutamate-like receptors are functional
dimers, characterised by a long N-terminus bearing a Venus Flytrap Domain (VFD)
whose role is to be the ligand binding domain. Centre: Rhodopsin-like receptors are
the prototypical GPCRs, whose peculiarities are mainly in the primary structure of the
receptors. Bottom left: Adhesion receptors display different cell-to-cell adhesion motifs
in their long N-terminus and a proteolytic cleavage site (GPS) immediately upstream
of TM1. Top right: Frizzled/Tas2 receptors have a different variety of functions and
ligands, and their similarities, as per rhodopsin-like receptors, reside more in conserved
motifs in their primary structures. Bottom right: Secretin-like receptors N-terminal, EL1
and EL2 domains show several conserved cysteines, responsible for a more constrained
extracellular region.
Blue represents transmembrane and extracellular secondary structures. Green repre-
sents ligands. Red represents cleavage sites. Yellow represents conserved cysteines in
extracellular domains.
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1.1.3 Function of a GPCR: signalling
GPCRs bind a wide variety of ligands, the dimensions of which lie between the size of
a photon and that of a large protein. The interaction of a ligand with the receptor
leads to a series of events that have been reported as activation. During activation
both extra- and intra-cellular regions play crucial roles: the extracellular domains of the
GPCR, together with the non-cytosolic regions of the transmembrane domains, usually
harbour the cognate ligand in a topological space called the orthosteric binding pocket,
allowing it to interact with the receptor at different depths (Zhang et al., 2015). Ligand
binding causes structural conformation changes in the ICLs, promoting the binding of
intracellular effectors (Nygaard et al., 2009). ICL2 and ICL3 have been reported to be
the G protein-interacting sites of GPCRs (Wess, 1997). According to the interacting
partner recruited the signal is transduced differently (Lefkowitz, 2000).
G proteins G proteins are heterotrimeric complexes that work as binary molecular
switches, with their biological activity determined by the bound nucleotide (Syrovatkina
et al., 2016). These complexes directly relay the signals from activated GPCRs. G
proteins are composed of α, β and γ subunits, each of which has several isoforms. The
inactive state of a G protein sees the heterotrimer complete and bound by a molecule of
guanosine diphosphate (GDP): upon agonist binding, the inactive G protein is recruited
by the GPCR which induces an exchange of the bound GDP with GTP (guanosine
triphosphate). The association of the GTP to the G protein causes the dissociation of the
Gα subunit from the Gβγ obligated heterodimer, each of which can work as a signalling
effector. Gα has a low intrinsic GTPase activity that works as a negative feedback
regulator for its signalling effects, and can be stimulated by GTPase-activating proteins,
which accelerate the inactivation process of the Gα subunit; Gβγ signalling instead is
terminated when Gα-GDP forms and allows re-association (Figure 1.2) (Milligan and
Kostenis, 2006).
Gα subunit There are different isoforms of Gα subunits, which are typically gath-
ered in four groups: the adenylyl cyclase modulators (up- and down-regulators), phos-
pholipase C β (PLC-β) activators and Rho-guanine nucleotide exchange factor (Rho-
GEFs) activators, which are respectively named Gαs , Gαi/0 , Gαq/11 and Gα12/13 . Gαs
stimulates adenylyl cyclase to convert ATP (adenosine triphospate) to cAMP (cyclic
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adenosine monophosphate): elevated cAMP levels result in the activation of protein ki-
nase A (PKA) and other cAMP-regulated proteins; in contrast, Gαi/0 proteins inhibit the
activity of certain isoforms of adenylyl cyclases, reducing cAMP production and decreas-
ing the basal activity of said proteins (Wettschureck and Offermanns, 2005). The Gαq/11
family activates PLC-β, an enzyme that cleaves phosphatidylinositol 4,5 bisphosphate
into inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG); the former is responsi-
ble for binding IP3 receptors on the endoplasmic reticulum causing intracellular calcium
release, the latter activates protein kinase C (Goo, 2001). The Gα12/13 family member
Gα13 can directly increase the activity of p115RhoGEF, PDZ-RhoGEF (PDZ domain-
containing Rho guanine nucleotide exchange factor) and leukemia-associated RhoGEF
by membrane recruitment and binding (Kozasa et al., 1998), Gα12 can interact with
Gap1 (General Amino acid permease 1), rasGAP, α-SNAP and p120-catenin, while both
Gα12 and Gα13 have been reported to interact with Bruton tyrosine kinases (Btk) and
cadherins (Syrovatkina et al., 2016).
Gβγ subunit The β and γ subunits of the G proteins are tightly bound to each
other, and can be regarded as a single functional unit. Gβ has five isoforms (Gβ1−5 , of
which Gβ5 is the only one specific to brain cells, while the others are more widespread; Gγ
subunit has eleven isoforms (Gγ1−5 and Gγ7−12) (Syrovatkina et al., 2016). Like the Gα
subunit, the Gβγ heterodimer can signal, regulating adenylyl cyclases, phospholipase C-
β, the inwardly rectifying potassium channel and voltage-gated calcium channels (Khan
et al., 2013).
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(GDP-GTP exchange)
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Legend
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Figure 1.2: G protein dependent signalling. Upon ligand binding, GDP-bound
G protein gets recruited to the activated GPCR. GDP-GTP exchange allows the het-
erotrimer to dissociate into the Gα and Gβγ subunits, which are responsible for regulation
of different signalling pathways. The GTP bound to Gα gets dephosphorylated by the
intrinsic GTPase activity of Gα itself, and the latter is able to form a complex with Gβγ
again and to initiate further signalling events.
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Non G protein-dependent pathways On the cytosolic side of the phospholipidic
bilayer GPCRs do not only interact with G proteins. The first compelling evidence
that non G protein-dependent pathways are relevant in cell physiology was provided by
studying the angiotensin II type 1 receptor (AT1R) in mouse heart. Since GPCR IL2 is
fundamental for G protein coupling, AT1R IL2 mutant-overexpressing transgenic mice
were generated and their phenotype was characterised compared to a transgenic control
which overexpressed WT AT1R (Zhai et al., 2005).
In vitro studies on this AT1R-i2m (intracellular [loop] 2 mutant) already showed an im-
pairment of Gαq and Gαi dependent signalling, but retained capability to activate Src
kinases and ERK (Seta et al., 2002).
Mutant IL2 mice showed greater cardiac hypertrophy, cardiac dysfunction, and brady-
cardia, but less cardiomyocyte apoptosis and heart fibrosis than the AT1R overexpressing
mice upon chronic administration of angiotensin II. This demonstrated for the first time
that the impairment of G protein signalling does not result in total receptor inertia, and
that two physiological phenomena can contribute to signalling pathways both G protein
mediated and non mediated (Rajagopal et al., 2005).
Now we know that the principal G protein-independent signal transducers are arrestins
and GRKs. GRKs will be discussed in the context of phosphorylation of GPCRs, in the
next subsection.
Arrestins Arrestins are a small family of proteins which are important in the reg-
ulation of GPCR downstream signal transduction.
They were first discovered in the late 1980s as part of a conserved two-step mechanism
that regulates GPCR activity in rhodopsin (Wilden et al., 1986) and in the β-adrenergic
system (Lohse et al., 1990).
The most widely described role of arrestins is as a component in GPCR desensitisa-
tion: after GRKs (G protein coupled Receptor Kinases) phosphorylate the C terminus
of GPCRs, arrestins can bind the receptors and mediate their removal from the plasma
membrane and the uncoupling from G proteins.
This interaction between arrestins and GPCRs can activate different signalling cascades,
such as ERK (Extracellular signal-Regulated Kinase) phosphorylation (Kumari et al.,
2017), Akt (Ak mouse strain thymoma) ser/thr-kinase, Src (v-src avian sarcoma vi-
ral oncogene homolog) tyrosine-kinase, NF-κB (Nuclear Factor κB) and PI3K (Phos-
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phatidylInositol 3 Kinase) (Smith and Rajagopal, 2016a). The role of arrestins in these
pathways is mainly as an adaptor protein or scaffold (Eichel et al., 2016).
There are four different types of arrestins:
• Arrestin-1, also known as the S-Antigen (SAG) or visual arrestin, it is expressed
at high levels in both retinal rods and cones
• Arrestin-2, the first non-visual arrestin cloned, this was named β-arrestin as be-
tween rhodopsin and β2-adrenergic receptors, it showed preference for the latter
• Arrestin-3, due to its cloning chronology, was named β-arrestin2 as it was the
second non-visual arrestin discovered
• Arrestin-4, called also X-arrestin or cone arrestin, as it is a visual arrestin expressed
predominantly by cone photoreceptor cells
Every mammalian cell expresses one or more arrestins: arrestin-1 and -4 are confined to
photoreceptor cells in the retina, while arrestin-2 and -3 are ubiquitous.
1.1.4 Regulation of GPCRs
Since GPCR signalling is fundamental to many important cellular functions, a negative
feedback regulation is essential as agonist stimulation can be persistent. GPCRs have
two ways to regulate their signalling: desensitisation and internalisation.
Desensitisation prevents potentially detrimental effects that chronic overstimulation of
GPCR signalling can have on cells and tissues, while internalisation is a physical removal
of both ligand-bound and unbound GPCRs that usually results in a lower amount of
receptor.
Desensitisation
Desensitisation, or tachyphylaxis, is defined from the International Union of Basic and
Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification
(NC-IUPHAR) as the
spontaneous decline in the response to a continuous application of an agonist,
or to repeated applications or doses (Neubig et al., 2003).
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Tachyphylaxis is commonly used to describe the loss of response in vivo or in patients,
while desensitisation refers to in vitro experiments.
Almost every GPCR studied so far undergoes desensitisation. Studying desensitisation
is therefore useful for clinical purposes: if it occurs, the therapeutic effectiveness of drugs
may decrease over time. Overcoming it would improve sensitively the treatment of pa-
tients, especially those who suffer of chronic diseases, as the receptor targeting and hence
the whole therapy would not lose its effectiveness (Rosethorne et al., 2015).
Desensitisation occurs when two families of proteins act coordinately, GPCR Kinases
(GRKs) and arrestins (Drake et al., 2006), supporting the action of proteins required for
endocytosis and ubiquitination (Rajagopal and Shenoy, 2018). Indeed GRK-mediated
phosphorylation alone is not sufficient to uncouple GPCR and G protein, there is need
for β-arrestin recruitment: the arrestin acts to sterically hinder the receptor, preventing
further interactions with the G protein.
Desensitisation is finely tuned by the different isoforms of GRKs and arrestins, and by
the modulation of these proteins by further accessory proteins.
This phenomenon can be dissected into individual processes: receptor phosphorylation,
β-arrestin recruitment, receptor internalisation, receptor recycling and resensitisation or
receptor down-regulation. All of these steps contribute to an overall loss of the cells
ability to respond to agonists, though recent studies showed that, for example, inter-
nalised receptors can still signal from the endosome (Feinstein et al., 2013); furthermore,
β-arrestin itself can mediate a series of non-G protein-mediated signalling pathways
(Smith and Rajagopal, 2016b).
Phosphorylation and GRKs GRKs are a group of seven different proteins whose
main function is to phosphorylate the C-terminal of GPCRs to promote desensitisation.
GRK1 and GRK7 are expressed respectively in retinal rods and cones, while the expres-
sion of GRK4 is limited to cerebellar, testicular and kidney tissues. GRK 2, 3, 5 and
6 are ubiquitously expressed (Pitcher et al., 1998). GRK5 and GRK6 are consitutively
located to the plasma membrane, while GRK2 and GRK3 localise to the membrane due
to their binding to the Gβγ subunit of G proteins. GRK6 is associated with the plasma
membrane as a result of its palmitoylation (Drake et al., 2006).
GPCR phosphorylation does not depend on GRKs only: PKA and PKC (Protein Kinase
C) may play a role in this process too, even though their action might originate from
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a different receptor activation, determining what is called heterologous desensitisation
(Rajagopal and Shenoy, 2018).
GPCRs have been described as being phosphorylated on the C terminal and third intra-
cellular loop (Alfonzo-Me´ndez et al., 2016). The residues that can undergo this functional
modification are serine, threonine and tyrosine, which can differentially get phosphory-
lated according to the ligand bound to the receptor and to the expression system. The
effects of a specific phosphorylation event however is determined by the kinase that car-
ries out the phosphorylation and the location of the phosphorylated residue (Kohout and
Lefkowitz, 2003). These patterns are called “phosphorylation barcodes”and they might
be useful in defining signalling outcomes from receptor activation (Butcher et al., 2011).
Down-regulation GPCR down-regulation is the part of the desensitisation process
where the receptors eventually undergo proteolysis, the outcome of which is a decrease
in the number of receptors available for signalling. During down-regulation receptors
are dismantled in lysosomes and additionally their mRNA level often decreases. Ubiq-
uitin, a 76 amino acid protein, attaches to a GPCR promoting its degradation through
progress from early to late endosomes or maturing vescicules (Kennedy and Marchese,
2015). Before the actual degradation process takes place, ubiquitin-specific proteinases
remove the ubiquitin moieties from the receptor: this process occurs also during receptor
recycling to the cell membrane (Alfonzo-Me´ndez et al., 2016).
Recycling and resensitisation When GPCRs are incorporated into the membrane
of an endosome, most of them are dephosphorylated and return to the plasma membrane
as resensitised receptors, able to undergo another round of stimulation and signalling;
this process requires both dephosphorylation and dissociation of the β-arrestin (Krupnick
and Benovic, 1998).
The dephosphorylation of the receptors occurs in acidified vescicle compartments, and
the need to be internalised before resensitisation has been shown using mutants defective
of the ability to undergo endocytosis (Luttrell and Lefkowitz, 2002).
Internalisation
Internalisation of a GPCR results in a drop in the total number of receptors present on
the plasma membrane, often causing a reduction of the cellular response upon agonist
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treatment: it is one of the key processes of GPCR regulation (Ferguson, 2001). However
internalisation and desensitisation should not be viewed as in a causative relationship, as
the loss of receptor due to internalisation might be irrelevant to alter the overall function
of the receptor. Indeed, there are cases in which those two phenomena occur inde-
pendently (Koenig and Edwardson, 1997). Moreover, relatively recent studies reported
that some internalised GPCRs remain active and can sustain signalling (Feinstein et al.,
2013), (Thomsen et al., 2016).
Many internalisation pathways have been reported in different cell types, or in the same
cell type under different conditions. A significant number of GPCRs are characterised
by the presence of different internalisation motifs in their sequence, and likely other
trafficking-related motifs are yet to be discovered. Arrestins and trafficking proteins
compete for these sites, but there is no consensus relationship between said motifs and
specific internalisation pathway (Gurevich and Gurevich, 2006).
Agonist-dependent It is widely documented that upon agonist stimulation GPCRs
undergo internalisation within minutes. Indeed, the activated GPCR undergoes phos-
phorylation and β-arrestins are recruited. This interaction increases the accessibility of
the adaptor protein complex 2 (AP-2) to the C tail of the GPCR, which is involved in
the formation of clathrin-coated pits as it constitutes the adaptor between the receptor
and the clathrin monomers (Kohout and Lefkowitz, 2003).
Clathrin-mediated internalisation is not the only mechanism involved in agonist-dependent
internalisation, indeed GPCRs can be internalised through the formation of non-coated
membrane invaginations named caveolae (Nichols and Lippincott-Schwartz, 2001). Cave-
olae are associated with a family of cholesterol-binding proteins named caveolins.
Agonist-independent Agonist-independent internalisation has been observed for many
GPCRs, including angiotensin 1A (AT1A) receptor, cannabinoid type 1 (CB1) receptor,
α1-adrenergic receptor, CXCR4, mGlu1R and mGlu5R, M2 muscarinic receptor and thy-
rotropin receptor (Xu et al., 2007). It is referred to also as constitutive internalisation,
and it works more slowly than the agonist-dependent form (Drake et al., 2006).
Constitutive internalisation can occur both clathrin-dependently and -independently
(Fourgeaud et al., 2003).
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1.1.5 GPCR quaternary structures
Classical models of GPCR interaction with either ligands or intracellular early messengers
have generally depicted the receptors as monomeric units. Now, however, we know that
GPCRs can form homo- and hetero-oligomers, a phenomenon which has been described
for a large number of GPCRs (Milligan, 2007).
The first characterisation of GPCR oligomerisation was functional, and dates back to the
discovery that Gamma Amino Butyrric Acid class B receptor (GABAB) was actually an
obligate heterodimer between the two isoforms GABABR-1 and GABABR-2 (Jones et al.,
1998), (Kaupmann et al., 1998). Since then the potential of GPCR oligomerisation has
been recognised, and possible interactions investigated. The current models of GPCR
oligomerisation suggest the involvement of elements of TM1 for the interaction between
rows of dimers, and of TM4 as well as TM5 for key interactions between monomers
(Fotiadis et al., 2004).
Different techniques have been used to study homo- and hetero-merisation. Figure 1.3
summarises the techniques and the receptors by which oligomerisation has been reported.
The first proposed role for GPCR oligomerisation has been linked to G protein binding.
Indeed interaction models of rhodopsin with its G protein transducin demonstrated that
a dimer of receptors would be necessary to accomodate the G protein, as the monomeric
cytoplasmic surface of rhodopsin is too small to dock the α and the βγ subunits (Fotiadis
et al., 2006). A similar conclusion has been reached for the leukotriene B4 receptor BLT1,
whose model showed that the signalling unit was made of two receptors and the G protein
heterotrimer (Baneres et al., 2003).
Although the scientific debate regarding the authenticity of GPCR oligomerisation is still
ongoing for a number of these interactions, various research groups have asigned both
stuctural and functional roles to this phenomenon. The former includes proper receptor
folding, maturation and physiological delivery to the plasma membrane (Milligan, 2007).
Functional consequences of the formation of quaternary structures instead involve the
modulation of signalling, for instance, the orexin-1 (OX1) receptor co-expression with
the cannabinoid receptor CB1 has been shown to enhance the potency of orexin-A 100
fold in ERK phosphorylation compared to the treatment of OX1-only transfected cells;
furthermore, the inhibition of CB1 with its antagonist rimonabant reduced the synergistic
effect (Ellis et al., 2006), (Ward et al., 2011).
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Figure 1.3: List of techniques (top) used to study GPCR oligomers (Guo et al., 2017),
and list of GPCRs that are described forming homo- and hetero-oligomers (George et al.,
2002). For abbreviations: see “List of abbreviations”
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1.2 Chemokines and chemokine receptors
The word “chemokine” was created as a portmanteau between the words “chemotac-
tic” and “cytokine”, and describes a class of mostly secreted proteins of size 8-12 kDa.
The etymology of the word suggests that these ligands belong to the family of the cy-
tokines, and that they are involved in cell migration. Indeed their action is implicated
physiologically in phenomena such as leukocyte migration, organogenesis, hematopoiesis
and immunomodulation; pathologically they play a crucial role in inflammation, allergy,
autoimmune disease, cancer and in all the processes that start from innate immunity,
such as leukocyte recruitment to a full delivery of antigen-presenting cells to the effector
cells of the adaptive immune system, including the maturation of lymphocyte them-
selves(Chen et al., 2018).
They are secreted by stromal cells and leukocytes, but their heparin-binding properties al-
low them to be displayed to leukocytes in the capillary lumen by glycosaminoglycan(GAG)-
coated endothelial cells.
Chemokine ligands are classified by their primary structure into four subfamilies, which
are known as CC, CXC, XC and CX3C. The first cysteine residue encountered starting
from the N terminal of these molecules is involved in a disulphide bridge that is very
important for their tertiary structure and can be followed by a second cysteine residue
directly (CC), spaced by a random amino acid (CXC), spaced by three amino acids
(CX3C), or can lack a proximal second cysteine (XC). Furthermore they can be roughly
classified into homeostatic or inflammatory chemokines, depending on whether they play
a role in physiological cell trafficking or they are secreted on demand in response to an
inflammatory cue(Ransohoff, 2009).
Chemokine receptors are GPCRs belonging to the family of rhodopsin-like receptors, γ
subgroup, chemokine receptor cluster, according to the GRAFS classification. Cytoge-
netically these receptors are located in clusters on different chromosomes, suggesting a
common ancestral origin: this might be due to several local gene duplications combined
with genome duplications (Fredriksson et al., 2003). Chemokine receptors are divided
into “typical” and “atypical” chemokine receptors, according to their ability to elicit a
G protein-mediated response. Furthermore, typical chemokine receptors are discrimi-
nated by the class of chemokine they bind: CCR bind CC chemokines, CXCR bind CXC
chemokines, XCR bind XC chemokines and CX3CR bind CX3C chemokines (Figure 1.4).
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Figure 1.4: Chemokine receptors and their cognate chemokine ligands (Bachelerie et al.,
2014).
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1.2.1 Chemokine ligands
Currently 45 human chemokine ligands are recognised by IUPHAR (Bachelerie et al.,
2014). CC and CXC chemokines generally have a short N-terminal domain, usually 6-10
amino acids long, that precedes the first structural cysteine, followed by a long loop
(N-loop), a 310 helix, three β strands and a C-terminal α-helix 20-30 amino acids long
with a high degree of structural disorder (Rajarathnam et al., 1995), (Allen et al., 2007).
This structural arrangement is conserved within the subfamilies, even though the se-
quence identity is highly divergent. The XC chemokine group contains only two members,
lymphotactin-α and -β(XCL-1 and XCL2), while the only CX3C chemokine, fractalkine
(CX3CL1), is membrane bound.
CXC chemokines are further divided into ELR+ and ELR− subgroups, due to the pres-
ence and absence respectively of a three amino acid glutamate-leucine-arginine motif in
their N-terminal region before the first conserved cysteine. ELR+ CXC chemokines are
grouped on chromosome 4 in humans, and they are chemoattractants of neutrophils and
have been shown to contribute to wound repair: their function is to attract neutrophils
and induce degranulation and respiratory burst. Production and secretion of ELR+ CXC
chemokines is promoted by pro-inflammatory cytokines such as IL-1, TNF-α or microbic
PAMPs (Baggiolini, 2001).
Both ELR+ and ELR− CXC chemokines have been linked to wound repair processes.
Absence of CXCR4 or its ligand CXCL12 impairs the vascularisation of the gastroin-
testinal (GI) tract in mice and CXCR2 is expressed by endothelial cells during wound
healing (Romagnani et al., 2004).
CC chemokines number at least 28 (CCL1-28) and signal through 10 known CC chemokine
receptors (CCR1-10). They are known to have a key role in the recruitment of mono-
cytes and macrophages, which are involved both in acute and chronic inflammation,
atherosclerosis, rheumatoid arthritis and adipose inflammation (Charo and Ransohoff,
2006).
Due to their only conserved cysteine, XC chemokines exist in two different conformations
that are in equilibrium with one another. The monomeric state resembles the conven-
tional chemokine fold, while the other conformation is a four-stranded β-sheet which
forms when the usually extended N terminal regions pairs with the third β-strand in the
sheet (Sonay Kuloglu et al., 2002).
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CX3CL1 is a mucin-like membrane protein with an extracellular chemokine domain that
usually works as a tight adhesion molecule, the chemokine domain can detach from the
membrane anchor upon protease action and behave like a secreted chemokine (Woj-
dasiewicz et al., 2014).
1.2.2 Chemokine receptors
Chemokines exert their effect upon interaction with 7 transmembrane domain recep-
tors, some of which are G protein-coupled. Six G protein-coupled receptors have been
identified as being able to bind CXC motif chemokines, named CXCR1-6, while CC mo-
tif chemokine-binding receptors comprise ten known members, CCR1-10. One receptor
binds the two lymphotactin proteins, XCR1, and CX3CR1 has been described to bind
CX3CL1(Bachelerie et al., 2014).
Along with G protein-coupled chemokine receptors, a small subfamily of atypical chemokine
receptors (ACKRs) has been identified. The main anomaly resides in their inability to
elicit a G protein-dependent response to chemokine binding, hence they have been pos-
tulated since their discovery to have scavenging or decoy roles upon chemokine ligand
binding(Ulvmar et al., 2011).
Within the family, there is 25-80% amino acid sequence homology, high enough to consti-
tute an independent family, and diverse enough to demonstrate how wide said family is.
Chemokine receptors are generally 340-370 amino acids long; they are characterised by a
relatively short N terminus, usually presenting N-linked glycosylation sites and might dis-
play sulphation of tyrosine residues. The core of these receptors are the seven α-helical
trans membrane domains, linked by three intracellular and three extracellular loops.
There is a highly conserved amino acid motif localised between TM3 and IL2, which is
often referred to as DRYLAIV motif, whilst the third intracellular loop is characterised
by its short length and by the prevalence of basic residues. EL1 and EL2 are linked by
a disulphide bridge, formed between two highly conserved cysteine residues. The C ter-
minus is characterised by a short α-helix directly downstream of TM7, and the primary
structure of the C terminus itself contains serine and threonine residues that function as
phosphorylation sites, which are important for receptor regulation(Allen et al., 2007).
Chemokine ligands interact with their receptors through their N terminal domain and
the proximal rigid loop of the ligand backbone formed by the disulphide bridge be-
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tween their second and third cysteines. Furthermore, alterations to the N terminus of
the chemokines whose structure, when in complex with their receptor docks within the
transmembrane binding pocket, have been characterised as crucial in the conversion of
a chemokine ligand from a receptor agonist to an antagonist. Due to these features, the
N terminal region of a chemokine is often referred to as CRS2 (Chemokine Recognition
Site 2). Chemokine Recognition Site 1 (CRS1) refers instead to the globular core of the
chemokine ligand, which interacts with the N terminal region of the chemokine receptor.
The nomenclature CRS1 and CRS2 is the result of several studies which led to the the-
ory of a two-step binding mechanism. Indeed, the interaction of monomeric chemokine
ligands with their receptor starts from the recognition of their globular core (CRS1)
from the N terminal domain of the receptor, which upon binding docks the N terminal
part of the ligand (CRS2) into the transmembrane domain binding pocket, triggering
the signalling (Kufareva et al., 2015). This model, represented in Figure 1.5, can explain
why alterations of the N terminus of the chemokine can transform an agonist into an
antagonist.
C
C
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C CRS1
CRS2
C
C
C
C
Recognition of CRS1
C
C
C
C
Docking of CRS2
C
C
C
C
Signalling
Figure 1.5: Two-step recognition binding model. The aminoterminal domain of the
chemokine receptor with the CRS1 of the chemokine ligand allows the docking of the
CRS2 into the chemokine receptor, allowing the latter to transmit the signal intracellu-
larly.
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1.2.3 CXCR4
CXC-motif chemokine Receptor 4 (CXCR4) is the most studied chemokine receptor,
as it is involved in fundamental biological processes such as embryonic development,
haematopoietic cell trafficking, mature leukocyte homing and angiogenesis (Wang and
Knaut, 2014). It is involved in different immunopathologies, such as the congenital im-
mune deficiency WHIM, acts as a co-receptor for the T-tropic HIV-1 protein gp120 (Bal-
abanian et al., 2004), and furthermore its expression is upregulated in different neoplastic
conditions (Vela et al., 2015), (Balkwill, 2004b), including Waldenstro¨m macroglobuli-
naemia.
CXCR4 is able to signal through different types of G proteins, predominantly the ones
belonging to the Gαi/0 family, but it has been described as also able to recruit Gα13 (Tan
et al., 2006) (Yagi et al., 2011) (Kumar et al., 2011), Gαq (Soede et al., 2001) and β-
arrestins. Upon activation of the receptor, inhibitory Gα proteins lead to the inhibition
of the adenylyl cyclase, reducing the amount of intracellular cAMP and the activity of
cAMP-dependent protein kinases. Gα13 protein signalling has been identified during Ju-
rkat T cell migration, where together with Rac, Rho GTPase was activated (Tan et al.,
2006), as well as in CXCR4-induced metastatic basal-like breast cancer cells (Yagi et al.,
2011). Activation of PLC-β (thus Gαq activation) was observed downstream of CXCR4
stimulation only in dendritic cells and granulocytes (Soede et al., 2001), suggesting that
the cellular context can have an impact on the signalling of a GPCR.
Non G protein-dependent signalling via CXCR4 is mediated by β-arrestins, which in-
fluence its internalisation, G protein signalling and chemotaxis. β-arrestin1 and 2 are
recruited once GRKs phosphorylate the intracellular side of the receptor, initiating the
formation of clathrin-coated pits. The C terminal region of CXCR4 is clearly involved
in the binding of β-arrestin, as shown by the congenital disease named WHIM (Warts,
Hypogammaglobulinaemia, Immunodeficiency, Myelokathexis) syndrome, whose patho-
genesis resides in a truncation of the CXCR4 C tail. WHIM patients’ cells are unable
to down-regulate CXCR4 expression on the membrane, resulting in a gain-of-function
phenotype that prevents mature granulocytes from leaving the bone marrow niche and
this leads to a chronic noncyclic neutropenia. However, the CXCR4 C tail is not the
only docking site for β-arrestin recruitment. Indeed residues on internal loop 3 (IL3) of
CXCR4 were also described as being sites of arrestin recruitment (Cheng et al., 2000),
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(Gustavsson et al., 2017).
The first whole genome sequencing (WGS) study of Waldenstro¨m macroglobulinemia
(WM) patients highlighted that nonsense mutations 20 amino acids upstream of the
physiological stop codon of CXCR4 and frameshift mutations of a region up to 40 amino
acid upstream of the same were almost equally frequent in patients. The driving force
for this disease is a gain-of-function mutation in MYD88, present in 90% of the patients,
but CXCR4 C tail mutations accounted for almost 30% of the cases, 98% of which were
concurrent with MYD88 (Myeloid Differentiation primary response 88) mutations. This
was the first report of WHIM-like mutations of CXCR4 in cancer (Treon et al., 2014).
WM indeed is a type of B cell proliferative disease (lymphoplasmacytoid tumour) half
way between non-Hodgkin lymphoma (lymphoid tumour) and multiple myeloma (plas-
macytoid tumour), in which cancerous WM cells grow in the bone marrow and can crowd
out the hemoatopoietic stem cells from their niche. This can lead to a drop in the level of
red blood cells (anemia), leukocytes (immune deficiency), platelets (thrombocytopenia)
and usually results in weak and fatigued patients with high susceptibility to bruising,
to excess bleeding and with problems in fighting infections. These cells produce large
amounts of IgM antibodies (macroglobulins), which thicken the blood and give symp-
toms such as alteration in vision, headaches, vertigo and changes in the mental status,
however blood tests for IgM level evaluation are pathognomonic and differential diagno-
sis can be made upon CT or X-ray scans of bones or soft tissue(Treon et al., 2014).
CXCR4 has been intensively studied because of its role in T-tropic HIV-1 infection of
T cells, even before its identity as a chemokine receptor was known. HIV-1 gp120 is an
envelope protein that binds with high affinity to CD4, a 55 kDa membrane protein found
predominantly on a subset of T cells named T helper (Th cells), but expressed also on
the surface of monocytes/macrophages and dendritic/Langerhans cells(Zaitseva et al.,
1997). As gp120 binds to CD4, gp120 itself undergoes a conformational change that
promotes its binding to one of the two major co-receptors (which are both chemokine
receptors), CCR5 if the HIV-1 strain is M-tropic (monocyte/macrophage tropic, named
also R5 virus), or CXCR4 if it is T-tropic (named also X4 virus). Many strains though
are dual tropic, as they can utilise both the CXCR4 and CCR5 receptors (named R5X4
viruses) (Bleul et al., 1997). Binding to the chemokine receptor leads to a process called
fusion, due to the exposure of another envelope protein named gp41 which anchors and
penetrates the target cell membrane and brings the virion together with the cell. CXCR4
35
Chapter 1. Introduction
is crucial for the fusion process, and so because of that one of its alternative names has
been “fusin”(Endres et al., 1996).
Several cancer cell types show alterations in CXCR4 expression, in some cases correlating
with an enhanced ability to invade other tissues and metastasise, therefore resulting in
a more aggressive phenotype, and lower disease-free and survival rates (Liu et al., 2009),
(Iwasa et al., 2009), (Liang et al., 2010). Overexpression of CXCR4 has been found in
more than 23 different human cancer types, such as blood, lung, brain, kidney, ovary,
pancreas and skin neoplastic diseases (Balkwill, 2004a).
Some of the upregulation mechanisms of CXCR4 have been described and are cogent
to what is known about cancer biology. Hypoxia-induced factor-1α (HIF-1α) activa-
tion, stimulation with basic fibroblast growth factor (bFGF), vascular endothelial growth
factor (VEGF) and epithelial growth factor (EGF), and activation of transcription fac-
tors such as nuclear respiratory factor-1 (NRF-1) are all events described both prior
to CXCR4 upregulation and, even if not present all at the same time within the same
neoplasia, in cancer growth (Phillips et al., 2005), (Wigerup et al., 2016), (Zhuo et al.,
2012).
The induction of the aggressive phenotype upon upregulation of CXCR4, resides in the
ability of the cells to hijack the CXCR4/CXCL12 signalling axis in order to facilitate
distant organ metastasis. This is supported by 1) common metastasis sites, such as
brain, liver, bone marrow and lung, express high levels of CXCL12, and 2) signalling im-
pairment of the CXCR4/CXCL12 axis significantly reduced the formation of metastases
in murine models of cancer (Chatterjee, Azad and Nimmagadda, 2014).
CXCR4 plays a significant role in embryo development, as CXCR4 knock-out (KO)
mice show aberrant vascular formation in the intestine (Tachibana et al., 1998), cardiac
ventricular malformations (Ivins et al., 2015) and abnormal migration of the cerebellar
neurons (Qing et al., 1999), (Zou et al., 1998), together with a severe impairment of
haemopoiesis, concerning particularly the myeloid progenitors and the B lymphoid lin-
eage (Qing et al., 1999). As a result of these developmental phenotypes, CXCR4 KO
mice die perinatally (Janssens et al., 2018).
The expression of CXCR4 in myeloid progenitors is decreased as the maturation of the
cells proceed. This observation, that CXCR4 is involved in hemopoiesis as it helps to
retain immature cells into the bone marrow hemopoietic niche until they reach a mat-
uration stage in which CXCR4 expression decreases and allow their release into the
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bloodstream, led to a breakthrough in clinical practice. A CXCR4 antagonist, named
plerixafor, was developed, and its main use in healthy volounteers is to allow hemopoietic
stem cell mobilisation from the bone marrow for transplantation to patients who received
immunodepletion treatments mainly as a therapy against blood cancer.
The physiological ligand of CXCR4 is the chemokine ligand Stromal-Derived Factor-1
(SDF-1), mainly known now as CXCL12 (CXC motif chemokine ligand 12). CXCL12 is
an ELR− CXC chemokine, expressed ubiquitously in most tissues and cells. It binds to
CXCR4, to the atypical chemokine receptor ACKR3 and to glycosaminoglycans (GAGs).
Human CXCL12 exists in six different splice variants (α to φ), each of which has a spe-
cific tissue distribution and activity (Janssens et al., 2018). CXCL12 KO mice display
similar hemopoietic, neurogenetic and cardiac phenotypes as CXCR4 KO, linking their
pharmacology to physiology.
Kaposi’s sarcoma Herpes virus, or Human Herpesvirus 8 (KSHV or HHV8) is a gamma-
herpesvirus which, upon infection, activates the production of a CXCR4 antagonist,
named v-MIP II or v-CCL2 (viral Macrophage Inflammatory protein II, or viral CC mo-
tif chemokine ligand 2). v-CCL2 works in concert with the other two viral chemokines
(vMIP I/v-CCL1 and vMIP III/v-CCL3) to antagonise the Th1-mediated antiviral re-
sponse: vCCL2 in particular acts as a neutral ligand to many chemokine receptors, in-
cluded CXCR4, and contributes to the immune evasion due to the blockade of chemokine-
mediated responses to viral infection (Nicholas, 2010).
Synthetic ligands, such as the already mentioned plerixafor (or AMD3100) and isothiourea-
1t (IT-1t), were initially developed as T-tropic HIV-1 blockers, but they failed to show
efficacy during clinical trials (Hendrix et al., 2004).
1.2.4 CXCR7/ACKR3
Atypical Chemokine Reeptor 3 (ACKR3), called also Receptor Dog cDNA-1 (RDC-1)
or CXC-motif chemokine receptor 7 (CXCR7), is a relatively new component in the
CXCR4/CXCL12 axis, being characterised by its interaction with CXCL12 only in 2005
(Balabanian et al., 2005). Unlike CXCR4, upon CXCL12 binding ACKR3 does not elicit
G protein dependent signalling, resulting only in β-arrestin recruitment. Indeed ACKR3,
like other atypical chemokine receptors, shows an altered DRYLAIV motif between TM3
and IL2, presenting a DRYLSIT sequence instead; however this is not the only obsta-
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cle to G protein recruitment. A chimeric version of ACKR3 with the DRYLAIV motif
has been engineered and its signalling characterised. However, it also failed to show
CXCL12-mediated G protein activation, intracellular calcium mobilisation, ERK phos-
phorylation or chemotaxis (Hoffmann et al., 2012), (Naumann et al., 2010).
G protein coupling though is not totally ruled out, as evidence has shown a BRET signal
between ACKR3-eYFP and Gαi2 that decreased upon treatment with GTP-γS, suggest-
ing that ACKR3 recruits Gαi/0 proteins during the resting state, but fails to activate
them (Levoye et al., 2009).
A large amount of literature describes ACKR3 as a decoy receptor for CXCL12, efficiently
internalising the ligand and shaping the extracellular chemokine gradient necessary for
CXCR4-mediated migratory responses (Boldajipour et al., 2008), (Dambly-Chaudie`re
et al., 2007). Upon CXCL12 treatment ACKR3 can recruit β-arrestin and result in Akt
and ERK activation and phosphorylation, together with JAK2/STAT3 (Janus Kinase
2/Signal Transducer and Activator of Transcription 3) activation (De´caillot et al., 2011),
(Hattermann et al., 2010), (O¨demis et al., 2012), (Rajagopal et al., 2010), (Torossian
et al., 2014), (Torossian et al., 2014). CXCL11 treatment induces β-arrestin recruit-
ment as well, showing ERK phosphorylation in HEK293 cells overexpressing ACKR3;
however, stimulation of untransfected rat vascular smooth muscle cells expressing en-
dogenous amounts of ACKR3 with CXCL11, failed to show phosphorylation of ERK
(Rajagopal et al., 2010), indicating the importance of the cellular context.
Unlike typical chemokine receptors, activation of ACKR3 does not actively drive cell
chemotaxis, but it triggers mainly internalisation pathways which have an indirect effect
on chemokine-dependent cell migration as the removal of part of the chemokine ligands
present in the microenvironment helps shape the gradient.
In the resting state, ACKR3-only transfectants express the receptor mostly on the mem-
brane of endocytic vescicles. A study showed that shortening the receptor C-terminal tail
in ACKR3-GFP resulted in an increased plasma membrane localisation by up to 100%
when the whole domain was missing (Ray et al., 2012). Receptor internalisation is β-
arrestin-, clathrin- and dynamin-dependent, thus in the presence of a dominant negative
dynamin (K44A dynamin mutant), all ACKR3 expression is localised on the cell surface.
This does not alter constitutive β-arrestin recruitment, but upon CXCL12 treatment, β-
arrestin recruitment significantly increased and ERK phosphorylation lasted significantly
longer. Therefore, ACKR3 is able to signal when located exclusively to the plasma mem-
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brane without the chance to be internalised (Ray et al., 2012).
Unlike CXCR4, whose expression decreases over time upon treatment with CXCL12,
ACKR3 membrane expression undergoes a slight decrease before being restored in the
presence of persistent stimulation with the chemokine ligand, after which it can resist
depletion from the plasma membrane for a prolonged time. Furthermore, through ra-
dioligand internalisation studies it was demonstrated that ACKR3 brings its chemokine
ligands to degradation, confirming its role as a scavenger receptor (Naumann et al.,
2010).
During embryo development, the chemokine distribution in the right place at the correct
time is crucial in lineage commitment, organogenesis and chemotaxis. The importance
of ACKR3 in development started to be investigated after the discovery that CXCL12
could bind this receptor. One of the first studies in vivo used the zebrafish embryo model.
The knock-down of ACKR3 through specific morpholinos resulted in an impairment of
the migration of primordial germ cells (PGCs), resulting in defective gonad development
(Boldajipour et al., 2008).
Almost simultaneously, ACKR3-KOmice were created and their unusual phenotype char-
acterised, More than 95% of the Cxcr7−/− mice died within 24 hours after birth, showing
abnormal heart valve development and an impaired expression of the angiogenic factor
Hbegf and of adrenomedullin in cardiac valves (Sierro et al., 2007).
Adrenomedullin genome duplications (Admhi/hi) in mice phenocopied the cardiac defect
seen in Cxcr7−/− mice, suggesting a link between the expression and/or the interaction
of the two proteins. Genetic dosage of the two molecules obtained by crossing mice
with mono- or bi-allelic adrenomedullin duplication or ACKR3 deletion reported pheno-
types with variable severity, further corroborating the hypothesis of an interdependence
between adrenomedullin and ACKR3. Furthermore, ACKR3-transfected HEK293 cells
displayed the ability to internalise biotinyl-adrenomedullin, providing stronger evidence
that adrenomedullin can be considered a ligand for ACKR3 (Klein et al., 2014).
ACKR3 has been reported to be expressed in several types of malignancies, such as lung,
brain, pancreatic and prostate cancer (Liu et al., 2013), (Heinrich et al., 2012), (Kallifa-
tidis et al., 2016).
Arteries upregulate the expression of ACKR3 following injury, and after myocardial in-
farction this promotes ischemia-induced angiogenesis and endothelial cell proliferation
(Hao et al., 2017). Moreover, in atherosclerotic plaques ACKR3 is expressed by res-
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ident macrophages and its expression is involved in their phagocytic activity through
MAPK-mediated signalling (Chatterjee, Borst, Walker, Fotinos, Vogel, Seizer, Mack,
Alampour-Rajabi, Rath, Geisler, Lang, Langer, Bernhagen and Gawaz, 2014).
Diabetic db/db circulating endothelial progenitor cells were isolated from the bone mar-
row and transfected to express more ACKR3 or to silence its expression. Both in vitro
and in vivo, their ability to generate new vessels during angiogenesis correlated with
the amount of ACKR3, revealing that this receptor is protective in hind limb ischemia
models (Dai et al., 2017).
HIV-1 and -2 gp120 proteins have been described as using ACKR3 as a co-receptor
(Shimizu et al., 2000) for viral envelope fusion with the plasma membrane, this has been
successfully inhibited in vitro using monoclonal antibodies targeting ACKR3 (D’huys
et al., 2018).
ACKR3 binds human chemokine ligands CXCL12 and CXCL11, the former of which has
been already discussed in the previous section. Human CXCL11, previously known as
Interferon-inducible T-cell alpha chemoattractant (I-TAC), is an ELR− CXC chemokine
whose expression is highly increased in response to interferon-β and -γ stimulation. Its
cognate typical chemokine receptor is CXCR3, and its role is mainly as a chemoattractant
for activated and memory T cells during the cell-mediated adaptive immune response.
Many studies have investigated the physiological implications of CXCL12/ACKR3 in-
teraction, while CXCL11/ACKR3 interaction has been characterised only pharmacolog-
ically (Quinn et al., 2018).
Non-chemokine endogenous ligands of ACKR3 include adrenomedullin, BAM22 peptide,
peptide I and peptide E from the adrenal opioid proenkephalin A gene.
Adrenomedullin is a vasodilator peptide belonging to the family of calcitonin-related
genes, and the study that first linked it to ACKR3 has been mentioned previously.
BAM22, peptide I and peptide E can activate β-arrestin recruitment through ACKR3
and modulate the circadian glucocorticoid oscillation, revealing a role of ACKR3 also in
human emotional behaviour (Ikeda et al., 2013).
Viral chemokine v-MIP II/v-CCL2, together with CXCR4, can also interact with ACKR3
(Szpakowska et al., 2016).
Attempts to design synthetic antagonist ligands against ACKR3 have been made, but
most of those molecules instead also function as receptor agonists (Wijtmans et al., 2012).
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1.2.5 Clinical significance of CXCR4 and ACKR3 targeting
One of the aspects of biomedical research is the impact of every discovery in a transla-
tional perspective, thus how something that occurs consistently at a lab bench can be
translated to a clinical setting.
Due to the physiological roles of CXCR4 and ACKR3, their targeting to date concerns
HIV gp120-mediated envelope fusion, metastasis and angiogenesis, the latter being re-
lated both to neoplastic and non-neoplastic diseases.
This thesis project was intended to investigate the oncological research field, thus greater
relevance will be given to the metastatic and angiogenetic aspects of chemokine receptor
targeting.
Cancer
Cancer is a very generic term that encompasses more than 270 different diseases. This
occurs as cancer can develop from virtually any type of human cell, hence the wide
variety, but it maintains a number of features that are universal to all the diseases,
which are referred to as “the hallmarks of cancer”. Even though each cell type differs
from one another, all the cells at some point undergo the same series of events during
duplication, they all are ruled by the same molecular checkpoints of the cell cycle, they all
live thanks to oxygen and the same classes of nutrients, they all can commit for apoptosis
if they receive determined stimuli. Likewise, cancer cells have common capabilities, which
according to the latest literature revision (Hanahan and Weinberg, 2011) are:
• Resist apoptosis
• Sustain mitogenic signaling
• Resist growth suppression
• Induce the formation of new vessels
• Resist anti-proliferative signals
• Activate invasion and metastasis
• Enable immune evasion
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• Reprogram cellular metabolism
• Accumulate genomic mutations (genomic instability)
• Support the inflammatory responses that facilitates the evolution of the tumour
Metastasis Metastases are neoplastic entities, which can be single cells as well as
masses, that have left the primary tumour site to reach different regions of the anatomy.
They are the major cause of death in cancer patients.
The expression of CXCR4 on tumour cells generally correlates with a more aggressive
phenotype (Zhao et al., 2014), (Zhao et al., 2015), meaning that the expression of this
chemokine receptor can be a biomarker of cells with high metastatic potential. The
role of ACKR3 in metastasis is not yet elucidated, as in non small cell lung carcinoma
(NSCLC) models it has not been conclusively implicated in CXCL12-CXCR4 dependent
behaviour (Choi et al., 2014), however, in a model of breast cancer the expression of
ACKR3 mitigated the metastatic phenotype due to CXCR4 (Hernandez et al., 2011),
while in another breast cancer model its activation promoted metastasis (Miao et al.,
2007). Therefore, further studies will be needed to assess its role in tumour metastasis.
Angiogenesis Mammal cells require a consistant provision of oxygen and nutrients
in order to survive, and this explains why blood vessels are the first organ to develop
in the embryo, and why the vascular network is the most extended organ in the body
(Carmeliet and Jain, 2000). Two processes regulate the initiation, extension and main-
tainance of the vessels: vasculogenesis and angiogenesis. Vasculogenesis occurs early
during embryo development, and is defined as the de novo generation of primitive ves-
sels, which will constitute the artero-venous system later on. Angiogenesis instead is
the formation of capillaries originating from pre-existing vessels and can occur at any
moment in a lifetime, from the extension of the primitive vasculature in the embryo to
the physiological neo-formation of vessels in post-natal life (Carmeliet, 2000), including
chronic inflammation- or tumour-induced vessel formation (Liekens et al., 2001).
The main components during this process are endothelial cells, soluble factors and extra-
cellular matrix (ECM) components. The angiogenic cascade starts with the activation
of endothelial cells in response to a hypoxic cue or a release of angiogenic and chemoat-
tractant factors. The vessels in close proximity to the stimulation source increase their
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permeability and lose most of their intercellular connections; also endothelial cells se-
crete proteases that degrade the basal membrane and the ECM, which favours cell mi-
gration. Endothelial cells proliferate and differentiate towards the area from which the
angiogenic stimulus originated, matching the neo-capillary tips coming from the corre-
sponding anastomotic vessel (arterious capillary with venous capillary). The primitive
tube then matures and all the structures required for the correct function of a capillary
vessel (i.e. pericytes, smooth muscle cells, basal membrane) are recruited (Risau, 1998).
Angiogenesis is a finely tuned phenomenon, which has master positive and negative reg-
ulators together with minor but not less important modulators.
VEGF and angiopoietins are the most important direct positive regulators of angio-
genesis, and act in concert with chemokines, cytokines and growth factors that con-
tribute to cell proliferation and migration toward the origin of the angiogenic cue.
Angiostatin, endostatin, trombospondin-1, interferon-γ, platelet factor-4, plasminogen
activator-inhibitor are all soluble inhibitors of angiogenesis, whose activity is either to
prevent growth factors binding to their receptor, or to inhibit ECM proteases (Carmeliet
and Jain, 2000).
Tumors, like healthy cells, need oxygen and nutrients to grow, thus the need for vascu-
larisation increases with tumour size. At the very early phases tumours can be avascular,
but as soon as the mass grows it acquires an angiogenic phenotype: the ability to trigger
a new vascular network around itself constitutes one of the hallmarks of cancer (Hana-
han and Weinberg, 2011). Tumor vessels are architecturally different from physiological
vessels, as they lack a complete and organised basal membrane, their structure is un-
organised, and the vessels are collapsed and scarcely differentiated. The structure does
not show any advantage concerning the provision of oxygen and food to the tumour, but
it allows an easy access to the bloodstream for the neoplastic cells (Kleiner and Stetler-
Stevenson, 1999).
Adrenomedullin (Ochoa-Callejero et al., 2016) and CXCL12 are both pro-angiogenic fac-
tors, and they are both able to interact with ACKR3. Thus targeting ACKR3 to prevent
the interaction with adrenomedullin and CXCL12 might add to current cancer multi-
therapy a further pathway to block, and may contribute to the overall control of the
neoplastic disease.
Angiogenesis might also be targeted for different conditions, for example post myocardial
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infarction (MI) ischemia or diabetes with microvascular complications.
In the context of myocardial infarction, activation of ACKR3 promoted post-ischemic
angiogenesis, increasing the survival, heart function and remodeling in mice (Hao et al.,
2017), suggesting that targeting ACKR3 as soon as possible after MI might offer cardiac
protection.
Microvascular complications of diabetes are due to both abnormal neo-vascularisation
(diabetic retinopathy) and to a lack of efficient neo-vascularisation (decreased response
to hypoxia, peripheral ischemic events and lack of endothelial regeneration). Endothe-
lial progenitor cells (EPCs) are the key players in post-ischemic neo-vascularisation, in
that they express ACKR3, and this expression in the EPCs of patients correlates with
their ability to contribute to angiogenesis and re-endothelisation (Dai et al., 2017). In
this case, ACKR3 might constitute a quantitative marker to be considered for EPC
transplantation in treating diabetic limb ischemia.
1.3 CRISPR/Cas9
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) are short se-
quences in prokaryotic genomes that work as an adaptive immunity strategy in bacteria
(Ishino et al., 1987). Indeed, as for eukaryotic adaptive immunity, it involves a genome
rearrangement whose consequence is the triggering of a pathogen-specific response that
impairs the biology of the pathogen itself, in an attempt to eliminate the causes of the
immune response. The main biological enemies of bacteria are viruses, called bacte-
riophages or phages. The strategy of the phages involves attachment to the bacteria
cell wall and the injection of viral DNA: viruses are not able to self-replicate, thus the
aim of this attack is to hack the bacterial machinery for DNA replication and protein
translation and give rise to new viral particles. However bacteria are not defenseless:
indeed they have at their service the Cas (CRISPR-associated gene) enzymes system,
which includes polymerases, nucleases and helicases. Cas proteins can detect exogenous
dsDNA (double stranded DNA), break it into small pieces (usually around 30 bp long)
and integrate it in the CRISPR Array sequence. The transcription of these sequences
is then processed as short crRNAs (CRISPR RNAs), which are joined with a tracrRNA
(transactivating crRNA) forming a sgRNA (single guide RNA, called also guide RNA
(gRNA)), loaded on other Cas protein complexes that, through sequence homology, can
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target and specifically cleave foreign dsDNA sequences upon re-exposure (Barrangou
et al., 2007), generating a double strand break.
1.3.1 Rationale of DSB induction for genome editing
The potential of CRISPR was long neglected, until in 2012 it was demonstrated that
this system could be programmed to target DNA cleavages in vitro, and in 2013 the
first CRISPR genome editing protocol was described for cell cultures (Jinek et al., 2012),
(Cong et al., 2013), (Mali et al., 2013). Transfected Cas9 loaded with gRNA generates
a double strand break in regions highly homologous to the guide itself, which works as
a template. A very important part of the guide RNA is the protospacer adjacent motif
(thereafter PAM), which is a set of 3-nucleotide long species specific sequences that need
to be upstream of the homology region and that is where the cut is localised. Automatic
software now exists that can detect the most suitable regions of a given gene and design
different guides according to the species of the Cas9 of choice.
The double strand break (DSB) generated by a loaded Cas9 can be employed in two
ways, as summarised in Figure 1.6: either the generation of a knock-out (KO), or the
generation of a knock-in (KI), exploiting two mechanisms of cellular DNA repair that are
respectively the non-homologous end joining (NHEJ) and the homology directed repair
(HDR).
The NHEJ is the prevalent pathway of DNA DSB repair, and almost all repairs hap-
pening when the cell cycle is not in phases G2 or S belong to this category (Beucher
et al., 2009). The DSB is recognised and bound early by the heterodimer Ku (Ku70 and
Ku80), which can recruit Artemis and DNA-dependent Protein Kinase catalytic subunit
(DNA-PKcs) nucleases with greater affinity than the DSB itself (Meek et al., 2008).
These nucleases are needed since the direct ligation of the DSB ends can be prevented
by nucleotide matching incompatibility or chemical modification of the bases, and thus
their role is mainly to prepare the ends for ligation (Pannunzio et al., 2018). When the
Ku-DNA complex recruits the nucleases complex, DNA-PKcs self-phosphorylates and
activates Artemis (Ma et al., 2002). Active Artemis can cut all the DNA structures that
differ from a stable double strand (Chang et al., 2016). After the double strand ends
are stabilised, DNA polymerases belonging to the family of Polymerases X participate
in the process. DNA Pol μ and Pol λ are attracted to the Ku-DNA complex, and can
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incorporate both dNTPs and rNTPs (Nick McElhinny and Ramsden, 2003) in both a
template-dependent and template-independent manner (McElhinny et al., 2005) in order
to create a stable ligatable joint. DNA ligase IV (Lig4), in complex with the enzyme X-
ray repair cross-complementing 4 (XRCC4), constitutes a central component in NHEJ.
In particular, XRCC4 stimulates the activity of Lig4 (Grawunder et al., 1997). XLF (or
XRCC4-like factor) and PAXX (PAralog of XRCC4 and XLF) are other two proteins
which are reported to participate in the ligation process, in particular XLF can interact
and contribute to the formation of the complex XRCC4-Lig4 (Ahnesorg et al., 2006) and
PAXX can interact with Ku (Ochi et al., 2015).
HDR (Moynahan and Jasin, 2010) instead is a process that takes place mostly during
phases G2 and S of the cell cycle in the proximity of a replication fork, when a ho-
mologous sequence is available (usually the sister chromatid) to the site of DSB. The
DSB begins processing by the complex MRN (MRE11/RAD50/NBS1), which acts as
an exonuclease able to create single stranded 3’ overhangs from the broken dsDNA end,
together with EXO1 and other exonucleases. The overhang is then bound by RPA, which
is then replaced by RAD51: at this stage these nucleoprotein filaments search and invade
homologous sequences. Upon action of the helicase SRS2, RAD51 dissociates and the
base-pairing of the invading and complementary donor strands takes place, together with
the subsequent strand extension by DNA polymerase. The freshly repaired strand then
either dissociates and anneals with the processed end of the non-invading strand on the
opposite side of the DSB, or if both ends invaded the donor filament, a double Holli-
day junction is produced, which is resolved to crossover or non-crossover recombinants
(Mimitou and Symington, 2009).
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Figure 1.6: Cas9 role in CRISPR. Cas9 dependent double strand breaking allows
the process of genome editing: when Cas9 and its gRNA are the only player in the
reaction (left), the DSB undergoes the non homologous end joining pathway, leading to
the formation of indels at the level of the DSB site and most likely generating a knock-
out of the target sequence. When a donor DNA participates in the reaction, the DSB is
more likely to undergo homology-directed recombination, which allows the generation of
a knock-in in the target sequence.
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1.3.2 Applications of CRISPR
The ability of Cas9 (and the other CRISPR enzymes) to generate a DSB and the knowl-
edge of the repair mechanism provided an essential boost to the development of CRISPR
technology. Indeed, by introducing a double strand break using Cas9 loaded with a guide
targeting a specific gene sequence, NHEJ will produce deletion and/or random insertions
in the gene, likely generating a frameshift and giving rise to a premature stop codon in
the mRNA resulting from the transcription of that gene. The result of this is a gene
knock out. Introducing a guide-loaded Cas9 together with a ssDNA homologous to the
targeted region but carrying a mutation or an insertion, HDR will contribute to the for-
mation of an edited version of the gene, which results in the generation of a specifically
mutated or tagged protein (knock in). The advantage of CRISPR generated KI is the
fact that the resulting protein is less subject to alteration of expression. This allows the
study of the behaviour of the protein itself in a context which is much closer to the real
physiology than a normal overexpression system (Cong et al., 2013).
The study of Cas9 mutants led to more applications, for instance dCas9 (nuclease dead
Cas9) was obtained as the result of two point mutations in the active sites of the enzyme,
D10A and H840A. The result is a Cas9 that is able to bind to a DNA strand comple-
mentary to its gRNA, but when it is bound to the non-coding strand it prevents the
transcription of the target sequence, modestly silencing the expression of the sequence
targeted (Qi et al., 2013).
Advances in CRISPRi, namely CRISPR-mediated interference, involve the fusion of
dCas9 to a KRAB (Kru¨ppel associated box) repressor domain, which works as a DNA
binding-dependent transcriptional repressor when fused to a heterologous DNA-binding
protein (Margolin et al., 1994). This approach is analogous to RNA interference tech-
niques, but instead of degrading RNAs the role of dCas9 is to hamper RNA polymerase-
mediated transcription. If the fusion protein of dCas9 with KRAB targets a promoter
region, the repression effectiveness is increased compared to dCas9 alone. However, not
all the gRNAs targeting the promoter give the same effectiveness, thus studies using this
system should use multiple gRNAs (Gilbert et al., 2013).
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1.4 Aim of the thesis
CXCR4 and ACKR3 represent, as described in the previous sections, potential ther-
apeutic targets for different types of human cancers and for tackling HIV-1 infection.
However, the mechanisms by which they signal remain poorly-characterised, as well as
the outcome that the two receptors can promote by acting in concert. As a consequence,
this thesis aimed to address the following research questions.
How do CXCR4 and ACKR3 signal upon stimulation by different ligands? Does their
response influence one another? To address these questions the project started with the
generation of BRET sensors: for G protein-dependend signalling the constructs were con-
stituted by the receptor (either CXCR4 or ACKR3), a BRET couple (Renilla Luciferase
and eYFP) and the α5 helix of either G protein, which is the domain of said signalling
molecule responsible for the interaction with GPCRs; for non-G protein-dependent sig-
nalling β-arrestin2 recruitment was chosen as readout.
Further, questions related to the behaviour that these receptors gives to the cells arose.
Since chemokines are responsible for cell migration triggering classic receptors, how does
the removal of the atypical receptor contribute to this phenomenon? In cancer, how does
the overexpression of ACKR3 contribute to the severity of the disease? The CRISPR
genome editing technique was used to generate Knock-Outs (KOs) to try to infer an
answer to these questions.
In parallel, a more recently characterised and debated ligand of ACKR3, namely adrenomedullin,
made its entrance in the literature with a work (Klein et al., 2014) that clearly demon-
strates that ACKR3 is involved in the clearance of said ligand during development. Does
adrenomedullin actually interact with ACKR3? Can this ligand be responsible for the
abherrant expression of this receptor in many cancer models? To disentangle these ques-
tions a library of extracellular-domain mutants to alanine was generated and the results
modelled externally.
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The following antibodies were purchased: mouse anti-hCXCR4 clone 12G4 (unlabelled
and APC-labelled) from BD Pharmingen, mouse anti-hACKR3 clone 8F11-M16 (unla-
belled and PE-labelled) and rat anti-mKi67 clone 16A8 from Biolegend, goat anti-GFP
clone ab5450 and rabbit anti-hCXCR4 clone ab124824 from ABCAM, and mouse anti-
hACKR3 clone 11G8 from R&D Systems.
All antibodies were used according to the manufacturers’ instructions.
The E. coli strain XL-1 blue was purchased from Agilent.
Cell lines Jurkat and LLC were purchased from ATCC, HEK293T were a kind gift from
prof. Martine Smit (VU Amsterdam), Flp/In-TREx 293 were bought from Thermofisher
Scientific.
The following kits were purchased: QuickExtract Solution (Lucigen), Monarch Miniprep
Kit (New England Biolabs), Wizard SV plus (Promega) miniprep kit, PureLink HiPure
Plasmid purification kit (InvitroGen) midiprep kit, QIAprep miniprep, midiprep and
maxiprep kit and QIAquik gel extraction kit (Qiagen).
Plasmid px461 and pcDNA3 was purchased from Addgene, plasmids pcDEF3-CKR
(Chemokine receptor) were a kind gift from prof. Martine Smit (VU Amsterdam),
plasmids pcDNA5-FRT/TO-SPASM and pcDNA3-βArr2-RLuc were a kind gift from
Dr. Brian Hudson (University of Glasgow), plasmid pOG44 was purchased from Ther-
mofisher Scientific.
Tissue culture plastics and 0.5 μm transwell inserts were purchased from Corning, cen-
trifuge tubes and pipettes were purchased from Sarstedt and 0.22 μm filters were pur-
50
Chapter 2. Materials and methods
chased from Sartorius.
Custom primers were purchased either from Thermofisher Scientific and IDT.
The following reagents were purchased: Alexa647-hCXCL12 from Almac, Dulbecco-
Modified Eagle Medium, Foetal Bovine Serum, HEPES, L-Glutamine, Phosphate Buffered
Saline, Penicillin-Streptomycin, RPMI1640 and Trypsin-EDTA (0.25% v/v) from Invitro-
Gen, BbsI and Q5 Polymerase from New England Biosciences, hCXCL11 and hCXCL12
from Peprotech, HindIII, KpnI, Pfu Polymerase, pGEM T-Easy and Taq Polymerase
from Promega, Acetic Acid, human Adrenomedullin, Agar, AMD3100, Amplicillin, Blas-
ticidin S HCl, Calcium Chloride, Dimethylsulphoxide (DMSO), Glycerol, Hydrochloric
Acid, Hygromycin B, Manganese Chloride, Sodium Chloride, Polyethylenimine (PEI),
Poly-D-Lysine, Rubidium Chloride, Tryptone, Yeast Extract and TE buffer 1x (Tris 10
mM, EDTA 1 mM, pH 8.0) from Sigma-Aldrich, BCA Pierce, Coelenterazine-h, DpnI
and ECL Pierce from Thermofisher Scientific.
Sequencing analyses were purchased from Dundee DNA Sequencing and Services and
Eurofins Genomics.
2.1 Molecular biology
Molecular biology techniques have been used extensively during this project. All the
techniques listed have some steps in common, as the final product of each of them is
a relatively large amount of the same sequence of DNA. Techniques such as PCR can
amplify a fragment of DNA by using a purified enzyme (DNA-polymerase) together with
two oligonucleotides that share sequence with a specific part of the target DNA (primers).
Amplification of bigger polynucleotides, such as whole plasmids, can be left to competent
bacteria (usually E. coli) and then purified using commercially available kits.
2.1.1 Microbiology
Escherichia coli is a widespread bacterium which is found in animal and human micro-
biota. There is a wide variety of E. coli strains, most of which are harmless to humans,
but a few strains are pathogenic and can cause food poisoning, urinary tract infection,
meningitis, gastrointestinal symptoms and hemolytic-uremic syndrome (HUS) (Kaper
et al., 2004). The E. coli strains used in molecular biology are all harmless if handed
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according to the standard safety guidelines. In particular, during this thesis work the
strain XL-1 blue was used.
Reagents for use with bacteria
E. coli culture and selection are well established processes, hence all the basic techniques
in microbiology were already well optimised, from the composition of growth medium to
protocols for bacteria transformation and plasmid purification.
LB broth recipe Per 1 L of medium:
• 10 g Tryptone
• 5 g Yeast extract
• 10 g NaCl
Stir until the powder is completely solubilised in about 800 mL of distilled water, adjust
the pH to 7.0, bring the volume to 1 L and autoclave.
Ampicillin 1000x stock recipe Dissolve ampicillin powder into distilled water (or in
ethanol) to a concentration of 100 mg/mL and filter sterilise it. Working concentration
will be 100 μg/mL.
LB-agar recipe Per 300 mL of gel (approx 30 Petri dishes):
• 3 g Tryptone
• 1.5 g Yeast extract
• 3 g NaCl
• 4.5 g Agar
Stir the tryptone, yeast extract and sodium chloride in distilled water until solubilised,
adjust the pH to 7.0, then add the agar powder and autoclave.
52
Chapter 2. Materials and methods
LB-agar Amp recipe Prepare LB-agar according to the previous paragraph. After
autoclaving, cool to 55◦C and dilute 1:1000 the ampicillin 1000x stock into the LB-agar.
Pour the LB-agar amp into an appropriate number of plates (approx 10 mL per dish)
and let it solidify.
Solution 1 for competent cells Recipe for 100 mL.
Potassium acetate (1M) 3 mL (30 mM final)
RbCl (1M) 1 mL (10 mM final)
CaCl2 (1M) 1 mL (10 mM final)
MnCl2 (1M) 5 mL (50 mM final)
Glycerol (80% w/v) 18.75 mL (15% w/v final)
Adjust the pH to 5.8 with 100 mM acetic acid, bring up the volume to 100 mL with
distilled water, filter sterilise it and store at 4◦C.
Solution 2 for competent cells Recipe for 40 mL.
MOPS (100 mM, pH 6.5) 4 mL (10 mM final)
RbCl (1M) 0.4 mL (10 mM final)
CaCl2 (1M) 3 mL (75 mM final)
Glycerol (80% w/v) 7.5 mL (15% w/v final)
Adjust the pH to 6.5 with concentrated HCl, bring up the volume to 40 mL with distilled
water, filter sterilise it and store at 4◦C.
Preparation of competent bacteria
The E. coli strain XL-1 blue was chosen to propagate plasmid DNA.
An LB-agar plate with no antibiotics was spread with non transformed XL-1 blue cells
to grow colonies overnight at 37◦C. One of the colonies was picked and grown in 5 mL
of LB broth with no antibiotics for the following night at 37◦C. Those 5 mL were then
subcultured in 100 mL of LB broth with no antibiotics and grown at 37◦C until the
optical density at 550 nm reached the value of 0.48.
After chilling 5 minutes on ice, cells were spun 2500 g for 10 min at 4◦C in 50 mL sterile
Falcon tubes. Each pellet was resuspended in 20 mL of solution 1 by gentle pipetting,
chilled for further 5 minutes and spun as previously. Each pellet was then resuspended in
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2.2 mL of solution 2, by gently pipetting up and down, chilled for a further 15 minutes,
then divided into 220 μL aliquots per microcentrifuge tube, and stored at -80◦C.
Transformation of competent cells with plasmids
50 μL of competent cells were kept on ice and incubated for 10 min with either 1 μL
of plasmid or 5 μL of ligation/mutagenesis product in microcentrifuge tubes. The tubes
were transfered to the water bath at 42◦C for 90 s, then re-transfered back onto ice for
further 2 min. 450 μL of LB-broth were added to the microcentrifuge tube, and the
bacteria were incubated on a shaker at 37◦C for 45-60 min. The tubes were spun 2
min at 2000 g in a table top minicentrifuges and 450 μL of supernatant discarded. The
bacteria were resuspended in the leftover volume, spread onto LB-agar amp plates and
allowed to grow overnight.
Output The output of transformation is a plate full of bacteria colonies. To proceed
to DNA purification, single colonies were picked from each plate and grown in 5 mL
aliquots of LB amp overnight.
Transformed bacteria were used to propagate desired DNA constructs. The purification
of plasmid DNA from bacteria is usually referred to as “prep”, and according to the
volumes of LB-amp in which bacteria have been seeded and to the amount of plasmid
we want to obtain, we can have minipreps (5 mL bacteria, up to 20 μg DNA), midipreps
(25-100 mL bacteria, up to 200 μg of DNA) and maxipreps (100-500 mL bacteria, up to
1000 μg of DNA). All the kits have common steps:
• resuspension of the bacteria
• lysis of the cells and subsequent neutralisation of the detergent
• separation (centrifugation) of the membranes (pellet) from the DNA-protein mix-
ture (supernatant)
• elimination of the impurities from the DNA through a column
• elution of purified DNA
All the prep kits were used according to the manufacturer instructions.
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Quantitation of purified DNA
Plasmid DNA purified from bacteria was quantified in a spectrophotometric system using
either cuvettes, single drops (in a Nanodrop) or in a Pherastar FS purpose-built plate
(BMG Tech).
Three wavelengths are usually used to quantify DNA and RNA to establish also their
degree of contamination with carryovers from the lysis or purification steps: 230 nm, 260
nm and 280 nm. DNA and RNA absorb efficiently ultraviolet light at 260 nm. Most
proteins, in particular the ones with aromatic residues, absorb UV light at 280 nm, thus
to assess the purity from proteins the ratio A260/280 is fundamental; likewise, guanidine
and phenol, which are used for the DNA extraction, absorb UV light at 230 nm, so the
ratio A260/230 gives an indication of how efficiently the washes have been to get rid of
phenol and guanidine compounds.
Rule of thumb, is that pure DNA shows ratios A230:260:280 1:1.8:1, while pure RNA
A230:260:280 is 1:2:1.
2.1.2 PCR
The polymerase chain reaction (PCR) is a fundamental reaction in molecular biology.
Since its discovery by Kary B Mullis (Saiki et al., 1985), the ability of DNA-polymerases
to synthesise complementary DNA given a template has given rise to several techniques,
from molecular cloning to DNA sequencing, and provided a useful potential investigation
tool.
Being enzymes, DNA polymerases can show temperature- or buffer-dependent activity
impairment: to this end, the study, purification and engineering of polymerases from
estremophil microorganisms gave the market more stable enzymes.
Furthermore, a desirable feature for DNA fragment synthesis in most applications is the
high proofreading activity: in nature this activity helps balancing the effects of exogenous
mutagenic events and from random mistakes that a DNA polymerase can make on the
cell in replication phase. For laboratory work, using an efficient proofreading polymerase
can facilitate cloning and give reliable results from sequencing reactions.
In the next subsection, “Molecular cloning”, there will be a thorough description of all
the PCR-dependent techniques used for this project.
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2.1.3 Molecular cloning
Herein molecular cloning refers to all the techniques used to generate multiple copies of
a desired wild-type or engineered DNA sequence.
For this project plasmid site-directed mutagenesis and CRISPR were used.
Plasmid Site-Directed Mutagenesis
Plasmid Site-Directed Mutagenesis (SDM) is a molecular biology technique that is used
to specifically edit a plasmid bourn DNA sequence by targeting that sequence with a
pair of oligonucleotides carrying a specific mutation, which can be a point mutation, an
insertion or a deletion.
For insertion or deletion, the primers can be designed partly by hand, taking care to put
a buffer sequence at the beginning of the primer should a 5’ restriction site be desired.
The insertion/deletion (indel) should be flanked by the sequence of the template in corre-
spondence of the area where the indel is desired. The same applies to the complementary
strand in proximity to the final part of the mutation.
For point mutation purposes the phase of primer design can be left to specific online soft-
ware packages, such as Agilent QuikChangeII (https://www.genomics.agilent.com/primerDesign
Program.jsp), which optimise the design according to the minimum energy cost (they
seek to minimise the difference of free energy between the plasmid and the oligonu-
cleotide) and to an annealing temperature of 65◦C (Novoradovsky et al., 2005).
High-fidelity Q5 polymerase (NEB) was used for this method, in order to reduce the
chance of random off-target mutation due to the lack of proofreading activity that many
commercially available DNA-polymerases have.
Component Amount
5X Q5 Reaction Buffer 5 μL
dNTPs (10 mM) 0.5 μL
Primer fwd (10 μM) 1.25 μL
Primer rev (10 μM) 1.25 μL
Template DNA up to 1 μg
Q5 High-Fidelity DNA Polymerase 0.25 μL
Nuclease-free Water to 25 μL
To insert specific sequences in the receptor plasmids described below, a classic PCR
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approach was used.
Step Temperature Time
Initial denaturation 98◦C 2 min
35 cycles 98◦C 10 s
68◦C 30 s
72◦C 30 s/kbase
Final extension 72◦C 2 min
Hold 4◦C ∞
The PCR protocol selected for the point mutagenesis was the touch-down approach,
which required the following steps:
Step Temperature Time
Initial denaturation 98◦C 2 min
25 cycles 98◦C 10 s
67◦C 30 s
72◦C 30 s/kbase
15 cycles 98◦C 10 s
60◦C 30 s
72◦C 30 s/kbase
Final extension 72◦C 2 min
Hold 4◦C ∞
After the PCR ends, the product consists of a mix of the mutated plasmids, generated
from purified polymerase, and the template plasmid, which was obtained from bacte-
ria. Plasmids purified from most bacteria, E. coli included, are methylated on every
adenine of the sequences 5’-GATC-3’ due to the activity of a bacterial enzyme called
Dam methylase (Deoxyadenosine methylase); treatment of the aforementioned mix with
the endonuclease DpnI, which recognises and cleaves only A-methylated 5’-GATC-3’ se-
quences, allows the digestion of the bacteria-generated mutagenesis template leaving only
the mutant DNA in the final product.
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Component Amount
10X FastDigest buffer 2 μL
FastDigest Enzyme DpnI 1 μL
Template DNA 2 μL (up to 1 μg)
Q5 High-Fidelity DNA Polymerase 0.25 μL
Nuclease-free Water 15 μL
After the digestion of the template at 37 ◦C for 5 minutes, the product was then trans-
formed into competent cells, a few clones were picked from the plate and DNA isolated
by miniprep.
To confirm that the mutagenesis product was correct, sequencing was outsourced.
Primers for CXCR4, FLAG-CXCR4, CXCR3, FLAG-ACKR3 and ACKR3 cloning into
pcDNA5/FRT/TO HindIII -GPR35-KpnI -eYFP or into HindIII -GPR35-KpnI -SPASM
sensors were the following (Italics: restriction site; underlined: Kozak sequence; bold:
FLAG tag):
Name Primer sequence (5’ -> 3’)
Fw HindIII-FLAG-CXCR4 CGATCGAAGCTT GCCACC ATG GATTACAAG-
GATGACGACGATAAG GAGGGGATCAGTATA-
TACACT
Fw HindIII-CXCR4 CGATCGAAGCTT GCCACC ATG GAGGGGATCA-
GTATATACACT
Rv KpnI-CXCR4 no stop GCTAGC GGTACC GCTGGAGTGAAAACTTGA
Fw HindIII-FLAG-ACKR3 CGATCGAAGCTT GCCACC ATG GATTACAAG-
GATGACGACGATAAG GATCTGCATCTCTTC-
GACTACTCA
Fw HindIII-ACKR3 CGATCGAAGCTT GCCACC ATG GATCTGCATCT-
CTTCGACTACTCA
Rv KpnI-ACKR3 no stop GCTAGC GGTACC TTTGGTGCTCTGCTCCAAGG
Fw HindIII-CXCR3 CGATCGAAGCTT GCCACC ATG GAGTTGAGGA-
AGTACGGCCCTGGA
Rv KpnI-CXCR3 no stop GCTAGC GGTACC CAAGCCCGAGTAGGAGGC
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The constructs were all fusion proteins, hence the stop codon at the end of each re-
ceptor was removed.
In order to build the first library consisting of 105 single mutations to alanine of human
ACKR3, the mutagenesis primers listed in Appendix 1 have been used.
2.1.4 CRISPR and validation
For the purposes of this project, Jurkat and LLC cells have undergone genome editing
processes. For all the products, after transfection and selection, cells’ genomic DNA have
been extracted, amplification of the gene of interest have taken place and pre-screened
by their size in an agarose gel; the desired PCR products have then been TA cloned
inside pGEM T-Easy vectors and sequenced.
Genomic DNA extraction
Genomic DNA was extracted using the QuickExtract Solution (Lucigen). The kit pro-
vided only a lysis buffer and did not require toxic chemicals or spin columns, only a
vortex mixer and heat.
The protocol requires a small number of cells:
• Place 100 μL of sample cells in a 0.2 mL PCR tube and spin briefly to deposit
them to the bottom of the tube
• Remove the supernatant and add 100 μL of QuickExtract Solution
• Vortex for 15 seconds
• Incubate at 65◦C for 10 minutes
• Vortex for 15 seconds
• Incubate at 98◦C for 2 minutes
• Genomic DNA is ready to use or to be stored at -5◦C
For CRISPR validation, the gDNA was amplified with specific genomic primers, the
product was run in a 2% agarose gel (120V for 30 minutes) and the sample of interest
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was identified from the size of the band. Selected PCR products were then purified from
gel according to the QIAquik gel extraction kit (Qiagen) protocol and prepared for the
TA cloning.
TA cloning
Amplification products were blunt ended dsDNA oligonucleotides, and required a dATP
single nucleotide 3’ overhang at each strand for TA cloning. The first step was an
incubation (72 ◦C for 25 minutes) in which only dATP was added to the dsDNA products
together with Taq polymerase (New England Biolabs) and its buffer.
pGEM T-Easy (Promega) is a linearised vector with a single dTTP 5’ overhang from
each strand.
pGEM T-Easy, single deoxyadenosinated PCR products and T4 DNA ligase (Promega)
were then incubated together according to the latter’s protocol in order to obtain a closed
vector with the amplification product integrated (overnight incubation at 4◦C).
Bacteria were transformed with the ligation product, single colonies grown, mimiprep
DNA prepared and then sequenced using a T7 primer. The T7 promoter is located
upstream of the 5’T overhang in pGEM T-Easy, so consequently the insert sequence was
obtained.
2.2 Tissue culture
Eucharyotic cells are perhaps the simplest model of tissue physiology. Plenty of informa-
tion can be derived from cell culture, and together with the use of molecular biology, deep
insights of what is happening inside the cell upon any kind of treatment or stimulation
can be observed and quantified. Of course important information necessary for drug de-
velopment such as most of the pharmacokinetic parameters are not obtainable from cell
culture, however tissue culture is able to give information on signalling quantification,
imaging and single cell physiology.
2.2.1 HEK293T cells
HEK293 cells are a cell line obtained in Leiden, The Netherlands, in 1973 in van der Eb’s
laboratory from the embryonic kidney of a legally aborted human foetus. The cells were
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cultured and transfected with the sheared DNA of Adenovirus 5, and the 293th clone
obtained was the only one showing stability as it could be cultured for several months.
Since whole kidney chunks were used for transfection, primary fibroblasts, endothelial,
epithelial cells or neurons could have been the ancestor of the HEK293 cell line (Graham
et al., 1977). To this end, later studies on HEK293 cells were done and showed that they
have a lot of functional properties in common with immature neuronal cells; moreover,
their transcriptome displays similarities to adrenal cells, whose medullar region originates
from the neural crest (ectoderm) (Lin et al., 2014). Given the topological proximity of
the adrenal gland to the kidney, it is plausible that HEK293 cells maybe derived from
it (Shaw et al., 2002). HEK293T is a variant of HEK293, developed from the latter cell
line and transformed with Simian Vacuolating Virus 40 large T antigen (SV40-TAg). As
most of the commercially available DNA vectors are designed including an SV40 episomal
replication promoter, SV40-TAg allows the high-copy replication of the transfected DNA.
Flp/In T-REx 293
Flp/In T-REx 293 (Thermofisher Scientific) is a HEK293 derived cell line which expresses
the Tet repressor from the integrated pcDNA6/TR regulatory plasmid and contains a
single stably integrated FRT (Flp Recombination Target) site. In 2.3.2 will be described
more thoroughly the use of this particular engineered cell line.
Maintenance and freezing procedures
HEK293T cells were cultured in D-MEM + 10% (v/v) FCS + Pen/Strep + 2 mM L-Gln.
They were passaged by incubating for 5 minutes at 37◦C in trypsin-EDTA 0.5 % (v/v)
when they reached 75-90% confluence.
Freezing medium was FCS + 10 % (v/v) DMSO. An 85% confluent T75 flask could be
frozen in 2-4 mL of freezing medium, 1 mL per cryovial.
2.2.2 Jurkat T cells
Originally called JM cells, Jurkat T cells are an immortalised cell line derived from a
T-cell Acute Lymphoblastic Leukemia (T-ALL) and isolated from the peripheral blood
of a 14 year old boy in the late 1970s (Schneider et al., 1977). Commercially available
Jurkat cells derive from a problem encountered in the early 1980s, when the cells from the
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original batch were found to be heavily contaminated with mycoplasma, and the curing
process led to the establishment of clone E6-1 as a perfectly non-infected starting culture
for expansion and retail (Abraham and Weiss, 2004). This model has been extensively
used to study T cell leukemia, T-Cell Receptor (TCR) components and signalling and
T-tropic HIV infection (Abraham and Weiss, 2004).
Maintenance and freezing procedures
Jurkat cells were cultured in RPMI 1640 + 10% (v/v) FCS + Pen/Strep + 2 mM L-Gln.
They were passaged by diluting 1:3-1:10 in fresh medium when they reached the concen-
tration of 0.8-1.2 x106 cells/mL.
Freezing medium was FCS + 10 % (v/v) DMSO. 5x105 cells/mL could be frozen in
freezing medium and stored 1 mL per cryovial.
2.2.3 LLC
The Lewis Lung Carcinoma cell line was first isolated from a spontaneous epidermoid
carcinoma of the lung in C57BL/6 mice in 1954 by Dr. Margaret Lewis (Rashidi et al.,
2000). It has been an important tumour model for cancer therapy, as it has helped
studying metastasis and angiogenesis and has been involved in developing antitumoural
chemoterapic drugs (Kellar et al., 2015).
LLCs hold an advantage that other tumour models do not have, deriving from the
fact that they were isolated by a spontaneous tumour in C57BL/6 mice, thus they are
immunologically compatible with this strain of mice, so they can be engrafted into im-
munocompetent mice and not be rejected by their immune system. This feature is called
syngeneism.
Together with the lack of immune-dependent obstacles, being syngeneic allows the study
of every aspect of the tumour microenvironment, including the role of the resident im-
mune cells.
Maintenance and freezing procedures
LLCs were cultured in D-MEM + 10% (v/v) FCS + Pen/Strep + 2 mM L-Gln.
They were passaged by incubating for 5 minutes at 37◦C in trypsin-EDTA 0.5 % (v/v)
when they reached 80% confluence, hence every second or third day due to their extremely
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efficient proliferation.
Freezing medium was FCS + 10 % (v/v) DMSO, the content of an 80% confluent T75
flask could be frozen in 2-4 mL of freezing medium, 1 mL per cryovial.
2.3 Cell biology
Cell biology experiments involve the use of live cells to get information about the status
and the behaviour of the cell upon perturbation of its homeostasis.
2.3.1 Optical microscopy
Optical microscopy involves passing visible light (transmitted through the sample or
reflected from it) through a system of lenses in order to give a magnified view of the
sample.
Fluorescence microscopy
When cells carrying a fluorophore-labelled protein get illuminated with light of the spe-
cific wavelength for the fluorophore excitement, said light is absorbed and a longer wave-
length radiation is emitted.
Fluorescent images were acquired using a Nikon TE2000-E inverted microscope (Nikon
Instruments, Melville, NY) equipped with a 40x (numerical aperture 1.3) oil immersion
Plan Fluor lens and a cooled digital CoolSNAPHQ charge-coupled device camera (Pho-
tometrics, Tucson AZ, USA).
This technique was used to assess the expression of SPASM sensors in stably transfected
Flp/In T-REx 293 cells by detecting mCitrine signal.
2.3.2 Transfection
To transfect means to deliver exogenous nucleic acids inside eukaryotic cells.
Transfection of HEK293T cells was done using polyethylenimine (PEI) or lipofectamine
2000 (Invitrogen), the latter used for LLCs as well. Optimal transfection of Jurkat was
obtained using electroporation.
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PEI-transfection
Polyethylenimine (PEI) is a cationic polymer made of repetitions of an imine (NH) group
spaced by two aliphatic carbons (CH2-CH2). PEI packs DNA into positively charged
particles, which bind to the anionic residues on the cell surface and are internalised by
endocytosis. Once the vescicle containing the PEI-DNA complex is inside the cell, acid-
ification of the intravescicular environment leads to protonation of the amines, resulting
in an influx of counter-ions and a progressive loss of osmotic equilibrium. The osmotic
swelling then bursts the vescicle, allowing the DNA-PEI complex to diffuse into the cy-
toplasm. If the complex decondenses, the DNA can diffuse to the nucleus (Akinc et al.,
2005).
Protocol for PET transfection of HEK293T cells:
• The day before transfection, cells were split from a confluent T75 flask 1:4 in 10
cm Petri dishes
• On the day of transfection DNA dilutions were prepared as follows: 5 μg of DNA
in 250 μL of sterile 150 mM NaCl
• PEI dilution was prepared as follows: 30 μL of PEI in 250 μL of sterile 150 mM
NaCl
• DNA dilutions and PEI dilutions were mixed
• PEI-DNA mix was vortexed and incubated RT for 10 minutes; in the meantime,
cells medium was changed
• PEI-DNA complexes were added to the cells dispensing 500 μL per dish in a drop-
wise manner.
Lipofectamine-2000 transfection
Lipofectamine (Invitrogen) is a cationic liposome formulation, which complexes with
negatively charged macromolecules such as DNA or RNA. The resulting complexes can
easily fuse with the negatively charged plasma membrane of living cells, allowing the
delivery of the complexed nucleic acids into the cytoplasm.
To be efficiently expressed the transfected product should reach the nucleus, therefore
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transfection is recommended on sub-confluent cells, which most likely undergo mitosis
during transfection (Dalby et al., 2004).
Protocol for HEK293T cells in 6 well plates:
• The day before transfection, half a million cells were seeded per well
• In one microcentrifuge tube, 5 μg of DNA was diluted in 200 μL of Opti-MEM
medium
• In another microcentrifuge tube, 5 μL of Lipofectamine 2000 was diluted in 200
μL of Opti-MEM medium
• The content of the two Eppendorf tubes were combined, then vortexed for 5 seconds
and incubated RT for 5 minutes to allow the formation of complexes
• 400 μL of each mix was dispensed dropwise into the well
The same protocol was used to transfect LLC cells.
Electroporation
Electroporation is a transfection technique based on the sudden and short exposure to
a strong electric field to increase cell membrane permeability to macromolecules which
would otherwise struggle to pass through the membrane under physiological conditions.
Its efficiency is calculated to be about 10 times higher than other chemical- or liposome-
based transfection techniques. Modern electroporators are devices on which voltage,
repetition, pulses and duration may be input, and are transferred through a docking
unit to a purpose-built pipette tip that contains the cell and transfectant suspension (in
10-100μL volumes) and acts as one of the two electrodes necessary for the exposure to
the electric field.
Electroporation was chosen to transfect Jurkat cells. The electroporator, Neon Trans-
fection System (Thermofisher Scientific), allowed for the use of 10 μL pipette tip elec-
troporation chambers, in which 2x105 Jurkat cells mixed with 500 ng plasmids mixture
were exposed to 3 1,325V pulses 10 ms wide.
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2.3.3 Generation of stably transfectant Flp/In T-REx 293
The Flp/In T-Rex 293 cell line was purchased from Thermofisher Scientific, and is a
HEK293 derived cell line which expresses the Tet repressor from the pcDNA6/TR regu-
latory plasmid and contains a single stably integrated FRT (Flp Recombination Target)
site. Generation of stably transfected cell lines took place when those cells were co-
transfected with plasmids pOG44 and pcDNA5/FRT/TO: pOG44 encoded for a Flp
recombinase, which integrated stably in the host genome the construct contained in
pcDNA5/FRT/TO by recombining the DNA through FRT sites. Selection was made
by adding Hygromycin B and Blasticidin S HCl to the medium since their resistance
sequences were carried respectively by pcDNA5/FRT/TO and pcDNA6/TR: it took ap-
proximately 3 weeks. As the promoter upstream of the integrated construct was repressed
by a Tet repressor, a 24 hours-long treatment with doxycycline was needed to express
the gene of interest.
2.3.4 Genome editing using D10A Cas9
Mutant D10A Cas9 encoded in px461 vectors (Addgene) was used to CRISPR Jurkat
cells and LLCs.
Mutation D10A impairs the DSB-formation ability of WT Cas9 giving it the capability
of generating a single nick on the complementary strand. Therefore, in order to generate
a DSB two mutant Cas9s are required, reducing greatly the likelihood of off target effects
(Chiang et al., 2016). The efficiency of the genome editing is reduced if the two gRNAs
are not about 20 nucleotides apart, making it more difficult to find a proper region in
which the two PAMs need to be rigidly spaced, but the advantage is that the genome
targeting is extremely precise.
2.3.5 β-arrestin2 recruitment assay
This assay constitutes a G protein-independent readout for receptor activation.
Receptor-eYFP and β-arrestin2-RLuc6 were co-transfected transiently into HEK293T
cells at a ratio of 1:5, and upon stimulation, when the tagged arrestin approaches the re-
ceptor to interact with it, the distance between RLuc6 and eYFP gets below the Fo¨rster
radius (10 nm) and in presence of a substrate such as coelenterazine-h, luciferase’s lumi-
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nescence excites the fluorophore and a BRET signal can be detected.
The protocol took place over four days, the first of which consisted of splitting HEK293T
cells 1:4 from a confluent T75 into a 10 cm Petri dish. On the second day this plate
was transfected and also a white 96-well plate poly-D-lysine coated. The cells were
transfered to the pre-coated 96-well plates on the third day, whilst on the fourth, after
washing the cells with HBSS to get rid of the phenol red contained in the medium (which
might interfere with the spectrum detected from one of the two fluorescent molecules),
agonist/antagonist treatment took place together with the administration of the sub-
strate for the luciferase (10 μM of coelenterazine-h), and BRET was calculated as ratio
of fluorescence (545 nm) over luminescence (475 nm).
2.3.6 G protein recruitment assay (SPASM sensor)
GPCR Systematic Protein Affinity Strength Modulation sensors (SPASM sensors) are
chimeric proteins (Malik et al., 2017) described as being formed by a GPCR, a FRET
couple separated by a flexible ER/K linker (Sivaramakrishnan and Spudich, 2011) and
the α5 helix of the G protein of interest. The rationale behind the design of this sensor
is that the α5 helix of the G protein has been reported as being a fundamental element
for the interface between GPCRs and G proteins (Mahoney and Sunahara, 2016). Upon
agonist binding, if the construct is made with the right G protein α5 helix, the FRET
couple get close enough to allow energy transfer.
A BRET version has been generated by cloning CXCR4 and ACKR3 upstream of mC-
itrine, ER/K linker, NanoLuc and each of the Gα subunits in pcDNA5/FRT/TO vectors.
NanoGlo (Promega) was used as substrate.
For a better resolution of the assay the use of stable transfectants is recommended.
The process was analogous to the protocol described for β-arrestin2 recruitment.
2.3.7 Fluorescent-ligand saturation binding assay
Fluorescent-ligand saturation binding is an assay in which different concentrations of a
fluorescent ligand are used to treat the cells, the excess washed away, and the binding is
measured as a function of the fluorescence detected by a flow cytometer.
The protocol was performed as follows and was carried out on ice:
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• 100,000 sample cells per well were seeded into a round-bottom 96-well plate, sus-
pended in 90 μL of PEB buffer (PBS without calcium and magnesium + 2 mM
EDTA and 0.5% (w/v) BSA)
• Cells were treated by adding 10 μL of 10x concentrated fluorescent ligand to each
well
• Cells were incubated 30 minutes at 4◦C
• Cells were washed twice with PEB buffer (300g, 5 minutes)
• Cells were resuspend in 150-200 μL of PEB buffer, ready for flow cytometry.
2.3.8 Transwell migration assay
Transwell inserts have been developed from the concept introduced by the Boyden
chemotaxis chamber. The latter is an ad hoc device made of two detatchable plastic
parts in which communicant wells are carved and separated by a porous filter (usually
polyvinylpyrrolidone-coated polycarbonate). A chemotactic agent is added to the lower
part whilst cells are introduced into the upper. The chamber is incubated for discrete
amounts of time during which the cells are allowed to migrate, the filters are then sub-
sequently washed, stained with hystology dyes and cells counted to assess chemotaxis.
Transwell inserts however have allowed the study of chemotaxis to move from the Boy-
den chamber to more common tissue culture plates (6 well to 96 well plate formats are
commercially available).
These inserts require an equilibration step, in which the migration buffer is allowed to fill
every pore of the filter to avoid the formation of microscopic air bubbles, which during
cell migration, can prevent the passage of the cells themselves. After the equilibration
step, the TC plates are filled with the chemotactic stimuli, the transwells are added with
cells, and the transfer of the inserts each well and subsequent incubation of the plate in
the TC incubator at 37◦C determines the starting point of the migration.
The evaluation of cell migration is done counting the cells in the lower part of the system.
• The inserts were equilibrated with migration buffer (RPMI + 1% (v/v) FBS) for
30 minutes at 37◦C
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• The stimuli were diluted in 600 μL of migration buffer
• Jurkat T cells were resuspended 2 x 106 cells/mL in migration buffer
• After the equilibration, migration buffer was removed from the inserts and from
the plate
• 600 μL of diluted stimuli were added to the plate, and 100μL of cells added inside
the transwell
• The inserts were put on the corresponding well and the plate was incubated 6 hours
at 37◦C
2.3.9 Flow cytometry
Flow cytometry is a standard laboratory technique fundamental to the evaluation of
hematopoietic cells, including the identification and discrimination of leukocyte popula-
tions, and for the thorough characterisation and description of the immunophenotype of
cells derived from a specific tissue.
The flow cytometer is the device through which this technique has been developed and
improved, and consists of a light source, photodetectors, optical light filters, electronics
and a computer. Fluidics is the heart of this technique. Briefly, the characterisation
starts with a fluorophore-tagged antibody-labelled sample consisting of cells in suspen-
sion in a buffer that ideally prevents them from sticking together. The cell sample is
injected into the fluidic systems flowing sheath fluid, which allows the establishment of
a hydrodynamically-focused single-file flow of cells that streams to the analysis point
maintaining the cells at the centre of the flow. The analysis point is the site of the
fluidic system in which the procession of cells is exposed to the light of different lasers
with different wavelengths, allowing the simultaneous excitation of all the fluorophores
attached to each cell. The illumination of the cells generates both nonfluorescent and
fluorescent signals, which are collected by a detection system consisting of optical filters
which select each wavelength band of interest and photodetectors which transform the
light into electricity according to its intensity. This way the intensity of each fluorophore
and the data relative to the scattering of non-fluorescent light is transformed into data
fitting scatterplots or histograms, that give information relative to each cell in the sample
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about the size (forward scatter), the granularity of the cytoplasm (side scatter) and the
expression of each labelled antigen (specific fluorescence).
Fluorescence-activated cell sorting (FACS)
Fluorescence-activate cell sorting is a special flow cytometry technique. This flow cy-
tometer is provided with an ultrasonic nozzle vibrator just upstream the size/fluorescence
detection system, while right downstream said system there is an electrical charging ring
that gives an electrical charge to the droplet that corresponds to the cell population
chosen on the software. The stream of droplets then passes through an electric field,
that deviate the trajectory of the charged droplets only.
2.3.10 Chemokine uptake assay
The chemokine uptake assay involves the use of a C-terminally fluorescently-labelled
chemokine: for this thesis project, AlexaFluor647-CXCL12 (Almac) was used at pEC80
concentration. Cells fluorescence was read in a flow cytometer, internalisation of the
chemokine is proportional to the fluorescence in the fluorophore channel (Le Brocq et al.,
2014).
Uptake medium was RPMI1640 + 0.5% (w/v) BSA.
The protocol was the following:
• In a round-bottom 96-well plate, 90 μL of sample cells were seeded, suspended in
uptake medium at the concentration of 1.1x106/mL (100,000 cells per well)
• 10 μL of 10x concentrated fluorescent chemokine resuspended in uptake medium
was added to the cells
• Cells were incubated at 37◦C for 1 hour
• Cells were washed twice (300g, 5 min, room temperature) with PEB buffer, resus-
pended in 150-200 μL of PEB, and at this stage were ready for flow cytometry
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2.3.11 Ki67 proliferation assay
Ki-67 is a protein which is located in the nucleus of eukaryotic cells. Antibodies against
Ki-67 are regularly employed as prognostic tools in the diagnosis of cancer as its level
strongly correlates with the proliferative capability of cells, making it a widely used
biomarker (Bullwinkel et al., 2006). The name Ki-67 was derived from the city where
the first monoclonal antibody against it was generated, namely Kiel, Germany, and the
number 67 refers to the number of the antibody clone that first detected it in a 96 well
plate (Gerdes et al., 1983).
The proliferation rate of the cells was detected by flow cytometry; the cells were stained
using the following protocol:
• 70% (v/v) ethanol was prepared and chilled overnight at -20◦C
• Cells were prepared
• Cells were washed with FACS buffer 300g 5 min 4◦C
• Supernatant was discarded and the pellet loosened by vortex mixing
• 1 drop of cold ethanol was added to the pellet, and the pellet vortexed; a micro-
centrifuge tube per sample was placed on ice
• 500 μL of ice cold ethanol was added to the pellet and vortexed
• Another 500 μL of ice cold ethanol was added to the pellet and the sample vortexed
for 30 seconds
• Cells were incubated for 1 hour at -20◦C
• Cells were washed 300g 5 min 4◦C and resuspended in FACS buffer
• Anti-Ki67 antibody was added to the samples at 1:220 dilution (15 μL in 3 mL)
• Samples were incubated in the dark at RT for 30 min
• Samples were washed 300g 5 min 4◦C and resuspended in FACS buffer before
reading in the flow cytometer
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2.4 Biochemistry
2.4.1 Membrane preparation
To generate an optimal working amount of membrane proteins 8 dishes per condition
were required. The protocol used was the following:
• Harvest the cells with 10 mL cold sterile PBS, and pipette to detach cells from the
dish
• Spin the cell solutions at ≥5400 g 4◦C for 5 min
• Wash and resuspend the pellet in 20 ml cold PBS
• Spin again ≥ 5400 g 4◦C for 5 min
• Remove the supernatant and store the pellet for at least 1h at -80◦C
• Thaw pellet on ice for 30 min
• Prepare membrane buffer (TE buffer (Sigma-Aldrich) + protease inhibitor cocktail
(Roche)) vortexing 1 tablet in 50 mL. It takes 5-10 minutes to dissolve
• Add 2 mL of membrane buffer to the thawed pellet, then homogenise in a teflon-
glass homogeniser (50 strokes)
• Transfer the homogenates into 7 mL bijoux, then use a 2 mL syringe with a 25G
needle to further disaggregate the homogenates by passing it through the needle 5
times
• Transfer the homogenates to 15 mL falcon tubes, then spin at 150 g, 4◦C 5 min to
remove cellular debris
• Transfer the supernatant to glass ultracentrifuge tubes, then spin at 80,000 g 4◦C
for 45 min to pellet the membrane
• Discard the supernatant, and resuspend each pellet in 700 μL of membrane buffer
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• Pass the resuspended pellet a further 10 times through a 25G needle using a 2
mL syringe, then use the BCA assay to quantitate the concentration of the total
membrane protein
• The protein can be stored for up to 3 months at -80◦C. Usually 5 μg of total protein
per point is required
2.4.2 BCA assay
The Bicinchonic Acid assay, informally referred to as the Pierce assay, is a biochemical
assay that is used to determine the amount of protein in a solution. It consists of two
solutions, Solution A is a pH 11.25 solution containing Bicinchonic acid, sodium carbon-
ate, sodium bicarbonate and sodium tartrate, while Solution B is copper sulphate.
The presence of carbo-amidic groups (peptidic bonds) reduces Cu2+ ions to Cu+, and
this phenomenon is proportional to the amount of total protein. Bicinchonic acid can
chelate Cu+ ions, and this complex absorbs light at 562 nm.
In practical terms, proteins are quantified in a spectrophotometer calculating the ab-
sorbance at 562 nm and comparing this value to a standard curve made with known
concentration of BSA.
Operative protocol was the following:
• Dispense in duplicate 10 μL of BSA standards (0 to 2 mg/mL, steps of 0.2 mg/mL)
in a 96-well microplate
• Dispense in duplicate 10 μL of sample lysates in different wells of the same mi-
croplate
• Add 200 μL of 50:1 Solution A:Solution B mixture to each well and incubate at
37◦C for 30 minutes in the dark
• Read the 562 nm absorbance and, after correlating through known concentrations
the standards and their absorbance value, calculate the concentration of the sample
lysates
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2.4.3 Radioligand saturation binding assay
The radioligand saturation binding assay allows the calculation of the affinity of a radi-
olabeled ligand for a receptor. The operative protocol was the following:
• Disaggregate the previously prepared membranes by passing them through a 25G
needle using a 2 mL syringe
• Prepare an high capacity 96 well plate and add 5 μg of membrane protein per
point, adding cold PBS to 75 μL final volume
• In Eppendorf tubes, make 75 μL/point of 4x concentrated radioligand ([125]I-
Adrenomedullin, specific activity 17 Ci/mg, stock of 10 μCi) for each point of
the dose-curve (values shown in Figure 5.7)
• Add 25 μL of radioligand to the plate
• Incubate plates on a shaker at room temperature at 600 rpm for 2 hours
• During incubation, pre-soak GF/C filters in a solution of 0.5% (w/v) PEI in dis-
tilled water
• Harvest the membranes and wash 2 times with 500 μL of cold wash buffer (300
mM HEPES, 6 mM CaCl2, 30 mM MgCl2, 3 M NaCl, pH 7.4)
• Dry the filters overnight at room temperature
• Put the filters into scintillation vials, label them, then add 3 mL of scintillation
fluid
• Count the vials in a gamma counter
2.4.4 Western blotting
The transfer of macromolecules from gels to microporous membranes is referred to as
“blotting”. The first blotting technique described was Southern blotting, by which
electrophoresis-resolved DNAs were transferred from an agarose gel to a nitrocellulose
membrane and hybridised with a radio-labelled RNA probe. The result of which was
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then acquirable through the process of autoradiography (Southern, 1975). A similar
process has been applied to RNAs, and named Northern Blotting as “geographically”
opposed to Southern. Protein blotting evolved later in time and was named Western
Blotting to maintain the “geographic” naming tradition.
Proteins are resolved through a sodium dodecyl sulphate polyacrylamide gel electrophore-
sis (SDS-PAGE) according to their molecular weight. SDS is a detergent, and its pres-
ence gives all the proteins in the sample a negative charge, allowing them all to migrate
towards the anode. The resolved gel is then juxtaposed with a membrane, usually nitro-
cellulose or polyvinyldenflouride (PVDF), and put into a “sandwich” made of absorbent
paper and sponges; the orientation of the gel and the membrane are such that the mem-
brane is closer to the anode plate, allowing the transfer of the proteins to the membrane
and not away from it. Subsequently unused binding sites on the membrane are blocked
and the membrane stained with antigen-specific antibodies, whose Fc is later targeted by
secondary antibodies that can be radiolabelled, enzyme-labelled or fluorophore-labelled,
and the blotting can then be detected by autoradiograph, photosensitive film chemilu-
minescence or by scanning the membrane in an infrared detector.
Sample preparation for SDS-PAGE:
Membrane protein samples were prepared as follows:
• The protein was diluted to a final concentration of 2 mg/mL in TE membrane
buffer
• The protein sample was then diluted in Laemmli buffer (5M urea, 0.17M SDS,
0.4M dithiothreitol, 50mM Tris-HCl, pH 8.0 and 0,01% (w/v) bromophenol blue)
to a final concentration of 1 mg/mL
• The samples were boiled for 5-10 minutes
• 10-20 μg of protein were loaded to each well of a precast SDS-PAGE protein gel
(Mini Protean II, BioRad)
Cell lysate samples were prepared as follows:
• Cells from a 10 cm Petri dish were washed in 1x PBS after the appropriate treat-
ment
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• Cells were lysed in 500μL of ice cold RIPA buffer (50 mM HEPES, 150 mM NaCl,
1% (v/v) TritonX-100, 0.5% (w/v) Sodium Deoxycholate, 0.1% (w/v) SDS, 10 mM
NaF, 5 mM EDTA, 10 mM NaH2PO4, 5% (v/v) Ehylenglycol, pH 7.3 + protease
inhibitor cocktail (Roche))
• Cells were then rotated 20 min in an Eppendorf tube at 4◦C
• The samples were centrifuged at 4◦C for 10 minutes at 15,000 g and diluted 1:4 in
Laemmli buffer
• The samples were then boiled for 5-10 minutes and 20μL loaded onto the gel
Samples were run at 200V 400 mA until the dye reached the bottom of the gel.
Following SDS-PAGE, proteins were electrophoretically transferred onto a nitrocellulose
or PVDF membrane at 100V 400 mA in transfer buffer (0.2 M Glycine, 0.025 M Tris and
20 % (v/v) methanol). The membrane was then blocked for 1 hour in 5% (w/v) fat-free
milk in 1x PBS-T (PBS + 0.2% (v/v) Tween-20) or pure Licor blocking solution. After
3 washes with 1x PBS-T, the membrane was incubated overnight at 4◦C with an appro-
priate dilution of primary antibodies (goat anti-GFP (ABCAM, clone ab5450), mouse
anti-hACKR3 (R&D Systems, clone 11G8) and rabbit anti-hCXCR4 (ABCAM, clone
ab124824) were used according to the manufacturer indications) in 1x PBS-T containing
1% (w/v) fat-free milk or Licor blocking buffer (Licor Biosciences).
On the next day the primary antibodies were removed and the membrane was washed 3
times with 1x PBS-T, then incubated with the secondary antibodies diluted 1:10,000 for
2 hours at room temperature. The membrane was washed 3 times with 1x PBS-T and
according to the secondary antibody labelling the blot was acquired on a photosensitive
film if labelled with an HRP-labelled secondary, or its immunofluorescence was read if
Licor secondary antibodies were used.
Chemiluminescence was detected using Pierce ECL Western Blotting Substrate (Ther-
mofisher Scientific). The substrate consisted in two solutions (Mix Detection Reagents
1 and 2) to be mixed 1:1 before applying to the membrane. The development of the
photographic film (Kodak) by the reaction happening onto the membrane took place in
a dark room inside a black box. Exposure times may vary according to the strength of
the signal given by the bands.
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For fluorescence detection method in Licor, IRDye secondary antibodies (Licor Bio-
sciences) 800CW donkey anti-mouse and anti-goat and 680DR donkey anti-rabbit were
used according to the manufacturer’s instructions.
2.4.5 GTP-γ-35S
GPCR activation involves the formation of a complex of ligand/receptor/G protein in
which GDP bound to G protein is replaced by GTP, allowing the Gα subunit to disas-
sociate from the Gβγ heterodimer and activate downstream effectors. GTP bound to Gα
is then hydrolysed to GDP to allow the G protein to reassemble and hence to be used
again for signalling. GTP-γ35S (specific activity: 539.24 Ci/mol) is a GTP analogue
whose third phosphate group is substituted by a dihydroxyphosphothiol, containing sul-
phur as a radioactive isotope. The advantage of using this GTP analogue is that the
bond is resistant to hydrolysis and the lifetime of the nucleotide-bound GTP is longer.
A dose response to agonist results in a sigmoidal curve which reveals the potency and
efficacy of the agonist in G protein recruitment.
• GTP-γ-35S buffer (HEPES 20 mM, MgCl2 5 mM, NaCl 160 mM, 0.05% (w/v)
BSA) was prepared, and the water bath set at 30◦C
• The ligand dilutions were prepared
• Glass tubes were prepared and labelled
• 60 μL of GTP-γ-35S buffer were added to each tube
• 20 μL of ligand dilutions were dispensed into each tube
• Membranes were diluted to 0.5 μg/μL, vortexed 3 times and 20 μL of diluted
membranes were added to each tube
• Assay mix (GTP-γ-35S 0.1 nM (50 nCi), GDP 1 μM in GTP-γ-35S buffer) was
prepared
• 100 μL of Assay mix was added to each tube, the tubes were vortexed and covered
with foil
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• The tubes were incubated for 45 minutes in the water bath (30◦C)
• During the incubation, ice cold 1x PBS was prepared, Whatmann paper filters
were soaked in PBS and the harvester made ready
• The contents of each tube were harvested, together with 3 tube washes, onto the
filters
• Filters were labelled and allowed to dry for at least 3 hours
• The dried filter discs were separated and put into scintillation vials
• 3 mL of scintillant fluid was added to each vial, the vials closed and the lids labelled
• The tubes were transferred to the TriCarb racks and put into the TriCarb scintil-
lation counter (PerkinElmer) to count the radioactivity
2.5 In vivo
In vivo research is a fundamental process in the development of science, both basic and
applied. Basic in vivo experiments allow us to better understand the mechanisms of
physiological processes that are too complex to be studied in vitro, helping as well to
provide proofs of concept about the roles of different macromolecules. Furthermore,
drugs tested and validated in vitro need to proceed to in vivo models to have their
pharmacokinetics and toxicity profile characterised before being subject to human safety
trials.
Since these models are whole living organisms, in vivo experimentation is strictly reg-
ulated by the government and ethics committees in order to prevent procedures that
might cause suffering without the support of a reasonable rationale behind.
2.5.1 C57BL/6 mice
C57BL/6, often called “C57”or “black 6”, refers to an inbred strain of mice widely used
in labs all over the world. Reasons for the success of this model are the fact that they are
breeded easily, they are robust and a lot of congenic strains are available for crossings.
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The strain C57BL/6 was created in 1921 at the Bussey Institute, and its genome was
the second whole genome ever sequenced.
Subcutaneous tumour cells injection
Wild type C57BL/6 mice back skin was shaved the day before injections. Male and
female animals were used, at least 12 weeks old (adults). Prior to injection, mice were
anesthesised with isoflurane, then 200,000 LLCs per mouse were injected directly beneath
their dorsal skin.
Tumors were measured every day from when a visible blister became visible on the mice
skin until their largest radius reached the length of 12 mm (in compliance to the project
license). At the end of the growth, mice were subjected to Schedule 1 procedures and
tumours were weighed.
All mice were housed in a 12-h light dark cycle with access to food (normal chow diet)
and water ad libitum. All experimental procedures were performed in accordance with
UK Home Office Guidance on the operation of the Animals (Scientific Procedures) Act
(1986), the “Guide for the Care and Use of Laboratory Animals” published by the US
National Institutes of Health (eighth edition) and institutional ethical approval (PLL
number 70//8377; PIL number ID34B8D13).
2.6 Statistical analysis
All data were presented as mean ± SEM of three or more independent experiments.
All statistical analysis of data was conducted using the software GraphPad Prism 5.0.
Assuming the normal distribution of the data, data were analysed either through two-
tailed unpaired student’s t-test or one-way analysis of the variance (ANOVA) if the
analysed groups were respectively two or more than two. Tukey’s or Dunnet’s multiple
comparison test followed respectively t-tests or one-way ANOVAs to determine the level
of significance between groups. Statistical significance was considered reached when
p-values were less than 0.05.
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Molecules active against either CXCR4 or ACKR3, especially blockers, can be developed
virtually to contribute to the targeting of tumour growth and metastasis when used
alongside current chemotherapic drugs. In order to develop drugs, a high-throughput
screening assay whose main characteristics are that it is statistically robust, relatively
cheap, rapid in terms of time and down-scalable are desirable.
For this project, BRET sensors for detecting either receptor-G protein or receptor-β-
arrestin2 interactions were generated by molecular cloning, and the experimental con-
ditions optimised for CXCR4 and ACKR3 responses. Furthermore, a BRET-based β-
arrestin2 recruitment assay has been used to characterise the antagonism, the potency
and the specificity of brand new anti-ACKR3 nanobodies. These nanobodies were syn-
thesised and supplied by Vladimir Bobkov, ArgenX, Belgium.
3.1 Procedures and results
3.1.1 Generation of constructs
Sequence details of vector constructions have been described previously in Materials
and methods. pcDEF3-hACKR3 and pcDEF3-3xHA-hCXCR4 were used as templates
for PCR and restriction site sequences were introduced to both the extremities of the
polynucleotide: in particular, HindIII was inserted 5’ of the ATG start sequence, and
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KpnI 3’ after the last amino acid, making sure not to include the stop codon. Backbone
vectors were pcDNA5/FRT/TO hGPR35 SPASM sensors or hGPR35-eYFP, from which
hGPR35 was cleaved by endonucleases HindIII and KpnI and substituted with HindIII -
hCXCR4(no-stop)-KpnI and HindIII -hACKR3(no-stop)-KpnI. Ligation products were
then sent for sequencing to confirm the success in the construction of the vectors. All
the sensors were produced both N-terminally FLAG-tagged and without a N-terminal
tag (Figure 3.1).
The rationale behind the use of this sensor is schematically illustrated in Figure 3.2.
Upon ligand treatment and in presence of the luciferase substrate, if the sensor carries
the α5 helix of the G protein elicited by said ligand, through BRET the fluorophore
should get lit in a concentration-dependent manner.
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Figure 3.1: Concept of SPASM vectors generation. Both SPASM sensors and
C-terminally eYFP-labelled receptors were produced from the same template by PCR,
adding the restriction sites onto the primer and were then ligated into the SPASM vectors
or the eYFP-carrying vectors respectively that had been produced previously for other
receptors. The ligation products were validated by sequencing.
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3.1.2 G protein-recruitment sensors development
The SPASM sensors were obtained from ready backbone vectors generated previously
for different GPCRs by Dr. Brian Hudson. The list is in Appendix 2.
Even though hACKR3 has so far never been shown to elicit G protein-dependent re-
sponses upon stimulation, these sensors were created to investigate whether the obser-
vation of basal hACKR3-G protein interaction described in the work of Levoye et al
(Levoye et al., 2009) could be shown in this system, which could then constitute an
interesting target for drugs.
1) Resting state 2) Ligand binding 3) Substrate addition 4) Receptor activation,
G protein fragment
recruitment
5) Energy transfer from
enzyme to fluorophore,
BRET signal
NanoLuc
ER/K linker
mCitrine
G protein
fragment
Ligand
Substrate
Recruitment
BRET
Figure 3.2: Schematics of SPASM sensor function. Upon ligand binding and sub-
strate addition, if the G protein of interest gets recruited to the activated receptor mC-
itrine and NanoLuciferase can generate a BRET signal.
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The constructs were used to generate stable cell lines using Flp/In T-REx 293
cells, by a co-transfection 1:1 of pOG44 (which encodes for FLP recombinase) and the
pcDNA5/FRT/TO SPASM sensors, followed by selection in blasticidin S HCl and hy-
gromycin B medium. The protocol dictates a selection timeframe of 20-30 days, during
which fresh antibiotic-containing medium should be used to replace the old medium ev-
ery third day. After this month-long selection process, the cells were maintained under
selective conditions and were used for the experiments.
Once obtained, the cells were validated for expression and correct membrane localisation
of the receptors: the cells were indeed lysed and the whole lysates run on an SDS-PAGE
gel to separate the proteins according to their molecular weight. The membranes were
then stained with goat anti-GFP primary antibodies, which were targeted with an in-
frared dye-labelled donkey anti-goat secondary antibody (Figure 3.3).
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Figure 3.3: Doxycycline titration curve. Stable transfectants of hCXCR4-Gαi1/2
SPASM were treated with increasing concentrations of doxycycline. The sensor has
approximatively a molecular weight slightly higher than the 90 kDa band, which is
compliant with the theoretical molecular weight calculation of 101.706 kDa. Panel A
shows the loading order of the lysates in the SDS-PAGE, Panel B shows the Western
Blot obtained from a single experiment.
The stable transfectants were grown on coverslips and induced with 50 μg/mL of doxy-
cyclin. The fluorescence of mCitrine was detected by fluorescence microscopy using a
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Zeiss inverted microscope. (Figure 3.4).
Brightfield mCitrine Merge
Dox-
Dox+
50 ug/mL
10 μm
Figure 3.4: SPASM sensor expression assessment by fluorescence microscopy.
Fluorescence microscopy of stable transfectants upon doxycyclin-induced SPASM sensor
expression. mCitrine showed a strong signal only in doxycyclin-treated cells. Represen-
tative images of 3 adjacent optic fields from one experiment.
Thus the expression of the transfected proteins was validated, so a first BRET screening
using the protocol that worked for GPR35 was performed (Figure 3.5). In order not
to waste reagents, the assay was performed on hCXCR4-Gαi1/2 and hCXCR4-nopeptide
SPASM sensors only, as the literature describes clearly hCXCR4 as the only receptor in-
volved in this study able to recruit G proteins, and that most of the signal is transduced
by Gαi family proteins.
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Figure 3.5: Panel A: concentration-response curve of hGPR35a-Gq SPASM to Lodox-
amide. The protocol used with this sensor was applied in Panels B and C to hCXCR4
SPASMS (Gαi1/2 and NoPeptide) upon stimulation with 500 nM hCXCL12 (EC80). Far
left point in each panel represent the vehicle-treated condition; the plots show the average
of three independent replicates (n=3).
Initial screening made it clear that further optimisation was needed.
The kinetics of the sensors were then investigated. A time frame of 30 minutes with 5
minutes intervals was considered, showing that the Gαi1/2 recruitment seemed to have a
peak after 10 minutes upon ligand addition (Figure 3.6).
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Figure 3.6: Kinetic Gαi1/2 protein recruitment to hCXCR4. Cells transfected with
hCXCR4-Gαi1/2 SPASM sensor were stimulated with 500 nM hCXCL12 for different
amounts of time. The plot obtained showed two significant peaks compared to time zero
(basal activity), the earlier 10 minutes after the stimulation, the later at 30 minutes.
Statistics were calculated using Student’s t-test; biological triplicates were run (n=3). *:
p<0.05 .
Gαi1/2 recruitment was therefore investigated after 10 minutes stimulation, but the dif-
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ference between the BRET ratios of chemokine-treated and -untreated samples did not
differ significantly (Figure 3.7).
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Figure 3.7: Concentration-response curve of Gαi1/2 protein recruitment to hCXCR4 after
10 minutes stimulation with 500 nM hCXCL12. Three independent experiments were
run (n=3). A curve could not be fitted by the software as the points do not converge.
Far left point represents the vehicle-treated condition.
Gαi protein activation is sensitive to pertussis toxin (PTX), a toxin secreted by the gram-
negative bacterium Bordetella pertussis. When PTX crosses the plasma membrane, its
subunit A catalyzes the ADP-ribosylation of Gαi locking the G protein in their inactive
state (GDP bound) and preventing its activation. Since the sensors lack the guanosine
nucleotide binding site, PTX treatment would impair only native G protein recruitment.
The rationale for treating with PTX was that, since almost 30% of total Gα protein
in HEK293 derived cell lines belongs to the Gαi family, the BRET ratio would become
higher if only the linked peptide was able to interact with the receptor.
PTX treatment was performed but the Gαi sensor and the no-peptide control did not
show any significant difference in their activation (Figure 3.8).
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Figure 3.8: Concentration-response curve of Gαi1/2 protein recruitment to hCXCR4 after
10 minutes stimulation with 500 nM hCXCL12 following pretreatment with PTX. Three
independent experiments were run (n=3). A curve could not be fitted by the software
as the points do not converge. Far left point represents the vehicle-treated condition.
To further enhance the BRET ratio, the receptors were cloned into sensors expressing
mNeonGreen (mNG) instead of mCitrine, as mNG has a higher Quantum Yield (QY)
(0.8 of mNG versus 0.72 of mCitrine), meaning that the photon transmission efficiency
(QY) is higher (0.8 photons are emitted from mNG for every photon that excites it), as
well as an higher brightness (92.8 of mNG versus 49.68 of mCitrine).
Stimulation was applied to whole cells, PTX-treated whole cells, crude membranes and
PTX-treated crude membranes. However, the results were as before with no significant
difference from the non-peptide sensor (Figure 3.9).
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Figure 3.9: Concentration-response curve of Gαi1/2 protein recruitment to hCXCR4 after
10 minutes stimulation with hCXCL12. The mNeonGreen SPASM sensors were tested
both as whole cell transfectants and as crude membranes, in presence of PTX or not.
Three independent experiments were run (n=3). Curves could not be fitted by the
software as the points do not converge. Far left point of each panel represents the
vehicle-treated condition.
At this point, the suspicion arose that the sensor was not working because of the receptor
functionality itself, even though the sequencing showed that the cloning did not in any
way alter its cDNA.
To rule out this possibility, GTP-γ35S G protein recruitment assays were performed as
described in Materials and Methods. Upon stimulation, both the Gαi1/2 and the non-
peptide sensor showed activation downstream of hCXCR4-hCXCL12 interaction (Figure
3.10).
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Figure 3.10: The expression and functionality of hCXCR4 in transduced cell lines were
assessed by western blot and GTP-γ35S assay respectively. Panel A illustrates the loading
order of the samples in the gel: the samples that actually expressed the transfectants,
namely the doxycyclin-induced, have been successfully detected by the western blot
antibodies anti-GFP (Panel B). Panel C shows the net concentration-response curve
for G protein activation upon treatment with hCXCL12. Since both the Gαi1/2 and
the control SPASM sensor encode for hCXCR4 and express it, both the samples behave
similarly showing extremely close potency values. Far left point in Panel C represents the
vehicle-treated condition; the plot represents the average of three independent replicates
(n=3).
3.1.3 β-arrestin2 recruitment assay
While hCXCR4 is the only receptor, of those involved in this project, that initiates a
G protein response, both hCXCR4 and hACKR3 are described as being able to recruit
β-arrestins.
To assess β-arrestin2 recruitment to the receptor upon stimulation, RLuc6-β-arrestin2
was used as BRET donor, and the receptor constructs hCXCR4-eYFP and hACKR3-
eYFP were used as luminescence acceptors. Because of Resonance Energy Transfer, if
receptor-eYFP construct stimulation results in β-arrestin2 recruitment, the enzyme and
the fluorophore come into close proximity, in presence of RLuc6 substrate Coelenterazine-
h, the enzyme itself emits light, and the energy of its emitted photons can then excite
an adjacent eYFP molecule, generating BRET signals that can be calculated as ratio
between eYFP fluorescence and RLuc6 luminescence (Figure 3.11).
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Figure 3.11: Schematics of β-arrestin2 recruitment principle. Upon ligand binding
and substrate addition, if β-arrestin2 gets recruited to the activated receptor, eYFP and
RenillaLuciferase can generate a BRET signal.
hCXCL12 was first interrogated for β-arrestin2 recruitment, in order to develop and
optimise the assay if needed. Kinetic curves were first obtained with a concentration
of 500 nM of each chemokine ligand (EC80) (Figure 3.12 Panel A). Five minutes af-
ter the stimulation with hCXCL12 the BRET signal reached the plateau, meaning that
this could be used as a reliable timepoint for the assay. Analogously, the inhibition
of hCXCL12 signal by 200 nM (IC80) AMD3100 gave information that the 5 minutes
timepoint could abrogate to basal values the β-arrestin2 recruitment extent (Figure 3.12
Panel B).
Similar conclusions could be drawn using the same concentrations of hCXCL12 (Figure
3.13 Panel A) and hCXCL11 (Figure 3.13 Panel B) on hACKR3.
In conclusion, this assay was used to characterise the potency of the following lig-
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Figure 3.12: β-arrestin2 recruitment kinetics were run for hCXCR4 using hCXCL12
(Panel A)and hCXCL12 inhibited by AMD3100 (Panel B) as ligands. The plots represent
the average of three independent replicates (n=3).
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Figure 3.13: β-arrestin2 recruitment kinetics were run for hACKR3 using hCXCL11 and
hCXCL12 as ligands. The plots represent the average of three independent replicates
(n=3).
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ands: hCXCL12 against hCXCR4 and hACKR3, AMD3100 against hCXCR4, hCXCL11
against hACKR3, VUF11207 against hACKR3, VUF11403 against hACKR3 (Figure
3.14).
VUF11207 and VUF11403 were two small molecules gently gifted by Prof. Dr. Martine
Smit which bind selectively hACKR3 with an high affinity, used to further assess the
robustness of the assay.
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Figure 3.14: β-arrestin2 recruitment assays were performed using both hCXCR4 (A-B)
and hACKR3 (C-D-E-F), observing an increase (or decrease for AMD3100) in the BRET
signal in a concentration-dependent manner. Far left point in each Panel represents
vehicle treated condition. All the plots in the Panels represent the average of three
indipendent replicates (n=3); potencies in the tables are expressed as LogEC50.
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3.1.4 ACKR3 nanobody screening
Nanobodies, or single domain antibodies, are 12-15 kDa proteins able to selectively bind
antigens. Called also VHH because of their lack of antibody light chain, they were
first characterised in camelids. Due to their small size, they have several basic and
translational advantages: they are more simple to manufacture in large amounts, they
are chemically more stable than full antibodies and hence can be stored under less strict
conditions, for longer, and can be delivered to targets in patients without the need for
injection into the bloodstream. In addition they have a longer and more flexible CDR3
region that allows them to reach cryptic epitopes or even enzyme active sites and finally
the bare VHH is safer as the absent Fc is not able to trigger any Fc-Receptor-dependent
immune reaction(Jahnichen et al., 2010).
The industrial partner of this project is a company named ArgenX BVA (Zwijnaarde,
BE), whose main manufactured products are nanobodies targeting GPCRs, and hACKR3
is a target in their pipeline.
The nanobodies received from the company were both VHH and bivalent nanobodies
(two VHH linked together by a human Fc) characterised for hACKR3 targeting action,
potency and specificity.
All the clones were found to be neutral antagonists (Figure 3.15 Panel D), and their
potency against hACKR3 was characterised.
VHH (Figure 3.15 Panel B) and bivalent nanobodies (Figure 3.15 Panel C) showed good
neutral antagonistic activity on hCXCL12-induced β-arrestin2 recruitment to hACKR3,
with similar affinity to the receptor of the two forms.
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Figure 3.15: Panel A illustrates the nature of the engineered llama immunoglobulins
used in this screening. Both VHH and VHH-Fc clones come from optimization phage
display rounds: the former are purified as nanobodies, the latter as bivalent nanobodies
genetically linked to a human crystallizable fragment. The different clones were named
with a code, i.e. 2C5, and their bivalent form consist of two copies of the same nanobody
expressed on a human Fc scaffold. Panels B and C were obtained challenging with
different concentrations of the nanobodies 500 nM (EC80) of hCXCL12. Panel D instead
showed that the effect of 1 μM (saturating) concentration of each nanobody construct
alone against hCXCR4 doesn’t elicit any β-arrestin2 recruitment to hACKR3. Panels B,
C and D show the average of five independent replicates (n=5). Far left point of Panel
B and C represent the vehicle-inhibited condition.
3.2 Discussion
Although different rounds of optimisation were tried, hCXCR4 SPASM sensors did not
show any significant BRET signal upon treatment with hCXCL12. The final goal fore-
seen for SPASM sensor use was ambitious, since if they managed to give a significant
signal they might have been used for further studies. For example the study of biased
signalling, namely to understand the priority that a particular downstream pathway
has upon receptor stimulation, which has been shown to be ligand-dependent in many
GPCRs. Furthermore, by introducing mutations which abolish such interactions on each
receptor, heteromerisation could have been studied functionally.
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β-arrestin2 recruitment instead showed a high reproducibility of the results, which were
generally robust. The optimisation of this assay did not require particular effort. The
assay can be easily miniaturised to 384-well plate (not shown), making it an even more
highly cost-effective signalling output assay.
All the ligands of hACKR3 and hCXCR4 were responding with potencies against the
receptors consistent with literature values (Figure 3.16).
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Figure 3.16: Comparison between experimental and reported potencies. The values
obtained experimentally correlate positively with the potencies described in the litera-
ture for the ligands used in this project, highlighting the suitability of the experimen-
tal methodology. References for ACKR3: CXCL11 (Benredjem et al., 2017), CXCL12
(Gravel et al., 2010), VUF11207 (Wijtmans et al., 2012), VUF11403 (Wijtmans et al.,
2012). References for CXCR4: CXCL12 (Gravel et al., 2010), AMD3100 (Charo et al.,
2019)
During the thesis project, β-arrestin2 recruitment was used to study adrenomedullin
interaction with the receptor hACKR3, and all the characterisation relative to this lig-
and will be described thoroughly in Chapter 5. Further, the kinetics of agonist-induced
β-arrestin2 recruitment (5’ timepoint) and inhibitor-induced signal blockade (30’ time-
point) were employed as well for the investigations described in Chapter 5.
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The reliability of β-arrestin2 assay was essential for the characterisation of the nanobod-
ies, that together with radioligand displacement data (not shown) obtained at VU Am-
sterdam (NL) contributed to the choice of the clone 2C5 as the best candidate. Subse-
quently its production has been upscaled and it has been re-named VUN700.
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To gain a better understanding of the implications of the role of ACKR3 in CXCR4
biology, functional studies are crucial. Jurkat T cells were chosen as the model for
these experiments, as they are well described for their expression of both hCXCR4 and
hACKR3, and for their extensive characterisation in chemotaxis assays.
Indeed, in the first part of this chapter chemotaxis was used as the final readout for
the study of the impact of hACKR3 on hCXCR4-dependent migration, in an attempt
to define physiologically the pharmacological effects that a specific inhibitor of hACKR3
would have on the motility of tumour cells showing upregulation of both of these recep-
tors.
This aim was pursued thanks to the employ of the genome editing technique CRISPR,
that allowed the generation of hACKR3 Knock-Out (KO) clones and their subsequent
use in transwell chemotaxis wells.
The second part of this chapter was dedicated to in vitro characterization of mACKR3-
KO LLC cells, and their subsequent use in vivo to study the impact of mACKR3 in
tumour growth.
The experiments shown in this chapter were carried on in collaboration with Angeliki
Karatza (University of Glasgow), and as such these results are shared.
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4.1 Procedures and results
4.1.1 Jurkat T cells and cell migration
Jurkat cells were first characterised for hACKR3 expression by performing western blots
and comparing the expression to that seen in THP-1 cells, also described as expressing
hACKR3. The latter cell line was used as a positive control, namely to understand
whether any eventual negative results were due to antibodies that cannot detect the re-
ceptors from cell lysates. Both cell lines express both receptors (Figure 4.1) as described
in the literature (Ottoson et al., 2001), (Melo et al., 2014), (Tarnowski et al., 2010). This
is also true of the relative abundancy of hACKR3 on Jurkat cells compared to THP-1
(Tarnowski et al., 2010).
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Figure 4.1: Assessment of the expression of hCXCR4 and hACKR3 in Jurkat and THP-
1 cells. 5 μg of THP-1 or Jurkat cell lysates were loaded as shown in Panel A and
resolved by SDS-PAGE, and subsequently transfered onto nitrocellulose membranes.
Anti-hCXCR4 (Panel B) and Anti-hACKR3 (Panel C) antibodies (see Materials and
Methods) were used to detect the expression of these receptors. Representative im-
munoblot of 3 independent experiments.
Having confirmed that the cell line of choice was compliant to its description in the
literature, the next step was to eliminate the expression of hACKR3 from these cells to
assess how this would modify the function of hCXCR4.
To obtain this CRISPR technique was chosen. Since all the genome-editing techniques
require the genome to be reached by whatever is supposed to edit it, and CRISPR does
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not make exception, transfection of the target cell population needed optimisation.
Lipofectamine-LTX and electroporation are the most used trasnfection techniques on
Jurkat cells, so they have been compared prior the use of the most suitable on actual
samples and subsequent genome editing. Rounds of optimisation using empty px461 D9A
Cas9-GFP vector resulted in the choice of electroporation over Lipofectamine-LTX, a low
toxicity transfection reagent that killed only half of the transfected cells (versus almost
70% that electroporation killed), but left only 4.5% cells efficiently transfected against
the 41% achieved by electroporation. In absolute terms also electroporation was shown
to be more efficient than Lipofectamine-LTX, as the latter gave 2% final efficacy, against
the 11% of the former (Figure 4.2).
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Figure 4.2: Transfection efficiency comparison between electroporation and Lipofec-
tamine LTX on Jurkat cells. Empty plasmid px461 D9A Cas9-GFP was used to compare
the two transfection techniques. Mock transfection (Panel A) helps to determine where
to set, on the histogram plot, GFP negativity. Forward- (FSC) and side-scattered (SSC)
light, which correspond to the physical parameters cell size and cell granulosity respec-
tively, help to establish that Lipofectamine-LTX (Panel B) is milder on cell viability than
electroporation (Panel C), killing only half of the sample versus the 70% achieved by the
latter. Once the population is selected though, the FITC (Fluorescein-Iso-Thio-Cyanide)
channel for reflected light, namely the channel in which the intensity of GFP fluorescence
is detected, showed that the amount of plasmid that permeated the membrane helped by
Lipofectamine-LTX was almost one order of magnitude inferior than what was achieved
by electroporation. Electroporation indeed yielded an outstanding efficiency rate both
relative only to live cells as well as in absolute terms (Panel D). The experiment was
repeated three times with similar results, and a single representative FACS plot is shown
for each condition. Student’s t-test was used for the statistical analysis; ***: p<0.001
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Guide RNAs were then designed (Figure 4.3), using the Zhang lab guide design tool
(Zhang, n.d.), and cloned into the px461 D9A Cas9-GFP (Nickase) vector.
13000 1400013500
hACKR3
ghACKR3-fw ghACKR3-rev
Alpha
Bravo
Figure 4.3: Rationale behind the design of the guide RNAs (Alpha and Bravo) and
the genomic primers (ghACKR3 for1 and ghACKR3 rev1) on the hACKR3 gene. The
software detected a suitable region with two close PAMs straight downstream of the start
codon, and the primers were designed in order to be more than 100 bp from the double
nick site. Further detail to CRISPR theory and nomenclature is provided in section
1.3 of the Introduction chapter and in subsection 2.3.3 of the Materials and Methods
chapter. On the gene, the elements depicted map as described: ghACKR3-fw: 13,142 -
13,161 ; ghACKR3-rev: 13,700 - 13,719 ; Alpha: 13,313 - 13,332 ; Bravo: 13,342 - 13,361
Transfected cells were single-cell sorted by BD FACSAria II for the presence of GFP
into 96-well plates, and the surviving clones were screened for genomic editing in prox-
imity of the hACKR3 gene (Figure 4.4).
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Figure 4.4: Representative genomic PCR screening. Since the distance between
the two genomic primers is some 600 nucleotides, a double strand break in between would
result in non homologous end joining events, which can lead both to random insertions
(longer fragments in the gel) or deletions (shorter fragments) (Panel A). Panel B shows
the gel from which Clones 26 and 30 were picked (ordered, from the left to the right,
from clone 22 to clone 36). Most of the clones were still bearing the wild-type allele,
while five clones showed a fragment not aligned with the wild-type control. Clones 32,
35 and 36 died in the selection process.
Three clones were identified as bearing biallelic deletions by fragment sequencing
after TA cloning, namely clone 9, clone 26 and clone 30 (Figure 4.5).
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hACKR3 WT sequence
hACKR3 KO clone 9
hACKR3 KO clone 26
hACKR3 KO clone 30
Figure 4.5: Sequencing results of the genomic amplification fragments. Clones 9, 26 and
30 showed biallelic deletion of the hACKR3 gene in proximity to the region delimited by
the guides. The blue box indicates in each allele where the premature stop codon occurs.
The resulting sequences were then translated to assess whether premature stop codons
were generated by the deletions (Figure 4.6).
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Figure 4.6: Translation of the sequencing results showed that both the alleles in all
the three clones resulted in a frameshift that led to the occurrence of a premature stop
codon 12-18 amino acids after the methionine start codon. The residues colored in blue
highlight the presence of sense mutations.
The clones were then labelled with PE-anti-hACKR3 and APC-anti-hCXCR4, to assess
whether any alteration of hCXCR4 expression occurred as a consequence of hACKR3
expression abrogation. Figure 4.7 showed that it did not.
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Figure 4.7: Expression of hACKR3 and hCXCR4 in Jurkat cells after CRISPR. Genome
editing revealed itself successful also in flow cytometry, as the expression of hACKR3
in the KO clones significantly dropped (Panel A). Nevertheless, hCXCR4 did not show
any sign of variation (Panel B), allowing for the statement that any functional difference
shown later depends almost exclusively from hACKR3-deficiency. Control was defined
Cas9null, which means that underwent the same transfection conditions as KO clones
but with an unloaded Cas9. Statistics of three independent replicates (n=3) for each
clone were assessed using Student’s t-test. **: p<0.01 relative to Cas9null, ns: non
significant.
The three clones were then characterised functionally for chemotaxis towards hCXCL12.
As a control, Jurkat cells which underwent electroporation with an empty Cas9-GFP
plasmid (Cas9 null controls) were employed (Figure 4.8).
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Figure 4.8: Transwell chemotaxis of the three Jurkat hACKR3-KO clones. All the clones
showed a reduction in the maximal response to hCXCL12 chemotaxis compared to a Cas9
null control. Migrated cells were plotted as percentage of the input, namely the amount
of cells put into the transwell at the beginning of the experiment. Statistics of three
independent replicates (n=3) for each clone were assessed using Student’s t-test. **:
p<0.01, ***: p<0.005 . P values are relative to vehicle control (0 pg/mL hCXCL12).
These three clones were then pooled as their migratory behaviour showed consistency,
and migration assays in the presence of the hCXCR4 inhibitor AMD3100 (Plerixafor)
were performed (Figure 4.9).
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Figure 4.9: The three clones listed in Figure 4.7, namely 9, 26 and 30, were pooled
and assayed for AMD3100-inhibited CXCL12-driven chemotaxis. The inhibitor showed
equal potency in both hACKR3-KO and Cas9-null cells, indicating that the affinity of
AMD3100 for hCXCR4 is not affected by the expression of hACKR3. The curves were
obtained using non linear regression assuming a Hill coefficient equal to 1. The average
of three (n=3) independent replicates is shown.
4.1.2 LLCs and tumour growth
LLC cells are broadly described to express mACKR3 but not mCXCR4 (Nian et al.,
2011), therefore they were chosen as a model to study the role of mACKR3 in tumour
growth in a mCXCR4-free system.
The cells showed a good transfection efficiency upon lipofection (not shown). CRISPR
guides design and insertion into a px461 D9A Cas9-GFP (Nickase) vector followed the
same workflow used for Jurkat cells. Transfected LLCs were single cell-sorted for GFP
positivity into 96-well plates, and the surviving clones were screened for genomic editing
in proximity of mACKR3 gene (Figure 4.10).
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Figure 4.10: Representative genomic PCR gels. The same rationale as Figure 4.4
applies here, with the difference that for this screening the wild type fragment is 1000
nucleotides long.
This process led to the selection of a single clone (clone 31) because of a poor survival
of the GFP-positive clones. This clone has then been characterised before in vivo use.
The alleles have then been sequenced and aligned to the mouse receptor, both of them
showing the occurrence of a premature stop codon (Figure 4.11).
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Figure 4.11: Allele sequencing translation of mACKR3-KO LLC clone 31. On the wild
type sequence, the yellow regions represent the transmembrane domains, in red are high-
lighted the non-transmembrane regions. Blue boxes represent the site on the reference
receptor where the premature stop codon of each allele is located.
Since the plan was to use it in a tumour growth setting, the crucial parameters to
evaluate were first of all the success of the mACKR3 knock-out, then the comparison
between the proliferation rates of the KO and the Cas9null control. Due to the lack
of reliable anti-mACKR3 antibodies in the market, the evaluation of the abrogation of
mACKR3 expression was performed through fluorescent CXCL12 uptake: indeed, the
KO clone showed a significant decrease of ligand uptake compared to the Cas9null control
(Figure 4.12 A). The proliferation rate instead was studied by Ki67 staining: in this case
the knock-out clone showed a comparable proliferation rate to its control, which means
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that eventual differences in tumour growth would more likely be due to the knock-out
itself than to underlying differences between the injected cells (Figure 4.12 B).
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Figure 4.12: Characterisation of LLC cells. The knock-out clone showed a significant
decrease of fluorescent CXCL12 uptake (Panel A), indicating the success in the abroga-
tion of mACKR3 expression. The proliferation rate did not show a significant variation
in the knock-out compared to its control, showing that the cells proliferate in a similar
manner (Panel B). Statistics of three independent replicates (n=3) for each group were
assessed using Student’s t-test. **: p<0.01, ns: non significant.
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The Cas9 null control and the mACKR3-KO were then injected subcutaneously into
C57BL/6 mice, which do not reject the tumour because of their isogeneity with the cells,
and grown until the major radius of the bigger tumour reached 12 mm (according to the
project license). Excised tumours were also weighed (Figure 4.13).
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Figure 4.13: Lack of mACKR3 impairs tumour growth in a subcutaneous LLC injection
model. mACKR3 KO LLC exhibited significant reduction in tumour growth after 18
days (Panel A), as well as in tumour weight (Panel B). In Panel C, Cas9null derived
tumours are displayed in the upper row, while mACKR3 KO derived tumours are in the
lower row. Seven and eight mice received a single subcutaneous injection of wild type
(n=7) and mACKR3-KO (n=8) LLC cells respectively. One-way analysis of variance
(ANOVA) was applied with Tukey’s correction for multiple comparisons to assess the
significance of the data obtained: **** : p<0.0001; ns: non significant.
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4.2 Discussion
The generation of hACKR3 CRISPR knock-outs required significant optimisation but
led to robust and significant results. hACKR3 was shown to have a supportive role in
hCXCR4-mediated T-cell migration. The fact that the migration is hCXCR4-driven was
shown upon inhibition with a hCXCR4-specific small molecule antagonist.
Lack of mACKR3 in a setting in which mCXCR4 is almost absent, such as in the squa-
mous cell carcinoma cell line LLC, showed a significant delay in subcutaneous tumour
growth, highlighting the importance of mACKR3 in significant aspects of neoplastic dis-
ease development.
Taken together, those two models made clear that ACKR3 has a role in cancer phys-
iology linked to those aspect that make a tumour particularly aggressive: growth and
metastatic potential.
Of course more sophisticated experiments must be done in order to address a specific
aspect of these phenomena impacted by the overexpression of ACKR3, still these data
alone allow for the speculation of encouraging future scenarios.
For example, targeting ACKR3 in order to slow down the growth of a primary tumour
can help to improve the efficacy of the surgical asportation and the efficacy of localised
radiotherapy. This just because reducing the size of the target site, the easier becomes
its excision and the smaller becomes the radiation exposed area. This way, side effects
due to these approaches become less impacting on overall patient health.
Targeting ACKR3 in order to reduce metastasis instead might allow to slow down the
aggressiveness of a tumour, likely enhancing the effect of current multitherapy anti-
neoplastic drugs.
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Even though a heavily cited paper dates the discovery of the binding of rat adrenomedullin
to mouse ACKR3 back to 1995, the article does not actually show this interaction(Kapas
and Clark, 1995). The first elegant study of the interaction of mouse adrenomedullin
with ACKR3 was reported only in 2014, where Klein et al showed that genetic dosage,
obtained both by gene duplication or allele deletion, of these two proteins in transgenic
mice led to similar disease and development phenotypes (Klein et al., 2014). Demon-
strating the geometry and the specificity of the interaction was outwith the aims of the
mentioned paper, but significant in vivo evidence resulted in the cue to take this path
for the work described in this thesis.
5.1 Procedures and results
The first step for the characterisation of the interaction between human adrenomedullin
and human ACKR3 was to study the pharmacology of their interaction. Since the
only readout available for hACKR3 was β-arrestin2 recruitment, an adrenomedullin
concentration-response curve was compared to those for hCXCL11 and hCXCL12. This
demostrated similar efficacy to the chemokine ligands, but of an order of magnitude
weaker in terms of potency (Figure 5.1).
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Figure 5.1: β-arrestin2 recruitment concentration-response curves of hACKR3 upon 5
minutes treatment with agonists hCXCL11, hCXCL12 or hAdrenomedullin (hADM).
Data were analysed by non linear regression assuming a standard slope with Hill coeffi-
cient equal to 1. The model curves were based on four independent experiments (n=4).
Potencies, expressed as LogEC50 were reported in the adjacent table.
To confirm that the interaction was due to a direct activation of hACKR3, a concentration-
response curve with a neutralizing immunoglobulin, namely anti-hACKR3 clone 8F11-
M16 (Biolegend), was performed, demostrating that blockade of the receptor did inhibit
the recruitment of β-arrestin2 despite the presence of high concentrations (pEC80) of
human adrenomedullin (Figure 5.2).
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Figure 5.2: β-arrestin2 recruitment concentration-response curve of hACKR3 blockade
with anti-hACKR3 8F11-M16 antibody. The effect was calculated using an EC80 concen-
tration of hAdrenomedullin for 5 minutes and an incubation of the neutralising antibody
of 30 minutes. Data were analysed by non linear regression of three independent exper-
iments (n=3) assuming a standard slope with Hill coefficient equal to 1.
One of the issues in studying such interactions is that the molecule of interest might
give aspecific signalling, thus preventing the first researchers who characterise them to
fully understand what is really happening in their system. To partially remove this,
the specificity of interaction was investigated by using other chemokine receptors which
share the same ligands with hACKR3, namely hCXCR3 and hCXCR4 (Figure 5.3),
and targeting hACKR3 with ligands that belong to the same family as adrenomedullin,
namely hCGRP (human Calcitonin Gene-Related Protein) and human adrenomedullin2
(Figure 5.4).
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Figure 5.3: EC80 concentrations of hCXCL11 and hCXCL12 were used to activate
hCXCR3 and hCXCR4 respectively, together with hAdrenomedullin, and all three of
the agonists were used to treat for 5 minutes hACKR3, to generate the histogram shown
in Panel A. Adrenomedullin failed to promote β-arrestin2 recruitment to hCXCR3 and
hCXCR4. The concentration-response curve in Panel B shows that hAdrenomedullin
promotes β-arrestin2 recruitment only through hACKR3. Data were analysed by Stu-
dent’s t-test (Panel A) and non linear regression assuming a standard slope with Hill
coefficient equal to 1 (Panel B). Statistics were calculated on three independent experi-
ments (n=3); *: p<0.05, **: p<0.01, ***: p<0.005 .
Neither of the aforementioned typical chemokine receptors gave significant signal over
basal upon human adrenomedullin treatment, and equally none of the other ligands be-
longing to the same family as adrenomedullin gave any signal via hACKR3.
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Figure 5.4: The only ligand of the Adrenomedullin family able to stimulate within 5
minutes a response through hACKR3 is hAdrenomedullin. Data were analysed by non
linear regression of three independent experiments (n=3) assuming a standard slope with
Hill coefficient equal to 1.
There is an extensive literature about hACKR3 downstream signalling subsequent to
chemokine ligand treatment that involves MAPK activation (ref). The most accessible
assay to detect MAPK activation as part of this work was the ERK phosphorylation kit
from Cisbio, which is based upon the use of hTR-FRET. The proximity of the europium-
cryptate tag on one of the two antibodies to the fluorophore d2 tag on the second antibody
generates a FRET signal in the presence of the appropriate excitation laser. However,
in this assay adrenomedullin failed to generate an ERK phosphorylation signal (Figure
5.5).
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Figure 5.5: hAdrenomedullin treatment fails to produce ERK1/2 phosphorylation in
hACKR3-transfected cells at any timepoint up to 15 minutes, whereas hCXCL11 and
hCXCL12 both showed phosphorylation of ERK after 5 minutes of treatment; hCXCL12
was able to sustain it until the 10 minute timepoint, while hCXCL11 showed a significant
decrease after 10 minutes from the stimulation and a second peak after 15 minutes.
Data were analysed by one-way ANOVA. Statistics were calculated on three independent
experiments (n=3). ; ns: non significant, **: p<0.01, ***: p<0.005 .
In order to strenghten the data, ligand-binding assays were performed, however with
disappointing results. Both fluorescently-labelled and radio-labelled ligand approaches
were used.
In the case of the fluorescent binding assays, both fluorescent adrenomedullin, specifi-
cally N-terminally Fluorescein amidite(FAM)-labelled adrenomedullin sold by Phoenix
Pharmaceuticals, and pre-conjugated biotinyl-Adrenomedullin with fluorescently labelled
streptavidin were used. The use of these ligands did not give consistant results (Figure
5.6).
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Figure 5.6: Saturation binding of 6-FAM labelled Adrenomedullin (Panel A) and
biotinyl-Adrenomedullin preconjugated with APC-Streptavidin (Panel B) to hACKR3-
overexpressing HEK293T cells. Results are plotted in function of Mean Fluorescence
Intensity (MFI). Representative outcomes are shown but results were inconsistent, as
the resulting shape of all of them was far from the expected canonical hyperbola. Three
independent experiments were run for all these assays (n=3).
A radioactive approach was then chosen as an alternative readout. [125I]-Adrenomedullin
was purchased and a saturation radioligand binding performed according to the protocol
described in Materials and Methods. The curves obtained from hACKR3-overexpressing
membranes and mock-transfected membranes were still diverging at the highest concen-
tration used, meaning that the plateau might have been obtainable with concentrations
of ligand that are not reachable cost-effectively (Figure 5.7). Indeed, given the modest
potency of human Adrenomedullin in functional assays, the saturation curve has shown
itself challenging to achieve.
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Figure 5.7: Radioactive saturation binding of [125I]-Adrenomedullin to hACKR3-
overexpressing HEK293T lysates. Results are plotted in function of bound radioligand
radioactivity, expressed in counts per minute (cpm). Both these plots show that the
amount of radioligand used do not allow the curve to reach a plateau. The saturation
binding model was applied to three independent experiments (n=3).
Despite the failure of the binding assays, the hypothesis that human Adrenomedullin
interacts directly with hACKR3 has been demonstrated already by means of functional
assays. Hence, to explore exactly where on the receptor does human Adrenomedullin
interact, an alanine scanning mutagenesis study was planned.
Site-directed mutagenesis was performed in order to mutate each of the extracellular
residues to alanine, with the aim of eliminating specifically any electric charge and/or
any steric hindrance. Treating the receptor mutants with high concentrations of human
Adrenomedullin and studying their signalling activity, expressed as β-arrestin2 recruit-
ment, would allow the detection of a library of 105 extracellular residue single mutants
where each residue was converted to alanine was created. Initially, the mutants were
screened in flow cytometry using a PE labelled antibody anti-hACKR3 clone 8F11-M16
to detect their correct expression, and this was cross-checked with their eYFP C-terminal
labelling. Then the mutants were screened in 384-well plates for β-arrestin2 recruitment
upon pEC80 stimulation with human adrenomedullin. Two mutants, L104A and Q106A,
were not correctly expressed, and twelve mutants gave information regarding where the
interaction maps (Figures 5.8, 5.9, 5.10, 5.11, 5.12, 5.13).
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Figure 5.8: Screening of hACKR3 N-terminal region mutants. The expression of each
mutant was first screened by FACS for eYFP expression (detected in the FITC channel,
Panel A) and hACKR3 labelling by APC-anti-hACKR3 (8F11-M16) antibody (Panel
B). β-arrestin2 recruitment after 5 minutes treatment was then investigated for each
of the mutants and non-responsive mutants were chosen for further analysis (Panel C).
Both expression and functional study statistic were calculated from five independent
experiments (n=5). The bold black bar represents the basal β-arrestin2 recruitment ac-
tivity; the bold red bar represents the response upon treatment of wild type hAKR3; the
black-striped bars highlight those residues whose activity failed to show any significant
difference from the basal activity.
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Figure 5.9: Screening of hACKR3 Extracellular Loop 1 (EL1) region mutants. The
expression of each mutant was first screened by FACS for eYFP expression (detected
in the FITC channel, Panel A) and hACKR3 labelling by APC-anti-hACKR3 (8F11-
M16) antibody (Panel B). β-arrestin2 recruitment after 5 minutes treatment was then
investigated for each of the mutants and non-responsive mutants were chosen for further
analysis (Panel C). Both expression and functional study statistic were calculated from
five independent experiments (n=5). The bold black bar represents the basal β-arrestin2
recruitment activity; the bold red bar represents the response upon treatment of wild
type hAKR3; the black-striped bars highlight those residues whose activity failed to
show any significant difference from the basal activity.
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Figure 5.10: Screening of hACKR3 Extracellular Loop 2 (EL2) region mutants. The
expression of each mutant was first screened by FACS for eYFP expression (detected
in the FITC channel, Panel A) and hACKR3 labelling by APC-anti-hACKR3 (8F11-
M16) antibody (Panel B). β-arrestin2 recruitment after 5 minutes treatment was then
investigated for each of the mutants and non-responsive mutants were chosen for further
analysis (Panel C). Both expression and functional study statistic were calculated from
five independent experiments (n=5). The bold black bar represents the basal β-arrestin2
recruitment activity; the bold red bar represents the response upon treatment of wild
type hAKR3; the black-striped bars highlight those residues whose activity failed to
show any significant difference from the basal activity.
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Figure 5.11: Screening of hACKR3 Extracellular Loop 3 (EL3) region mutants. The
expression of each mutant was first screened by FACS for eYFP expression (detected
in the FITC channel, Panel A) and hACKR3 labelling by APC-anti-hACKR3 (8F11-
M16) antibody (Panel B). β-arrestin2 recruitment after 5 minutes treatment was then
investigated for each of the mutants and non-responsive mutants were chosen for further
analysis (Panel C). Both expression and functional study statistic were calculated from
five independent experiments (n=5). The bold black bar represents the basal β-arrestin2
recruitment activity; the bold red bar represents the response upon treatment of wild
type hAKR3; the black-striped bars highlight those residues whose activity failed to
show any significant difference from the basal activity.
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Figure 5.12: Representation of the extracellular residues of hACKR3 involved in the
interaction with hAdrenomedullin. Residues involved in this study are shown in colour
and concentrate on the extracellular domains of the receptor. Residues labelled in blue
were those whose expression was not detectable at all, either in the FITC channel or in
the APC channel. Residues labelled in red represent those aminoacids whose substitution
had no effect. The green labelled residues identify those mutants that showed interaction
impairment for hAdrenomedullin.
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Figure 5.13: Activity versus expression dot plot of the extracellular residues of hACKR3.
The red quadrant delineates those residues which exhibited good expression together with
low activity. In this region lie the mutants in which the interaction has been impaired
by the mutation to alanine. Mean of five independent experiments were plotted.
To obtain confirmation that the lack of signal was not due to incorrect delivery
of the mutant to the membrane, these 12 residues (L5, D7, G12, K118, I210, D275,
I276, I279, T286, C287, E290 and L293) were screened for β-arrestin2 recruitment upon
stimulation with hCXCL11 and hCXCL12 (Figure 5.14). Three mutants (D7, K118 and
D275) showed a lack of signal also upon chemokine ligand treatment, and the most likely
reason is because of their extremely high basal recruitment activity (Figure 5.15); indeed
the basal activity could have been so saturated that the treatment could not increase
the β-arrestin2 recruitment level.
127
Chapter 5. Results 3: Study of the Adrenomedullin-ACKR3 interaction
L5
A
D7
A
G1
2A
K1
18
A
I21
0A
D2
75
A
I27
6A
I27
9A
T2
86
A
C2
87
A
E2
90
A
L2
93
A
Ve
hic
le W
T
0
1
2
3
4
5
CXCL11
CXCL12
ADM
Fo
ld
 o
ve
r 
ba
sa
l
Figure 5.14: hAdrenomedullin-non-responding mutants screening versus pEC80 concen-
tration of chemokine ligands hCXCL11 and hCXCL12 for 5 minutes. Mutants D7A,
K118A and D275A, unlike the other mutants, did not show functionality when treated
with the chemokine ligands, revealing that the other residues selected are functional for
at least one of the chemokine ligands hence their surface expression might be unaffected
by the mutation. The plot is the result of three (n=3) independent experiments.
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Figure 5.15: Basal β-arrestin2 recruitment of the mutants that do not respond to hA-
drenomedullin. Mutants D7A, K118A and D275A did not respond to either chemokine
ligands or hAdrenomedullin and it is not possible to distinguish between non interaction
with the ligand and an inability of ligands to further increase the high observed basal
interacions. The plot has been obtained from three independent experiments (n=3).
From these data, a model of interaction was obtained in collaboration with Dr Martin
Gustavsson from the laboratory of Professor Tracy Handel (University of California San
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Diego) using molecular docking and protein structure alignment techniques (Figure 5.16,
5.17, 5.18). Based on the known model of CXCL12-ACKR3 interaction, the structural
domains of human Adrenomedullin were aligned to the most analogous structures present
on CXCL12, and docking was performed according to this analogy, obtaining predictions
relative to the most likely interacting residues on the ligand side.
YRQSMNNFQGLRSFGCRFGTCTVQKLAHQIYQFTDKDKDNVAPRSKISPQGY
N-term
C-term
Figure 5.16: The 3-dimensional structure of human Adrenomedullin (PDB: 2L7S) is
generally unstructured due to the presence of only two structural domains: a disulphide
bridge between the cysteines 16 and 21, and an alpha helix running from threonine 22
to threonine 34. All the sections up- and down-stream of these structural motifs are
not spatially constrained, giving different steric configurations. Courtesy of Dr. Martin
Gustavsson (UCSD)
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Figure 5.17: Comparison of hAdrenomedullin and hCXCL12 interaction with hACKR3.
On the left hand-side, the residues crucial for the interaction of hACKR3 with hA-
drenomedullin (red) were mapped onto a model of hACKR3:hCXCL12 interaction.
Shown in cyan are the key residues for the interaction with both hAdrenomedullin and
chemokine ligands. On the right hand-side three hACKR3 residues are highlighted; of
these, D275 and E290 are shared between hCXCL12 and hAdrenomedullin interactions.
Courtesy of Dr. Martin Gustavsson (UCSD)
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Figure 5.18: Highlighting the likely geometric analogy between the ligands hA-
drenomedullin and hCXCL12. The mutagenesis data obtained so far suggest that the
N-terminal region of hAdrenomedullin, together with the disulphide bridge, is responsible
for the interaction with hACKR3. For the chemokine ligand hCXCL12 the interaction
is slightly analogous, as its N-terminal region is also involved in the binding. However
the N-terminal region of hCXCL12 is very short and interacts with hACKR3 N-terminal
region. Furthermore, hCXCL12 has a more defined structure than hAdrenomedullin, so
it is hard to determine from this comparison whether the N-terminal region of hACKR3
is involved in the interaction as well. On the right hand-side, arginines 8 and 12 of
hCXCL12 are highlighted, establishing a possible analogy to hAdrenomedullin’s arginines
2 and 8 in the interaction with the residues D275 and E290. Courtesy of Dr. Martin
Gustavsson (UCSD)
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5.2 Discussion
The data presented in this chapter corroborate the initial hypothesis that human Adrenomedullin
interacts with hACKR3, and represent the first thorough quantitative characterisation
of the interaction between hACKR3 and human Adrenomedullin. hAdrenomedullin has
been shown to elicit β-arrestin recruitment to hACKR3 with a potency only one order
of magnitude weaker than the receptor’s most characterised ligands. This β-arrestin
recruitment to hACKR3 due to hAdrenomedullin treatment has been reverted to basal
levels when the receptor was occupied by a bulky specific anti-hACKR3 antibody, mak-
ing it possible to state that this signalling pathway triggering is not dependent on a
receptor other than hACKR3.
The unusual nature of this interaction across such different families to which the two
interacting partners belong has been established to be unique, at least considering the
members of both said families which show between each other the highest degree of ho-
mology.
The receptor intracellular interacting partners remain to be discovered, and this might
help to have a clearer idea of the biological significance of this interaction. At this point
it can only be stated that the activation of hACKR3 upon hAdrenomedullin treatment
fails to show ERK phosphorylation within 15 minutes from the administration of the lig-
and, suggesting that it is likely that other signalling pathways than MAPK are involved
in hAdrenomedullin-dependent hACKR3 pathophysiological roles.
Given the modest potency of hAdrenomedullin to the receptor and its relatively high
manufacturing costs, the attempts made so far to describe its binding to hACKR3 have
revealed themselves unsuccessful and not cost-effective. Competition binding might have
been a different way to show binding through labelled ligand displacement, which could
have helped to assess whether the highest point reached in both the plots represented in
Figure 5.7 was specific or not, though the costs and delivery time of these reagents did
not allow these experiments to be performed.
A different kind of study instead has been pursued. Indeed, the interaction between
hACKR3 and hAdrenomedullin was investigated through the screening of receptor mu-
tants lacking, each, one of the extracellular aminoacids which likely is crucial for the
interaction with the ligand, substituted by an alanine, which lacks of any polarity and
gives a reduced steric hindrance.
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The mutagenesis study led to the identification of 9 residues which are correctly expressed
to the membrane and activate β-arrestin dependent signalling when treated with at least
one of the hACKR3 cognate chemokine ligands, but fail to show any activity upon hA-
drenomedullin treatment.
These data were used to understand the geometry of the interaction in collaboration with
the laboratory of Professor Tracy Handel, based in UCSD and devoted to chemokine re-
ceptor structures.
Even though hAdrenomedullin is a protein mostly free of structural constraints (it only
has a relatively short α-helical domain and a single disulphide bridge), its only docu-
mented conformation involved in an interaction has been compared to the conformation
of hCXCL12 bound to hACKR3, showing some analogies.
These data together constitute a robust statement that the interaction does occur, and
it can be used as a strong starting point for several projects.
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The project started with the very ambitious goal of finding out exactly how the presence
of an atypical receptor such as ACKR3 could impact on CXCR4 signalling. Sharing one
of the most important ligands for the development of almost all of the animal species,
namely CXCL12, and being often expressed together in those biological processes in
which CXCL12 plays a crucial role (i.e. embryo development, haemopoiesis, leukocyte
trafficking, immune surveillance, angiogenesis and cell migration, both in a disease-free
context as well as during pathological events), it would have been interesting to study
ACKR3 contribution.
BRET-based sensors have been developed for this purpose, each one of which was de-
signed to be able to detect a specific Gα isoform-dependent signal. Several rounds of
troubleshooting and optimisation have been made with the intention of solving the prob-
lems that the sensors might have encountered in pursuing the purpose for which they
have been generated. Nevertheless, the data obtained from these sensors have been sub-
optimal and apparently not amenable to further improvement.
In parallel to the G protein signalling investigation, β-arrestin2 recruitment assays has
been optimised for both CXCR4 and ACKR3, and in this case a body of interesting
data has been collected regarding the latter. Indeed, the optimisation and the validation
of this assay for ACKR3 has allowed the selection of a candidate biological drug, the
nanobody VUN700, whose affinity had been previously characterised by another group.
Due to their reduced size, compared to a classic antibody, and their comparable antigen-
binding affinity, the nanobody-based market is expanding. Their high solubility and
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chemical stability makes them desirable for several applications, from diagnostics to the
development of drugs with a particularly long shelf life. Scientific research has itself been
exploiting nanobodies properties for years; due mainly to their small size, they can eas-
ily reach cryptic epitopes and stabilise large protein complexes prior to crystallographic
studies, a feature that especially in GPCR structural biology allows also for the study
of receptor activation states.
The investigation of the role of ACKR3 in CXCR4-dependent signalling continued with
the development of a pair of cancer cell lines defective for ACKR3 expression and the
study of their behaviour.
Jurkat cells, or adult T-cell leukemia cells, have been described already in the literature
as expressing both of the two chemokine receptors of interest. A western blot confirmed
this, and the genome editing through nickase Cas9 CRISPR led to the generation of three
different clones of ACKR3-KO Jurkat cells. The sequencing of genomic PCR products
confirmed that the two chromosomes underwent mainly deletions, which resulted in all
cases in biallelic premature stop codon occurrence a few nucleotides further downstream
from the 5’ATG.
Jurkat cells are a suspension cell line, and their migration through transwell membranes
has been extensively studied. Hence, a chemotaxis assay was performed to identify be-
havioural differences between wild type Jurkat cells and their corresponding ACKR3 KO
clones, revealing a significantly deficient quantitative response to the chemokine CXCL12
of the latter compared to the wild type cells. Moreover, by blocking CXCR4 with the
small molecule AMD3100, the migration was reduced to zero in both the groups, reveal-
ing that in both cases the chemotactic response was driven by CXCR4 alone, and the
action of ACKR3 only enhances what is driven by CXCR4.
These data agree with what was seen in Burkitt’s lymphoma cell line NC-37 by block-
ing ACKR3 with the proprietary drug CCX771 (Chemocentryx) during transendothelial
tumor cell migration (Zabel et al., 2011), and with the behavioural observation that
ACKR3-KO VAL cells (B lymphoma model) injected in a mouse model had the ten-
dency not to infiltrate into draining lymph nodes (Puddinu et al., 2017).
LLCs instead are mouse-derived squamous lung cell carcinoma cells, with a really use-
ful peculiarity that served excellently for this study: only a very small portion of these
heterogeneous cells express mCXCR4, namely about the 0.18%. This allowed for the
study of the action of mACKR3 in a setting in which the main receptor for CXCL12 was
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absent.
The validation of the only mACKR3-KO clone required a different method for the quan-
titation of mACKR3 expression, still it revealed itself a good model for tumour growth
and as such gave very important results. The conclusions that can derive from this second
chapter were that ACKR3 has an impact on tumour growth and metastasis development,
as its vacancy gives strikingly different phenotypes in both the models employed, though
the mecanisms that make this happen can only be objects of speculation at this point.
Previous analogous works showed that upon RNA silencing of ACKR3 in three differ-
ent cell lines, namely 4T1 (mouse breast cancer), MDA-MB-435s (human breast cancer)
and LLC (mouse lung carcinoma), in vivo tumour growth was inhibited compared to
the behaviour of the corresponding wild type model (Miao et al., 2007), while the use
of ACKR3-KO VAL cells in a model of disseminated xenograft (intravenous injection)
in NOD/SCID/common-γ-chainko mice showed a milder clinical manifestation and a re-
duced organ invasion compared to wild type VAL cells (Puddinu et al., 2017).
All together, these data corroborate the hypothesis by which ACKR3 contributes to
tumour malignancy by means of a higher cell motility, a higher capability to enter the
bloodstream to give rise to metastases and a greater ability to enhance tumour growth.
The final part of the project focused on one of the ligands that, in concert with the
presence of ACKR3, might exert a crucial role for tumour vascularisation, which is
adrenomedullin.
Adrenomedullin is able to make ACKR3 recruit β-arrestin2, but fails to show MAPK
signalling. Several rounds of optimisation of the binding assay using commercial N-
terminally labelled adrenomedullin failed to show binding.
A large library of 105 single mutants of the extracellular domains of ACKR3, was interro-
gated for adrenomedullin interaction, obtaining enough data to simulate a 3-dimensional
docking.
So far, the experiments have shown that ACKR3 and adrenomedullin do interact and
the characterisation has indicated the crucial residues and regions involved in both the
interaction partners.
These data allow speculation about the role of ACKR3 in various ways and each of these
areas of speculation can become a supporting hypothesis for future experiments, such as:
• Charge swap experiments. By swapping the crucial aminoacids from hACKR3
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to the corresponding interaction site on hAdrenomedullin and viceversa. If no
interaction impairment is seen, then this gives indication that the geometry and
the charge distribution along the interaction surface is not changed, making it
possible to state that this precise interaction occurs.
• Transmembrane residue mutagenesis to alanine. This kind of experiment can give
really useful details about the interaction, by establishing to what depth into the
receptor the interaction can reach during the docking and if the microswitch do-
mains show analogies with what is already described in the literature for hCXCR4.
• Generation of in vivo models able to exclude a single ligand binding impairment.
This would require the greatest investment in time, but would show with great
detail which ligand exerts the biggest impact on embryo development impairment.
• Generation of ligand selective cell lines by CRISPR knock-in. This would be more
oriented to the study of tumour growth, as it would help establish which ligand
can determine a more striking phenotype in tumour growth and invasiveness.
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Appendices
Appendix 1 - Mutagenesis primers
Position Aminoacid Primer sequence (5’ -> 3’)
2 D→A gtcgaagagatgcagagccatggtggcaagctt
aagcttgccaccatggctctgcatctcttcgac
3 L→A gagtagtcgaagagatgcgcatccatggtggcaagcttaag
cttaagcttgccaccatggatgcgcatctcttcgactactc
4 H→A tctgagtagtcgaagagagccagatccatggtggcaag
cttgccaccatggatctggctctcttcgactactcaga
5 L→A gctctgagtagtcgaaggcatgcagatccatggtgg
ccaccatggatctgcatgccttcgactactcagagc
6 F→A ctggctctgagtagtcggcgagatgcagatccatgg
ccatggatctgcatctcgccgactactcagagccag
7 D→A ccctggctctgagtaggcgaagagatgcagatc
gatctgcatctcttcgcctactcagagccaggg
8 Y→A gatctgcatctcttcgacgcctcagagccagggaactt
aagttccctggctctgaggcgtcgaagagatgcagatc
9 S→A aagttccctggctctgcgtagtcgaagagatgc
gcatctcttcgactacgcagagccagggaactt
10 E→A cgagaagttccctggcgctgagtagtcgaagag
ctcttcgactactcagcgccagggaacttctcg
11 P→A ccgagaagttccctgcctctgagtagtcgaa
ttcgactactcagaggcagggaacttctcgg
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12 G→A ccgagaagttcgctggcctctgagtagtcgaa
ttcgactactcagagccagcgaacttctcgg
13 N→A gctgatgtccgagaaggcccctggctctgagtag
ctactcagagccaggggccttctcggacatcagc
14 F→A ccagctgatgtccgaggcgttccctggctctgag
ctcagagccagggaacgcctcggacatcagctgg
15 S→A ccagctgatgtccgcgaagttccctggct
agccagggaacttcgcggacatcagctgg
16 D→A catggccagctgatggccgagaagttccctg
cagggaacttctcggccatcagctggccatg
17 I→A gttgcatggccagctggcgtccgagaagttccct
agggaacttctcggacgccactggccatgcaac
18 S→A gctgttgcatggccaggcgatgtccgagaagttc
gaacttctcggacatcgcctggccatgcaacagc
19 W→A gctgctgttgcatggcgcgctgatgtccgagaag
cttctcggacatcagcgcgccatgcaacagcagc
20 P→A gctgctgttgcatgcccagctgatgtccg
cggacatcagctgggcatgcaacagcagc
21 C→A cagtcgctgctgttggctggccagctgatgtc
gacatcagctggccagccaacagcagcgactg
22 N→A gatgcagtcgctgctggcgcatggccagctgatg
catcagctggccatgcgccagcagcgactgcatc
23 S→A gctggccatgcaacgccagcgactgcatcg
cgatgcagtcgctggcgttgcatggccagc
24 S→A ccacgatgcagtcggcgctgttgcatggcc
ggccatgcaacagcgccgactgcatcgtgg
25 D→A ccaccacgatgcaggcgctgctgttgcat
atgcaacagcagcgcctgcatcgtggtgg
26 C→A gtgtccaccacgatggcgtcgctgctgttgca
tgcaacagcagcgacgccatcgtggtggacac
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27 I→A ccgtgtccaccacggcgcagtcgctgctgt
acagcagcgactgcgccgtggtggacacgg
28 V→A caccgtgtccaccgcgatgcagtcgct
agcgactgcatcgcggtggacacggtg
29 V→A acatcaccgtgtccgccacgatgcagtcg
cgactgcatcgtggcggacacggtgatgt
30 D→A gacacatcaccgtggccaccacgatgcag
ctgcatcgtggtggccacggtgatgtgtc
31 T→A gggacacatcaccgcgtccaccacgatgc
gcatcgtggtggacgcggtgatgtgtccc
32 V→A tgttgggacacatcgccgtgtccaccacg
cgtggtggacacggcgatgtgtcccaaca
33 M→A ggcatgttgggacacgccaccgtgtccaccac
gtggtggacacggtggcgtgtcccaacatgcc
34 C→A gttgggcatgttgggagccatcaccgtgtccacc
ggtggacacggtgatggctcccaacatgcccaac
35 P→A gggcatgttggcacacatcaccgtgtcc
ggacacggtgatgtgtgccaacatgccc
36 N→A cgcttttgttgggcatggcgggacacatcaccgtgt
acacggtgatgtgtcccgccatgcccaacaaaagcg
37 M→A ggacgcttttgttgggcgcgttgggacacatcaccg
cggtgatgtgtcccaacgcgcccaacaaaagcgtcc
38 P→A aggacgcttttgttggccatgttgggacacatc
gatgtgtcccaacatggccaacaaaagcgtcct
39 N→A gagcaggacgcttttggcgggcatgttgggacac
gtgtcccaacatgcccgccaaaagcgtcctgctc
40 K→A tgtagagcaggacgcttgcgttgggcatgttgggac
gtcccaacatgcccaacgcaagcgtcctgctctaca
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103 S→A ccagtctgggtggtcgctctcgtgcagcacaa
ttgtgctgcacgagagcgaccacccagactgg
104 L→A gtgctgcacggcactgaccacccagactgg
ccagtctgggtggtcagtgccgtgcagcac
105 V→A actggttgtgctgcgcgagactgaccacc
ggtggtcagtctcgcgcagcacaaccagt
106 Q→A ggccactggttgtgcgccacgagactgaccac
gtggtcagtctcgtggcgcacaaccagtggcc
107 H→A atgggccactggttggcctgcacgagactgac
gtcagtctcgtgcaggccaaccagtggcccat
108 N→A ccatgggccactgggcgtgctgcacgagac
gtctcgtgcagcacgcccagtggcccatgg
109 Q→A gcccatgggccacgcgttgtgctgcacg
cgtgcagcacaacgcggtggcccatgggc
110 W→A ctcgcccatgggcgcctggttgtgctgc
gcagcacaaccaggcgcccatgggcgag
111 P→A gctcgcccatggcccactggttgtg
cacaaccagtgggccatgggcgagc
112 M→A cgtgagctcgcccgcgggccactggttg
caaccagtggcccgcgggcgagctcacg
113 G→A cacgtgagctcggccatgggccact
agtggcccatggccgagctcacgtg
114 E→A ttgcacgtgagcgcgcccatgggcc
ggcccatgggcgcgctcacgtgcaa
115 L→A gtgactttgcacgtggcctcgcccatgggcc
ggcccatgggcgaggccacgtgcaaagtcac
116 T→A tgtgactttgcacgcgagctcgcccatgg
ccatgggcgagctcgcgtgcaaagtcaca
117 C→A gaggtgtgtgactttggccgtgagctcgcccatg
catgggcgagctcacggccaaagtcacacacct
118 K→A gatgaggtgtgtgactgcgcacgtgagctcgccc
gggcgagctcacgtgcgcagtcacacacctcatc
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184 K→A cgcagacgtgacggtcgccaggtagtaggtgtca
tgacacctactacctggcgaccgtcacgtctgcg
185 T→A cgcagacgtgacggccttcaggtagtagg
cctactacctgaaggccgtcacgtctgcg
186 V→A tggacgcagacgtggcggtcttcaggtag
ctacctgaagaccgccacgtctgcgtcca
187 T→A gttggacgcagacgcgacggtcttcaggt
acctgaagaccgtcgcgtctgcgtccaac
188 S→A ctgaagaccgtcacggctgcgtccaacaatg
cattgttggacgcagccgtgacggtcttcag
189 A
190 S→A ggtctcattgttggccgcagacgtgacgg
ccgtcacgtctgcggccaacaatgagacc
191 N→A gcagtaggtctcattggcggacgcagacgtgacg
cgtcacgtctgcgtccgccaatgagacctactgc
192 N→A ccggcagtaggtctcagcgttggacgcagacgtg
cacgtctgcgtccaacgctgagacctactgccgg
193 E→A gaccggcagtaggtcgcattgttggacgcag
ctgcgtccaacaatgcgacctactgccggtc
194 T→A ggaccggcagtaggcctcattgttggacg
cgtccaacaatgaggcctactgccggtcc
195 Y→A ggtagaaggaccggcaggcggtctcattgttggacg
cgtccaacaatgagaccgcctgccggtccttctacc
196 C→A ggggtagaaggaccgggcgtaggtctcattgttg
caacaatgagacctacgcccggtccttctacccc
197 R→A ctcggggtagaaggaccgcgcagtaggtctcattg
caatgagacctactgcgcgtccttctaccccgag
198 S→A tcggggtagaaggcccggcagtaggtc
gacctactgccgggccttctaccccga
199 F→A tgtgctcggggtaggcggaccggcagtagg
cctactgccggtccgcctaccccgagcaca
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200 Y→A gctgtgctcgggggcgaaggaccggcag
ctgccggtccttcgcccccgagcacagc
201 P→A atgctgtgctcggcgtagaaggaccgg
ccggtccttctacgccgagcacagcat
202 E→A ccttgatgctgtgcgcggggtagaaggac
gtccttctaccccgcgcacagcatcaagg
203 H→A ccactccttgatgctggcctcggggtagaaggac
gtccttctaccccgaggccagcatcaaggagtgg
204 S→A cagccactccttgatggcgtgctcggggtagaag
cttctaccccgagcacgccatcaaggagtggctg
205 I→A gatcagccactccttggcgctgtgctcggggtag
ctaccccgagcacagcgccaaggagtggctgatc
206 K→A ccgatcagccactccgcgatgctgtgctcggg
cccgagcacagcatcgcggagtggctgatcgg
207 E→A tgccgatcagccacgccttgatgctgtgc
gcacagcatcaaggcgtggctgatcggca
208 W→A ctccatgccgatcagcgcctccttgatgctgtgc
gcacagcatcaaggaggcgctgatcggcatggag
209 L→A cagctccatgccgatcgcccactccttgatgctg
cagcatcaaggagtgggcgatcggcatggagctg
210 I→A gaccagctccatgccggccagccactccttgatg
catcaaggagtggctggccggcatggagctggtc
211 G→A gaccagctccatggcgatcagccactc
gagtggctgatcgccatggagctggtc
212 M→A cggagaccagctccgcgccgatcagccact
agtggctgatcggcgcggagctggtctccg
213 E→A caacggagaccagcgccatgccgatcagc
gctgatcggcatggcgctggtctccgttg
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274 L→A atggagaagatgtccgccagcaccgccacgtg
cacgtggcggtgctggcggacatcttctccat
275 D→A ggatggagaagatggccagcagcaccgcc
ggcggtgctgctggccatcttctccatcc
276 I→A tgcaggatggagaaggcgtccagcagcaccgc
gcggtgctgctggacgccttctccatcctgca
277 F→A gtagtgcaggatggaggcgatgtccagcagcacc
ggtgctgctggacatcgcctccatcctgcactac
278 S→A atgtagtgcaggatggcgaagatgtccagcagc
gctgctggacatcttcgccatcctgcactacat
279 I→A aaagggatgtagtgcagggcggagaagatgtccagcag
ctgctggacatcttctccgccctgcactacatcccttt
280 L→A gtgaaagggatgtagtgcgcgatggagaagatgtccag
ctggacatcttctccatcgcgcactacatccctttcac
281 H→A caggtgaaagggatgtaggccaggatggagaagatgtc
gacatcttctccatcctggcctacatccctttcacctg
282 Y→A ggcaggtgaaagggatggcgtgcaggatggagaaga
tcttctccatcctgcacgccatccctttcacctgcc
283 I→A ccggcaggtgaaaggggcgtagtgcaggatggag
ctccatcctgcactacgcccctttcacctgccgg
284 P→A ccggcaggtgaaagcgatgtagtgcagga
tcctgcactacatcgctttcacctgccgg
285 F→A ctgcactacatccctgccacctgccggctgga
tccagccggcaggtggcagggatgtagtgcag
286 T→A ctccagccggcaggcgaaagggatgtagt
actacatccctttcgcctgccggctggag
287 C→A cgtgctccagccgggcggtgaaagggatgt
acatccctttcaccgcccggctggagcacg
288 R→A ggcgtgctccagcgcgcaggtgaaaggg
ccctttcacctgcgcgctggagcacgcc
289 L→A gagggcgtgctccgcccggcaggtgaaa
tttcacctgccgggcggagcacgccctc
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290 E→A agagggcgtgcgccagccggcag
ctgccggctggcgcacgccctct
291 H→A cgtgaagagggcggcctccagccggcag
ctgccggctggaggccgccctcttcacg
292 A
293 L→A cagggccgtgaaggcggcgtgctccagc
gctggagcacgccgccttcacggccctg
294 F→A atgcagggccgtggcgagggcgtgctcc
ggagcacgccctcgcgacggccctgcat
295 T→A catgcagggccgcgaagagggcgtg
cacgccctcttcgcggccctgcatg
296 A
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List of SPASM sensors generated for this project
All these vectors had been validated by sequencing (not shown).
• FLAG-hCXCR4-NanoLuc-ER/K-mCitrine-nopeptide
• FLAG-hCXCR4-NanoLuc-ER/K-mCitrine-Gαi1/2
• FLAG-hCXCR4-NanoLuc-ER/K-mCitrine- Gαi3
• FLAG-hCXCR4-NanoLuc-ER/K-mCitrine- Gαs
• FLAG-hCXCR4-NanoLuc-ER/K-mCitrine- Gαq
• FLAG-hCXCR4-NanoLuc-ER/K-mCitrine- Gα13
• FLAG-hACKR3-NanoLuc-ER/K-mCitrine-nopeptide
• FLAG-hACKR3-NanoLuc-ER/K-mCitrine-Gαi1/2
• FLAG-hACKR3-NanoLuc-ER/K-mCitrine- Gαi3
• FLAG-hACKR3-NanoLuc-ER/K-mCitrine- Gαs
• FLAG-hACKR3-NanoLuc-ER/K-mCitrine- Gαq
• FLAG-hACKR3-NanoLuc-ER/K-mCitrine- Gα13
• hCXCR4-NanoLuc-ER/K-mCitrine-nopeptide
• hCXCR4-NanoLuc-ER/K-mCitrine-Gαi1/2
• hCXCR4-NanoLuc-ER/K-mCitrine- Gαi3
• hCXCR4-NanoLuc-ER/K-mCitrine- Gαs
• hCXCR4-NanoLuc-ER/K-mCitrine- Gαq
• hCXCR4-NanoLuc-ER/K-mCitrine- Gα13
• hACKR3-NanoLuc-ER/K-mCitrine-nopeptide
• hACKR3-NanoLuc-ER/K-mCitrine-Gαi1/2
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• hACKR3-NanoLuc-ER/K-mCitrine- Gαi3
• hACKR3-NanoLuc-ER/K-mCitrine- Gαs
• hACKR3-NanoLuc-ER/K-mCitrine- Gαq
• hACKR3-NanoLuc-ER/K-mCitrine- Gα13
• hCXCR4-NanoLuc-ER/K-mNeonGreen-nopeptide
• hCXCR4-NanoLuc-ER/K-mNeonGreen-Gαi1/2
• hACKR3-NanoLuc-ER/K-mNeonGreen-nopeptide
• hACKR3-NanoLuc-ER/K-mNeonGreen-Gαi1/2
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ABSTRACT
G protein–coupled receptors (GPCRs) are regulated by complex
molecular mechanisms, both in physiologic and pathologic
conditions, and their signaling can be intricate. Many factors
influence their signaling behavior, including the type of ligand
that activates the GPCR, the presence of interacting partners,
the kinetics involved, or their location. The two CXC-type
chemokine receptors, CXC chemokine receptor 4 (CXCR4) and
atypical chemokine receptor 3 (ACKR3), both members of the
GPCR superfamily, are important and established therapeutic
targets in relation to cancer, human immunodeficiency virus
infection, and inflammatory diseases. Therefore, it is crucial to
understand how the signaling of these receptors works to be
able to specifically target them. In this review, we discuss how
the signaling pathways activated by CXCR4 and ACKR3 can
vary in different situations. G protein signaling of CXCR4
depends on the cellular context, and discrepancies exist
depending on the cell lines used. ACKR3, as an atypical
chemokine receptor, is generally reported to not activate G
proteins but can broaden its signaling spectrum upon hetero-
merization with other receptors, such as CXCR4, endothelial
growth factor receptor, or the a1-adrenergic receptor (a1-AR).
Also, CXCR4 forms heteromers with CC chemokine receptor
2 (CCR2 Q:6), CCR5, the Na1/H1 exchanger regulatory factor 1 ,7,
CXCR3, a1-AR, and the opioid receptors, which results in
differential signaling from that of the monomeric subunits. In
addition, CXCR4 is present on membrane rafts but can go into
the nucleus during cancer progression, probably acquiring
different signaling properties. In this review, we also provide an
overview of the currently known critical amino acids involved in
CXCR4 and ACKR3 signaling.
Introduction
G protein–coupled receptor (GPCR) signaling involves
numerous factors that influence cellular functions. These
include: 1) the variety of ligands binding to the receptor, 2)
the kinetics of the processes, 3) the location of the GPCR, and
4) the available interactome or cellular context:
1. Different ligands can induce a variety of conforma-
tional changes in a receptor and, therefore, adopt
several conformations (Kim et al., 2013; Manglik et al.,
2015; Masureel et al., 2018). These conformations could
preferentially activate different pathways, which is
1J.H., C.P.V., and A.I. contributed equally to this work.
2These authors have been listed alphabeticallyQ:4 .
This research was funded by the European Union’s Horizon2020 MSCA
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known as biased agonism (Vaidehi and Kenakin, 2010;
Lane et al., 2017).
2. GPCR activation is also influenced by the kinetics of
both ligand binding and receptor signaling, which can
possibly lead to the observation of bias profiles, such as
in the case of the dopamine D2 receptor (Klein Here-
nbrink et al., 2016).
3. Most GPCRs signal from the plasma membrane, where
they gather in separate compartments rich in G
proteins (Huang et al., 1997) and interact with other
partners (Hur and Kim, 2002). Nevertheless, increas-
ing evidence suggests that GPCRs also signal after
internalization (Calebiro et al., 2010; Vilardaga et al.,
2014; Eichel and von Zastrow, 2018) and from sub-
cellular sites, including the endoplasmic reticulum,
Golgi apparatus, and nucleus (Rebois et al., 2006;
Boivin et al., 2008; Godbole et al., 2017). These
internalized receptors could activate signaling path-
ways distinct from those activated by the same
receptors at the cell surfaceQ:8 .
4. Different cellular contexts contain different sets of
proteins that may directly or indirectly interact with
the GPCR and hence alter its signaling. Therefore, the
signaling pattern of one GPCR can strongly vary
between cell types. For instance, although class A
GPCRs can function as monomers (Whorton et al.,
2007), they can also form and function as homo- and
hetero-oligomers, which might result in altered signal-
ing properties compared with those of the individual
monomers (Jordan and Devi, 1999; Ferré et al., 2014).
In this respect, the existence of membrane compart-
ments can facilitate the interaction between different
partners and result in a variety of cellular outcomes.
Is this complexity in signaling also applicable to the GPCRs’
CXC chemokine receptor 4 (CXCR4) and atypical chemokine
receptor 3 (ACKR3)? Both receptors bind the same chemokine,
CXC motif ligand 12 (CXCL12), but interestingly their
signaling outcomes are different (Busillo and Benovic, 2007;
Rajagopal et al., 2010). In addition, ACKR3 also binds
CXCL11, although with lower affinity (Burns et al., 2006).
Under physiologic conditions, CXCR4 is involved in vascular-
ization (Tachibana et al., 1998), neurogenesis (Cui et al.,
2013), angiogenesis (Salcedo and Oppenheim, 2003) and
homing of immune cells in the bone marrow (Sugiyama
et al., 2006), while ACKR3 has a role in the development of
the central nervous system (Wang et al., 2011), angiogenesis
(Zhang et al., 2017), neurogenesis (Kremer et al., 2016), and
cardiogenesis (Ceholski et al., 2017).
Similar to most chemokine receptors, CXCR4 and ACKR3
are important therapeutic targets due to their involvement in
immune-related diseases and cancer. The CXCL12/CXCR4
axis is involved in over 23 types of cancer, including breast,
lung, colon, and ovary cancer (Guo et al., 2014; Panneerselvam
et al., 2015; Zheng et al., 2017; Raschioni et al., 2018), and acts
as a coreceptor for the human immunodeficiency virus (HIV)
to enter host T cells (Feng et al., 1996). The discovery of
ACKR3 as another CXCL12 receptor added complexity to the
understanding of the CXCR4/CXCL12 signaling axis
(Balabanian et al., 2005a). ACKR3 is also overexpressed in
many cancer types, playing an important role in tumor
development and metastasis by promoting cell survival and
adhesion (Burns et al., 2006; Miao et al., 2007; Wang et al.,
2008). Importantly, ACKR3 has a functional cross-talk with
CXCR4, and they are proposed to heteromerize (Balabanian
et al., 2005a; Burns et al., 2006; Levoye et al., 2009; Decaillot
et al., 2011). Several other receptors can also alter the function
of CXCR4 and ACKR3, either through a functional cross-talk
or as a consequence of heteromerization (Contento et al., 2008;
Martínez-Muñoz et al., 2014; Becker et al., 2017; Dinkel et al.,
2018).
Studies regarding CXCR4 and ACKR3 have been performed
using a variety of cellular systems in which interacting
proteins may not necessarily be identical, and often in trans-
fected conditions, which could lead to the artificial induction of
oligomerization (Meyer et al., 2006). Hence, there is increasing
interest in investigating their signaling in a native-like
context. In this review, we discuss these issues and the
importance of location, kinetics, and interactions with other
receptors/effectors in the scope of CXCR4 and ACKR3 signal-
ing in physiologic and pathologic conditions.
CXCR4 and ACKR3 Signaling
A number of signaling pathways are known to be activated
by CXCR4 and ACKR3, with outcomes differing depending on
the cellular context. Generally, CXCR4 is able to signal
through multiple G proteins and is also regulated by b-arrest-
ins through different interacting regions. Conversely, ACKR3
signals predominantly via b-arrestins and is generally not
able to activate G proteins. Nevertheless, as discussed in the
following section, there is still conflicting evidence in relation
to the precise details of their signaling.
G Protein–Dependent Signaling through CXCR4.
CXCR4 couples predominantly to G proteins of the Gai/o
family. Upon activation of the receptor, this family of G
proteins generally leads to the inhibition of adenylyl cyclase,
and as a consequence, cAMP production and the activity of
cAMP-dependent protein kinases are reduced.
Many G protein activation studies are performed using
bioluminescence resonance energy transfer (BRET)–based
and Förster resonance energy transfer (FRET) –based tech-
niques in transfected cells, which provide a very goodmodel to
study the possible signaling pathways triggered by a receptor.
However, the disadvantage of such studies is the need to
transfect cells, which could generate artifacts as a result of
overexpression of the corresponding proteins (Meyer et al.,
2006). Studies using these recombinant systems have shown
that CXCR4 can engage and activate different Gai/o proteins,
including Gai1, Gai2, Gai3, and Gao, in response to CXCL12
stimulation. In particular, it seems that CXCR4 might couple
more efficiently to the Gai1 andGai2 subtypes than to Gai3 and
Gao (Kleemann et al., 2008; Quoyer et al., 2013). No activation
of Gaz, the only member of the Gai family that is resistant to
pertussis toxin, has been demonstrated, although the
CXCR4/CC chemokine receptor 2 (CCR2 Q:9) hetero-oligomer is
capable of stimulating Gaz-driven Ca
21 mobilization through
the CCR2 receptor (Armando et al., 2014).
In addition to its coupling to the Gai/o subfamily, CXCR4 can
also signal through other G proteins. Studies using a more
endogenous-like setting suggested that CXCR4 mediates
some of its functions through Ga13. For example, migration
of Jurkat T cells in response to CXCL12 is controlled not only
by Gai through the activation of Rac but also by Ga13 through
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the activation of Rho (Tan et al., 2006). Importantly, it seems
that the coordinated activation of these two pathways is also
essential for the CXCR4-induced migration of metastatic
basal-like breast cancer cells in vitro and in vivo in response
to CXCL12 (Yagi et al., 2011). The coupling of CXCR4 to the
noncognate G protein Ga13 might be relevant in specific
contexts, such as in metastatic breast cancer cells, where
Ga13 is potentially overexpressed (Yagi et al., 2011; Rasheed
et al., 2015). In addition, CXCR4 trafficking into Rab111
vesicles upon CXCL12-induced endocytosis in T cells is known
to be dependent on Ga13, which, together with Rho, mediates
the polymerization of actin necessary for this process. It is
thought that in this subcellular compartment, CXCR4 forms
heterodimers with the T lymphocyte Ag receptor (Kumar
et al., 2011).
CXCL12 stimulation of CXCR4 also led to activation of Gaq
(Soede et al., 2001), a strong activator of members of the
phospholipase C-b subfamily. However, this was only the case
in dendritic cells and granulocytes, but not in T and B cells,
where CXCR4 signaling and, ultimately, chemotaxis were
shown to be Gai-dependent (Shi et al., 2007). Altogether, these
examples suggest that the cellular context can potentially
have an impact on the signaling properties of this GPCR,
although some caution must be taken when comparing the
different studies, since the assays used could differ in their
sensitivity and selectivity.
G Protein–Independent Signaling through CXCR4.
Similar to the majority of GPCRs, CXCR4 can also be
regulated by b-arrestins at a number of levels, including
CXCR4 internalization, G protein signaling, and chemotaxis.
Following activation of a receptor, G protein–coupled re-
ceptor kinases (GRKs) phosphorylate the intracellular side of
the receptor, resulting in the recruitment of b-arrestins-1/2 and
subsequent internalization of the receptor through clathrin-
coated pits. Interestingly, coexpression of CXCR4 with
b-arrestin-2 notably increased internalization of CXCR4 upon
CXCL12 stimulation in contrast to b-arrestin-1. However, this
difference disappeared when GRK2 was overexpressed, sug-
gesting that b-arrestin-1–mediated internalization highly de-
pends on the phosphorylation state of CXCR4 (Cheng et al.,
2000).
Several studies have shown that the arrestins attenuate G
protein signaling. In human embryonic kidney 293 (HEK293)
cells, overexpression of CXCR4 with either b-arrestin reduced
inhibition of cAMP production in response to CXCL12, in-
dicating that both b-arrestin-1 and -2 play an important role
in signaling regulation (Cheng et al., 2000). In accordancewith
this, using endogenous levels of CXCR4, lymphocytes isolated
from b-arrestin-2 knockout mice showed a decreased desensi-
tization and enhanced G protein coupling to CXCR4 (Fong
et al., 2002). This attenuating effect on G protein signaling
could be abolished by truncating the C terminus of the
receptor, revealing a functional interaction of the receptor’s
C terminus with the arrestin. However, receptor internaliza-
tion and extracellular signal-regulated kinase (ERK) activa-
tion were not affected, suggesting that a different region of
CXCR4, in addition to the C terminus, is involved in the
binding of these proteins with a different functional role
(Cheng et al., 2000). This other region appears to be the
intracellular loop 3Q:10 of the receptor, as it was also first
described by Wu et al. (1997) and Cheng et al. (2000). Overall,
b-arrestins appear to regulate CXCR4 signaling through at
least two different and independent interacting regions on the
receptor (Cheng et al., 2000). In accordance, the presence of
mutations or truncations in the C terminus of CXCR4 is the
cause of a rare congenital disease named warts, hypogamma-
globulinemia, immunodeficiency, and myelokathexis syn-
drome (Hernandez et al., 2003; Balabanian et al., 2005b; Luo
et al., 2017).
Last, b-arrestin-2 also plays a key role in CXCR4/CXCL12-
mediated chemotaxis of HeLa cells, enhancing the chemotactic
efficacy of the ligandmainly through the p38mitogen-activated
protein kinase pathway (Sun et al., 2002).
Kinetics of CXCR4 Signaling. GPCR activation and
downstream signaling kinetics have been extensively studied
within the last two decades with the aid of emerging
fluorescence microscopy methods. Unlike many other recep-
tors (Lohse et al., 2008; Stumpf and Hoffmann, 2016), only a
few studies have been published on the kinetics of CXCR4
activation and its corresponding downstream signaling
processes. Even so, using BRET studies, activation kinetics
by CXCL12 and the pepducin ATI-2341 Q:11were compared.
CXCL12 has been shown to rapidly induce Gai protein
recruitment to CXCR4 and lead to a full activation with a
t1/2 value of approximately 32 seconds. The kinetics of Gai
protein recruitment were similar for the pepducin, although
activation of Gai was significantly slower (Quoyer et al., 2013).
One study also focused on the phosphorylation kinetics of
intracellular sites of CXCR4 in both HEK293 and human
astroglial cells and suggested that Ser-324, Ser-325, and Ser-
339 were phosphorylated rapidly by GRK6 after CXCL12
exposure, while the kinetics for Ser-330 phosphorylation were
significantly slower. Such phosphorylation is directly involved
in the association of arrestin to the receptor and hence can
finely regulate CXCR4 signaling (Busillo et al., 2010). Another
group also demonstrated that Gai engagement Q:12to CXCR4 upon
CXCL12 stimulation led to the phosphorylation of Tyr resi-
dues in the receptor via the Janus kinase 2/3 kinases Q:13within a
few seconds (Vila-Coro et al., 1999).
Key Residues for Signaling in the CXCR4 Receptor.
The intracellular loop 3 Q:14and the C-terminal tail of the receptor
seem to be important for b-arrestin recruitment and G protein
activation, and accordingly, mutations in these regions have a
considerable impact on signaling. Several mutational studies
have been performed to unravel howCXCL12 binds to CXCR4,
and how the signal is transmitted from the extracellular part
of the receptor through the transmembrane regions to the
intracellular part, where interactions with protein partners
involved in signaling occur. In these regards, previous studies
have identified, with nearly atomic resolution, the pathway
from the binding of the chemokine to the G protein coupling,
and that several mutations in the receptor impair ligand
binding and signaling (Wescott et al., 2016). A schematic
summary including important residues relating to the func-
tion of CXCR4 is provided in Fig. 1.
G Protein–Dependent Signaling through ACKR3.
Many studies have shown that ligand binding to ACKR3 does
not result in either coupling to or activation of G proteins, or
the triggering of signaling pathways typical of G proteins, in
contrast to CXCR4. In fact, ACKR3 lacks the specific DRY-
LAIV motif on the intracellular side of the receptor that is
essential for G protein interaction in other chemokine recep-
tors, and instead presents a DRYLSIT motif (Ulvmar et al.,
2011). However, efforts on creating a chimeric ACKR3 where
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the DRYLSIT is replaced by the corresponding DRYLAIV
motif of CXCR4 failed to induce CXCL12-mediated signaling,
such as G protein activation, intracellular Ca21 mobilization,
G protein–mediated ERK phosphorylation, or chemotaxis
(Naumann et al., 2010; Hoffmann et al., 2012). This implies
that the missing DRYLAIV motif in ACKR3 is not the only
determinant for the lack of G protein–dependent signaling.
Fig. 1. Snake plot of human CXCR4 with highlighted residues important for receptor function as determined in the following studies: 1Wescott et al.
(2016), 2Berson et al. (1996), 3Zhou et al. (2001), 4Cronshaw et al. (2010), 5Rapp et al. (2013), 6Doranz et al. (1999), 7Brelot et al. (2000), 8Tian et al. (2005),
9Armando et al. (2014), 10Ballester et al. (2016), and 11Martínez-Muñoz et al. (2018). Snake plot adapted from GPCRdbQ:34 (Pándy-Szekeres et al., 2018).
WHIM, warts, hypogammaglobulinemia, infections, myelokathexis.
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Nonetheless, the interaction of ACKR3 with G proteins has
been proposed in two studies. In the first case, a specific BRET
signal was detected between ACKR3–yellow fluorescent pro-
tein (YFP) andGai1–Renilla luciferase (RLuc), which decreased
upon treatment with guanosine 59-3-O-(thio)triphosphateQ:15 , sug-
gesting that ACKR3 can interact withG proteins in the absence
of an agonist but fails to activate them (Levoye et al., 2009). In
the second case, CXCL12 was still able to promote Gi/o protein
activation in primary astrocytes after CXCR4 depletion but not
after ACKR3 depletion. In addition, ACKR3-only-expressing
astrocytesQ:16 also led to ERK and Akt activation in response to
both CXCL12 and CXCL11, although only the former appeared
to be G protein dependent (Ödemis et al., 2012). Both Gi/o and
ACKR3 are highly abundant in astrocytes and glioma cells
(Schönemeier et al., 2008; Tiveron et al., 2010; Ödemis et al.,
2012; Banisadr et al., 2016), and therefore, a hypothesis is that
ACKR3might be able to activateG proteins specifically in these
cell types, indicating once again how important the interactome
might be for a given GPCR.
Overall, although there is conflicting evidence on the role of
ACKR3 in relation to G protein–dependent signaling, there is
increasing evidence for a b-arrestin–biased receptor in most
cell types. Moreover, studies have shown that ACKR3 could
modulate other cellular signaling pathways, potentially by
forming a heteromeric complex with other receptors, which is
discussed in a later section of this review.
G Protein–Independent Signaling through ACKR3.
Many studies have shown that ACKR3 can act as a “decoy” or
“scavenging” receptor, since it can efficiently internalize its
chemokine ligands CXCL11 and CXCL12 (Naumann et al.,
2010). By internalizing CXCL12, ACKR3 finely tunes the
CXCL12 gradient necessary for the CXCR4-mediatedmigration
(Dambly-Chaudière et al., 2007; Boldajipour et al., 2008; Donà
et al., 2013). Nevertheless, ACKR3 is not only a “decoy” receptor,
it can also activate downstream pathways via b-arrestins, in
response to both CXCL11 and CXCL12Q:17 , directly promoting Akt
and mitogen-activated protein kinase activity, ERK phosphor-
ylation (Hattermann et al., 2010; Rajagopal et al., 2010;
Decaillot et al., 2011; Ödemis et al., 2012; Torossian et al.,
2014), and activation of the Janus kinase 2Q:18 /signal transducer
and activator of transcription 3Q:19 pathway (Hao et al., 2012).
CXCL11-dependent ERK phosphorylation could be seen in
ACKR3-overexpressing HEK293 cells but not in rat vascular
smooth muscle cells (VSMCs) that endogenously express
ACKR3, again demonstrating the importance of the cellular
context (Rajagopal et al., 2010). Interestingly, AMD3100, an
antagonistic small-molecule against CXCR4, can have an
agonistic effect onACKR3. In high concentrations, thismolecule
can induce b-arrestin recruitment to ACKR3 and increase
CXCL12 binding to the receptor (Kalatskaya et al., 2009). A
similar scenario was observed with the CXCR4 inverse agonist
TC14012, which acts as an agonist on ACKR3 (Gravel et al.,
2010). Therefore, when considering CXCR4 as a therapeutic
target, it should be taken into account that a molecule can have
unexpected effects via ACKR3 and vice versa.
Although ACKR3 is constitutively internalized via clathrin-
coated pits by b-arrestins (Luker et al., 2010), it has also been
described that ACKR3 internalizes in a ligand-dependent
manner in response to both CXCL11 and CXCL12, leading
to different patterns of receptor internalization (Rajagopal
et al., 2010; Canals et al., 2012).
Ubiquitination, a constitutive modification on ACKR3, is
the key modification responsible for the correct trafficking of
the receptor from and to the plasma membrane (Canals et al.,
2012). Also, the phosphorylation of serine and threonine
residues at the cytoplasmic C-terminal tail of ACKR3 has
been implicated in ACKR3 internalization, chemokine scav-
enging, and receptor-arrestin interactions (Ray et al., 2012).
There are some controversies regarding the involvement of
ACKR3 in chemotaxis. Some reports suggest that ACKR3
induces migration of different cell types via ACKR3 exclu-
sively (Rajagopal et al., 2010; Chen et al., 2015), while others
report a role in migration by only modulating the CXCR4
function (Abe et al., 2014). Hence, this role of ACKR3 awaits
further clarification.
Key Residues for Signaling in the ACKR3 Receptor.
In two studies, mutational analysis was performed to identify
the key residues of ACKR3 in ligand binding (CXCL11 and
CXCL12), recruitment of b-arrestins, the scavenging capacity
of chemokines (Benredjem et al., 2017), and trafficking of
ACKR3 (Canals et al., 2012). These key residues are shown in
Fig. 2.
Key residues for CXCL11 and CXCL12 binding were mostly
present in the extracellular loops. Surprisingly, no N-terminal
residues of the receptor were required for CXCL12 binding in
contrast to CXCL11 binding, highlighting the different bind-
ing mechanisms of these ligands (Benredjem et al., 2017).
Certain C-terminal residues are ubiquitinated and very
important for receptor internalization and recycling (Canals
et al., 2012). Recently, the residues protected by CXCL12 were
determined by radiolytic footprinting (Gustavsson et al.,
2017).
Oligomerization of CXCR4 and ACKR3
Influences Signaling
CXCR4 and ACKR3 Homomerization. CXCR4 is
known to potentially form dimers, and in accordance, it has
been crystallized as a homodimer in the presence of various
ligands (Wu et al., 2010; Qin et al., 2015). There is also
evidence that CXCR4 might form higher-order oligomers,
demonstrated using bimolecular fluorescence complementa-
tion (Armando et al., 2014). A FRET signal between CXCR4–
cyan fluorescent protein and CXCR4-YFP could be detected in
intact tumor cells, and when the energy transfer was de-
creased, by depletion of cholesterol in lipid rafts or using a
transmembrane (TM) 4 peptide analog, tumor cells signifi-
cantly lost their capacity to migrate toward CXCL12. Al-
though the decrease in FRET signal does not necessarily imply
a disruption of the homomer, it does suggest that changing the
conformation of a CXCR4 homomer can influence signaling
(Wang et al., 2006). The observation of ligand-induced confor-
mational changes within the CXCR4 homodimer unit was also
reported prior to this work (Percherancier et al., 2005). In
addition, pertussis toxin treatment reduced the amount of
CXCR4 oligomers detected by single-molecule microscopy,
suggesting that these oligomers play a role in G protein–
mediated signaling. In the same study, it was shown Q:20that
CXCR4 dimers also have more tendency to internalize than
monomers (Ge et al., 2017). However, as stated previously in
the Introduction, increasing CXCR4 expression levels could
also increase the amount of homomers present, which should
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be accounted for when using transfected cell lines. Meanwhile,
using single-moleculemicroscopy, at very low expression levels,
CXCR4 was predominantly present in a monomeric state, and
increasing its expression levels led to a higher degree of
oligomers. This could suggest that higher-order oligomers
might be present in cancer cells, where CXCR4 is expressed
abundantly (Lao et al., 2017), which is consistent with the
involvement of dimers in migration (Wang et al., 2006). Re-
cently, nanoclusters of CXCR4 were also observed in Jurkat
T cells using single-molecule tracking and super-resolution
Fig. 2. Snake plot of human ACKR3 with highlighted residues important for receptor function as determined in the following studies: 1Benredjem et al.
(2017), 2Canals et al. (2012), and 3Gustavsson et al. (2017). Snake plot adapted from GPCRdb (Pándy-Szekeres et al., 2018).
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microscopyQ:21 (Martínez-Muñoz et al., 2018). CXCL12 promoted
the formation of thesenanoclusters by decreasing the amount of
monomers and dimers. The disruption of these nanoclusters
using a TM6 analog strongly impaired CXCR4 functioning,
suggesting that not only dimers but also bigger clusters of
CXCR4 might be involved in signaling. Coexpression of cluster
of differentiation 4 (CD4) or inhibition of the actin cytoskeleton
reduced the size of CXCR4 nanoclusters and hence reduced the
Ca21 flux (Martínez-Muñoz et al., 2018). So, the presence of
CD4 in the cellular system seems to be important when
interpreting the signaling outcome mediated via CXCR4.
The dimeric interface in the crystal structure of CXCR4
consists of the fifth and sixth transmembrane domains when
the receptor is in complex with IT1t (a specific small-molecule
antagonist), and of the third and fourth helix when it is in
complex with CVX15 (a small cyclic peptide) (Wu et al., 2010).
However, mutations in those regions did not significantly
decrease the specific BRET signal detected between lucifer-
ase- and green fluorescent protein–tagged CXCR4 receptors,
indicating that multiple homomerization interfaces might
exist (Hamatake et al., 2009). Since evidence exists that
dimerization has an influence on CXCR4 signaling (Ge et al.,
2017), the dimer conformation might also have important
consequences in downstream activation. Since different li-
gands can induce different conformational changes, it can be
speculated that these ligands can also lead to different
homodimer interfaces, as could be seen for the crystal
structures of CXCR4 (Wu et al., 2010). Hypothetically, these
complexes could have different signaling properties
(Percherancier et al., 2005).
To our knowledge, two publications suggest the existence of
constitutive ACKR3 homomers in transfected HEK293T cells.
In both papers, a specific BRET signal was observed between
ACKR3-RLuc and ACKR3-YFP (Kalatskaya et al., 2009;
Levoye et al., 2009). The costimulation with CXCL12 and
AMD3100 caused an increase in the BRET signal between the
tagged ACKR3 receptors that was significantly higher than
when using CXCL12 alone, which is in accordance with the
idea that AMD3100 might be an allosteric agonist for ACKR3
(Kalatskaya et al., 2009). Yet, no other publications focused on
ACKR3 homomerization.
CXCR4 and ACKR3 Heteromerization. CXCR4 func-
tion can be influenced by the interaction with other receptors,
as shown by many publications that demonstrated CXCR4
heteromerization or cross-regulation with/via other chemo-
kine receptors. The occurrence of heterodimers might be
feasible, since chemokine receptors are often coexpressed in
the same cell types and, in some cases, even bind the same
chemokines. For example, several studies using transfected
cells showed that CXCR4 is able to form heteromers with
CCR2, CCR7, CCR5, and CXCR3, among others.
In the first example, using BRET assays, CXCR4was shown
to heteromerize with CCR2, and coactivation of both coex-
pressed receptors led to a potentiation in Ca21 release. In
addition, this heteromer has been shown to recruit b-arrestin-
2 using bimolecular fluorescence complementation. However,
using BRET again, it has been seen that while the CXCR4
homodimer was able to recruit the Ga13 protein, the
CCR2/CXCR4 heteromer completely lost this ability
(Armando et al., 2014). Moreover, in radioligand binding
assays, binding of the respective chemokines to either CCR2
or CXCR4 impaired chemokine binding to the other receptor,
suggesting a negative cooperativity within the heteromer.
This has been shown in recombinant cells aswell as in primary
leukocytes, where CCR2 and CXCR4 are endogenously pre-
sent, suggesting that these two receptors might form hetero-
mers even in a native context (Sohy et al., 2007). In the second
example, CXCR4 not only formed heteromers with CCR7, as
shown by proximity ligation assay, but also required the
presence of CXCR4 to be properly expressed on the CD41
T-cell membrane. When activated by the HIV glycoprotein
gp120, CXCR4 enhanced CCR7-mediated migration of CD41
T cells to the lymph nodes, significantly facilitating HIV
infection (Hayasaka et al., 2015). In another study, using
bimolecular fluorescence complementation, Hammad et al.
(2010) showed that CCR5 homomers could interact with an
important GPCR regulatory protein named Na1/H1 ex-
changer regulatory factor 1 (NHERF1 Q:22). However, upon for-
mation of CCR5/CXCR4 heterodimers, this receptor could no
longer interact with NHERF1. Therefore, one should account
for heteromerization when targeting CCR5 in HIV infection
(Hammad et al., 2010). In the last case, the existence of
CXCR3/CXCR4 heteromers has been seen by coimmunopre-
cipitation, saturation BRET, time-resolved FRET, and GPCR-
heteromer identification technology. A negative cooperativity
for ligand binding was observed as well for CXCR3/CXCR4
heteromers. Addition of a CXCR3 antagonist impaired
CXCL12 binding to CXCR4, but not the other way around.
This heteromer could specifically recruit b-arrestin-2 accord-
ing to an analysis that used GPCR-heteromerization identifi-
cation technology (Watts et al., 2013).
CXCR4 has also been suggested to heteromerize with other
class A GPCRs, such as adrenergic and opioid receptors (Pello
et al., 2008; Tripathi et al., 2015; Gao et al., 2018). For
example, activation of the a1-adrenergic receptor (AR) led to
the recruitment of b-arrestin-2 to CXCR4, and a specific
agonist of a1-AR induced the internalization of CXCR4, as
shown using the PRESTO-Tango assay in HEK293 cells.
Neither of these effects could be inhibited by AMD3100 or
the 12G5, an antagonist and internalization-blocking CXCR4
antibody, respectively, but both could be abolished Q:23by disrupt-
ing the heteromer using a peptide analog of TM2 of CXCR4,
suggesting a tight cross-regulation within the a1-AR/CXCR4
complex (Gao et al., 2018). In addition, CXCR4 also influences
the adrenergic function (Tripathi et al., 2015). a1-AR/CXCR4
heteromers were detected in a completely endogenous context,
on the cell surface of rat and human VSMCs, via a proximity
ligation assay. Disrupting the a1-AR/CXCR4 heteromer with a
TM2 analog of CXCR4 or CXCR4 silencing impaired the
association of these two receptors, as well as inhibited
adrenergic-mediated responses in response to an agonist Q:24,
such as Ca21 mobilization or myosin light chain 2 phosphor-
ylation. As a result, the authors proposed that targeting the
a1-AR/CXCR4 heteromer might be an alternative for the
currentmedications against ɑ1-AR Q:25tomodulate blood pressure
(Tripathi et al., 2015). The significance of this work comes
from it being an exceptional example of detecting oligomers at
endogenous expression levels in vivo, rather than detection of
overexpressed receptor probes with epitope tags.
Another example of how such cross-talk can affect currently
used treatments is the cross-talk between CXCR4 and the
opioid receptors. In mice studies, CXCR4 activation by
CXCL12 decreased the effect of antinociceptive drugs on the
m- and d-opioid receptors, but activation of these opioid
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receptors did not desensitize CXCR4 (Chen et al., 2007). A
cross-desensitization in both directions could be detected only
between CXCR4 and the k-opioid receptor in several cell lines
and in vivo (Finley et al., 2008). Such evidence suggests that
the effect of painkillers is decreased when CXCR4 is present.
Nonetheless, only CXCR4/d-opioid receptor heteromers have
been observed using FRET experiments (Pello et al., 2008);
thus, the cross-talk between CXCR4 and the other opioid
receptors might not necessarily be due to heteromerization,
but rather as a consequence of sharing the same intracellular
signaling pathways.
Not only human receptors from the class A GPCRs are able
to change the signaling of CXCR4, but also some viruses can
take advantage of the alterations in receptor signaling
potentially caused by heteromerization. For example, the
Epstein-Barr virus encodes in its genome a viral GPCR named
BILF1, which heteromerizes with human CXCR4 according to
BRET experiments. Coexpression of the constitutively active
BILF1 impairs CXCL12 binding to CXCR4 and, ultimately,
the CXCL12-mediated G protein signaling (Nijmeijer et al.,
2010).
Altogether, the function of CXCR4 seems to be strongly
dependent on the interacting partners found in the cells, and
consequently, it significantly varies between cell types. It is
important to keep in mind that the change in the CXCR4
function due to the presence of certain proteins is not always
due to oligomerization, but can also be due to a cross-talk in
signaling pathways. In pathology, the degree of oligomeriza-
tion and the type of oligomers could be heavily altered. For
example, using BRET, the authors observed that CXCR4–
warts hypogammaglobulinemia, infections, myelokathexis
mutants can oligomerize with the wild-type CXCR4 and
possibly retain it at the plasma membrane (Lagane et al.,
2008).
Regarding ACKR3 heteromerization, there is evidence of
the presence of a1-AR:ACKR3:CXCR4 hetero-oligomers in
VSMCs, and the activation of ACKR3 can lead to the in-
hibition of the a1-AR activity (Albee et al., 2017). ACKR3 is
also known to interact with the epithelial growth factor
receptor (EGFRQ:26 ) in a b-arrestin-2–dependent manner and is
implicated in the phosphorylation of the EGFR. Together,
they are involved in mitosis of breast cancer cells (Salazar
et al., 2014).
Cross-Talk between CXCR4 and ACKR3. Upon the
discovery of ACKR3 as a receptor that can also bind CXCL12,
whichwas previously known as aCXCR4-exclusive chemokine
(Balabanian et al., 2005a), several studies focused on coex-
pression of CXCR4 and ACKR3 in diverse cell types and the
influence of a possible CXCR4:ACKR3 interaction and/or
cross-talk on the signaling properties. CXCR4 and ACKR3
are coexpressed in diverse cell types. These include human T
and B lymphocytes (Balabanian et al., 2005a), dendritic cells
(Infantino et al., 2006), monocytes (Sánchez-Martín et al.,
2011), renal progenitor cells (Mazzinghi et al., 2008), VSMCs
(Evans et al., 2016), vascular endothelial cells (Schutyser
et al., 2007), and zebrafish primordial germ cells (Boldajipour
et al., 2008).
A number of studies hypothesized that ACKR3 might
regulate CXCR4 activity by scavenging or segregating
CXCL12. ACKR3 generates a gradient of available ligand for
CXCR4, thus finely tuning CXCR4-mediated cellular signal-
ing and hence controlling, for example, primordial germ cell
migration in zebrafish (Boldajipour et al., 2008; Naumann
et al., 2010). Thework of Naumann et al. (2010) suggested that
themodulation of CXCR4 activation via ACKR3 is achieved by
the scavenging activity of ACKR3, rather than heterodimeri-
zation, as they did not observe any cointernalization of these
receptors.
Other studies shifted the focus more onto the mechanisms
that may be involved, including the physical interaction of
both receptors and subsequent modulation of their functions.
For example, ACKR3 inhibition can act as a negative modu-
lator of CXCR4-mediated lymphocyte integrin adhesiveness
in human T lymphocytes and CD341 cells (Hartmann et al.,
2008). In this case, ACKR3-mediated modulation of CXCR4
activation was suggested to be due to a physical interaction
between the two receptors. Indeed, the hetero-oligomerization
of CXCR4/ACKR3 in intact HEK293 cells in the absence of
CXCL12 was demonstrated using the FRET acceptor photo-
bleaching method (Sierro et al., 2007). This study also
highlighted that their coexpression potentiated Ca21 flux
mediated by CXCR4 activation and delayed ERK
phosphorylation.
A follow-up study investigating CXCR4/ACKR3 hetero-
oligomerization confirmed the heteromer formation in
HEK293T cells using BRET.However, they Q:27showed a negative
modulation of the Ca21 flux when both receptors were coex-
pressed. In accordance with this result, GTP binding potency
of Gai upon CXCR4 activation with CXCL12 decreased in cells
coexpressing ACKR3. Moreover, ACKR3 coexpression with
CXCR4 in HEK293 cells induced a conformational change
between the precoupled CXCR4-YFP andGai-RLuc. The same
study also demonstrated that knockdown of ACKR3 expres-
sion in T lymphocytes resulted in more potent migration at
lower CXCL12 concentrations, addressing the scavenging
function of ACKR3 (Levoye et al., 2009).
Another study also linked direct interactions of
CXCR4/ACKR3 with oligomerization-specific functional out-
comes (Decaillot et al., 2011). In this case, the evidence of
CXCR4/ACKR3 hetero-oligomerization comes from the coim-
munoprecipitation of overexpressed CXCR4-C9 and ACKR3-
FLAG Q:28in HEK293 cells. In the same study, coexpression of
ACKR3 with CXCR4 inhibited CXCR4/Gai-mediated inhibi-
tion of cAMP production. In addition, activation of ACKR3
with CXCL11 restored CXCR4-dependent inhibition of cAMP
production. Moreover, expression of CXCR4 increased the
constitutive and ligand-induced recruitment of b-arrestin to
ACKR3 heteromers, enhanced b-arrestin–mediated ERK
phosphorylation, and increased migration of rat VSMCs
(Decaillot et al., 2011).
Some cautionmust be taken when studying CXCR4/ACKR3
signaling, since their endogenous expression patterns can
differ in different cell types andmight influence the outcome of
the experiments. Regarding drug development, one must
acknowledge the complexity of targeting CXCR4 in different
diseases and tissues, since heteromerization or cross-talk with
other receptors can strongly impact its signaling.
Location of CXCR4 and ACKR3 Can Influence
Receptor Signaling
Signaling of CXCR4 in Microdomains. As CXCR4 is
expressed in diverse tissues, different microenvironments
8 Heuninck et al.
within different cell types play an important role in the
manner of CXCR4 signaling. CXCR4 localizes to membrane
rafts (Mañes et al., 2000), which aremicrodomains enriched in
cholesterol, sphingolipids, and proteins (Brown and London,
1998). The presence of cholesterol in these rafts seems to play
an important role in CXCL12 binding (Nguyen and Taub,
2002), and the activation of CXCR4 can lead to cross-
activation of other membrane proteins, such as human
epidermal growth factor receptor 2 (HER2) and EGFR in the
raft (Conley-LaComb et al., 2016).
Upon activation of CXCR4, the receptor is rapidly internal-
ized and can be either recycled back to the membrane or
degraded at the lysosome (Marchese et al., 2003). Evidence
suggests that phosphorylation of specific residues is involved
in the determination between recycling and degradation
(Marchese and Benovic, 2001). In renal cell carcinoma cells,
CXCR4 moved to the cell nucleus after CXCL12 binding, and
this nuclear location led to an increased Matrigel matrix
invasion. In addition, histologic sections showed that CXCR4
was present in the nucleus only in metastatic renal cell
carcinoma lesions (Wang et al., 2009). This might have
important consequences for targeting CXCR4, since drugs
would need to penetrate into the nucleus to attack metastatic
cells. While the location of CXCR4 within a cell seems to be
important, the location of these CXCR4-expressing cells
within an organism might also influence outcomes. During
the development of the lateral-line primordium of zebrafish,
CXCR4 was present at the front cells while ACKR3 was at the
back. This differential spacing might contribute to the estab-
lishment of a CXCL12 gradient that is important for the
correct development of this species (Valentin et al., 2007; Donà
et al., 2013).
Depending on its location, CXCR4 can activate different
signaling pathways and can hence trigger different cellular
responses. This might explain how CXCR4 has so many
different roles in many organs and cell types and how its role
might change in a pathologic condition, such as cancer.
Signaling of ACKR3 in Microdomains. In contrast to
CXCR4, which is mostly expressed on the plasma membrane
and the early and recycling endosomes, ACKR3 is mainly
expressed on themembrane of endocytic vesicles in the resting
state (Zhu et al., 2012). Shortening the receptor’s C-terminal
tail in ACKR3–green fluorescent protein increasedmembrane
localization by up to 100% when the whole domain was
missing. Although truncating the C terminus did not alter
CXCL12 binding to the receptor, it significantly reduced the
scavenging of the ligand as well as b-arrestin recruitment and
activation of ERK1/2. In the presence of the dominant
negative mutant K44A dynamin, all ACKR3 was located on
the cell surface (Ray et al., 2012). This did not alter constitu-
tive b-arrestin recruitment, but upon CXCL12 treatment,
b-arrestin recruitment significantly increased and ERK phos-
phorylation lasted significantly longer. Thus, ACKR3 can
show thorough signaling when localized exclusively to the
plasma membrane without the chance to be internalized (Ray
et al., 2012).
Meanwhile, upon chemokine ligand treatment, ACKR3
membrane expression over time did not decrease, as is the case
for CXCR4, but after a small decrease, its presence on the
membrane was slightly restored and resisted the depletion
from the plasmamembrane for a prolonged time. Furthermore,
through radioligand internalization, it was demonstrated that
ACKR3 brings its chemokine ligands to degradation, confirm-
ing its role as a scavenger receptor (Naumann et al., 2010). In
platelets, where CXCR4 andACKR3 are both present, CXCL12
induced the internalization of CXCR4 but, at the same time, the
externalization of ACKR3. This latter process was CXCR4-
mediated, since blocking CXCR4 abolished ACKR3 external-
ization (Chatterjee et al., 2014). The same study showed that
ERK1/2 phosphorylation was important for the cyclophilin A–
mediated ubiquitination of ACKR3, an essential modification
for the membrane location of ACKR3.
Some studies have observed ACKR3 predominantly on the
membrane (Hattermann et al., 2012, 2014; Kumar et al.,
2012). For example, in MCF-7 breast cancer cells, CXCR4 and
ACKR3 were mostly observed on the membrane, using
immunofluorescence light microscopy and electron micros-
copy. After CXCL11 or CXCL12 treatment, receptors were
internalized individually or in proximity. A cross-talk between
both receptors was also seen, since CXCL11 could induce the
internalization of CXCR4 (Hattermann et al., 2014).
Discussion
In this review, we summarized how CXCR4 and ACKR3
signaling can be influenced by their expression levels, local-
ization, and interacting proteins (cross-talk and oligomeriza-
tion) (a summary can be found in Tables 1 and 2). All of these
aspects have important consequences, especially when a
GPCR is being targeted for drug development.
Many of the examples discussed in this review investigated
CXCR4 and ACKR3 location and signaling in immortalized
cell lines using an expression of reporter/recombinant proteins
that was often much higher than endogenous expression
levels Q:29. It is evident that these studies explain several crucial
biologic outcomes that are governed by CXCR4 and ACKR3.
However, it is worth noting that overexpression of receptors
and/or downstream effectors might bias the receptor and
downstream signaling behavior. Chabre et al. (2009) pro-
posed, for example, a hypothesis for the apparent negative
cooperativity between two receptors in ligand binding exper-
iments: overexpression of receptors might lead to an insuffi-
cient amount of G proteins available for the receptor, causing
receptor heterogeneity; some receptors would be coupled to a
G protein, while others would not. These two states might
present different affinities for the ligand and hence create an
artificial negative cooperativity (Chabre et al., 2009). In
addition to this, interaction partners can modulate the
signaling properties of a receptor. Moreover, the cellular
content (i.e., types and amounts of effector proteins that a
receptor can activate) can also greatly influence the biologic
outcomes of a specific receptor or receptor oligomer activation.
Signaling pathways associated with the activation of CXCR4
and ACKR3 are vast. However, balance and dynamics of these
pathways can be different in each tissue type. Thus, choice of a
cell type while studying CXCR4 and ACKR3 oligomerization/
signaling is crucial, and there is a need for studies in a more
endogenous or disease-related context.
In various cell types, receptors can be found in different
cellular compartments. Spatial and temporal aspects of
chemokine receptor signaling may vary, depending on the
receptor location in different cell and tissue types. The location
of CXCR4 and ACKR3 can result in the activation of different
signaling pathways. In targeting such receptors, such as in
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cancer, knowing the cellular location of the receptor is
relevant—for instance, CXCR4 can localize and signal at the
nuclear membrane of metastatic cells (Wang et al., 2009).
Despite several reports using diverse types of assays, GPCR
oligomerization is still highly disputed. While certain reports
demonstrate oligomerization of a certain receptor, others may
dispute Q:30. This is mostly due to the type of assays that are used
and even the manner of setting up the experimental condi-
tions and analysis methods for a certain assay. Despite giving
valuable information on receptor-receptor interactions, en-
ergy transfer–basedmethods BRET and FRET lack the ability
to elucidate the kinetics of individual events. Since the
observed resonance energy transfer Q:31signal comes from all of
the receptors within a cell or a pool of cells, it is not possible to
resolve whether the observed signal is due to a stable or
transient interaction. With the help of advanced imaging
methods, it is now possible to track the movements and
interactions of single receptors with other receptors and
interacting partners with high spatiotemporal precision
(Sungkaworn et al., 2017). Such methods, combined with
fluorescent labeling of endogenous receptors with minimal
tags (Coin et al., 2013), can open a new avenue to study
receptor-receptor and receptor-effector interactions with su-
perior spatial and temporal resolution at endogenous expres-
sion levels in biologically relevant cell types. It is also worth
recognizing the importance of knockout studies, as these can
demonstrate the role of receptors and/or effectors in certain
cellular signaling pathways and their consequent biologic
importance in both health and disease conditions. Advancing
CRISPR technologies have recently been used to study
signaling bias and cross-activation of signaling pathways
(Grundmann et al., 2018). Such studies can also be extended
toward GPCR oligomerization, i.e., knocking out one of the
heteromerizing partners, or knocking out a downstream
effector that is believed to be activated only in the case of a
heteromer activation, and studying its effects on downstream
signaling.
A heteromer can have completely different signaling prop-
erties in comparison with the monomers (Milligan, 2009;
Urizar et al., 2011). Thus, therapeutically targeting one
particular GPCR might be too simplistic. As evidence on the
biologic significance of class A GPCR heteromerization is
increasing, targeting the pathologically relevant heteromers
can be a novel approach to therapy. As allosteric modulators of
GPCR dimers, bivalent ligands that could specifically target a
heteromer might be an option for future investigation into
whether it Q:32has therapeutic potential. However, determining to
what extent oligomerization is relevant in vivo yet remains as
a crucial question to be answered.
Overall, in this review, we focused on the advances in the
signaling properties of CXCR4 and ACKR3 in a health and
disease context. Previous studies shed light on distinct
outcomes of complex cell-type-dependent signaling, receptor-
receptor interactions, and receptor cross-talk. However, our
knowledge for an accurate picture of CXCR4/ACKR3-
mediated signaling is still not complete. Since model cells
and overexpressing systems might bias receptor location,
receptor-receptor interaction, and signaling outcome, choice
of experimental methods and cell types must be well consid-
ered. Yet, novel fluorescent labeling, advanced imaging, and
genetic engineering in model organisms and primary cells, as
well as computational and structural methods, will allow us toTA
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study CXCR4 andACKR3 signaling in amore endogenous and
disease-related context in the near future.
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